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Efrat Bruck, B.S. ‘12, majored in Honors Biology. 
GENETICALLY MODIFIED T-CELLS EXPRESSING 
CHIMERIC ANTIGEN RECEPTORS IN THE TREATMENT 
OF CANCER 
Efrat Bruck 
ABSTRACT 
Dr. Carl June and his colleagues at the University of Pennsylvania have succeeded in 
treating patients with Chronic Lymphocytic Leukemia using gene therapy. Two of the three 
patients treated sustained a complete remission and one a partial remission. The procedure 
involved transducing the patients’ T cells to express chimeric antigen receptors which target a 
particular protein found on both healthy and cancerous B cells. Following infusion of the 
newly transduced T cells, each patient developed clinical symptoms associated with an intense 
immune response. Shortly thereafter, tumors were completely eliminated in two of the patients 
and partially eliminated in the third. All three patients were pre-treated with conventional 
therapies and responded poorly. This study coalesces volumes of research in genetics, 
immunology, and molecular biology in what might just be the future of cancer treatment.  
INTRODUCTION 
Harnessing the body’s own immune system to battle cancer has always been 
understood by medical scientists as the ideal avenue for treatment. An astounding 
Phase-1 Clinical Trial recently conducted at the University of Pennsylvania (UP) may 
prove to be a breakthrough in this area. The study represents a culmination of twenty 
years of intense research in immunology and gene therapy. Dr. Carl June and his 
colleagues at UP treated three patients having advanced chemotherapy-resistant CLL 
(chronic lymphocytic leukemia), a cancer of B-Cells. The trial involved transducing 
the patients’ own T-cells to express chimeric antigen receptors, a fairly recent 
biomolecular invention, generally referred to as CARs (June et al. 2011). CARs, 
genetically engineered receptors, are generally comprised of a constant region that is 
similar to that of any T-cell receptor and a variable region that targets a specific 
antigen (Eshhar et al. 1989). With the correct genetic engineering and biomolecular 
construction, T-cells can be induced to express CARs that target a gamut of antigens. 
In the trial led by Dr. June, the patients’ T-cells were transduced via an HIV-1 based 
lentiviral vector to express a CAR with specificity for CD19 (cluster of differentiation 
19), a protein found on both healthy and cancerous B-cells. The modified cells are 
referred to as CART19 (chimeric antigen receptor T 19) cells.  
Following exogenous transduction, the patients’ T-cells were infused 
intravenously. Within one to three weeks, all three patients developed symptoms that 
were indicative of a serious immune response. The CAR T-cells expanded in vivo at 
least a thousand fold and successfully eliminated both healthy and cancerous B-cells. 
The effector-to-target (E/T) ratios observed in the patients were 1: 93,000; 1:2,200; 
and 1:1,000. Hence, in the patient with an E/T ratio of 1:93,000, an infusion of 1.4 x 
1011 CART19 cells resulted in the remarkable elimination of 1.3 x 1012 CLL cells.  Two 
of the three patients sustained complete remission, and one patient experienced a 
partial remission. Furthermore, in the two patients achieving complete remission, a 
population of memory CART19 cells was observed months after treatment, indicating 
the possibility of prolonged immuno-surveillance (June et al. 2011).  
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CHIMERIC ANTIGEN RECEPTORS  
The original construct of T-cells expressing chimeric antigen receptors was 
designed two decades ago by Dr. Zelig Eshhar and his colleagues at the Weizmann 
Institute of Science (Bridgeman et al. 2010). Their CAR T-cell was transduced with 
rearranged gene segments coding for the variable domain (VH and VL chains) of an 
anti-trinitrophenyl antibody attached to constant region (either alpha or beta) of a T-
cell receptor. The transmembrane and cytoplasmic domains of a typical T-cell receptor 
were maintained. The resulting T-cells then produced an efficient immune response 
when exposed to trinitrophenyl. In response to the hapten, the CAR T-cells 
proliferated, produced interleukin 2, and targeted cell lysis (Eshhar et al. 1989).  
The fact that T-cells can be endowed with antibody-type specificity is highly 
significant. Typically, T-cells only respond to an antigen that is bound to MHC (major 
histocompatibility) protein, either I or II. When antigen-presenting cells, such as 
macrophages; B cells; and dendritic cells, encounter an antigen, they process it. The 
procedure involves ingesting the foreign molecule, synthesizing an MHC molecule, 
fusing the two, and attaching this antigen-MHC complex to the plasma membrane of 
the cell. T-cells only respond to an antigen presented in this way. More specifically, 
CD4 cells react to antigens bound to MHC-II molecules, and CD8 cells respond to 
antigens that are bound to MHC-I molecules. The necessity of having an antigen 
bound to an MHC molecule in order to elicit an immune response in T-cells is known 
as MHC restriction (Tortora and Derrickson 2009). 
MHC restriction can be circumvented with CARs. Since the CAR has the 
variable region of an antibody, it acts as one. Antibodies react with antigens in their 
native state to elicit an immune response. Thus, CARs can be used to target antigens 
that would normally not be presented with an MHC molecule (Eshhar et al. 1989), 
such as in the UP trial where the CARs targeted the CD19 protein found on B cells. In 
addition, in situations where MHC-I may be somewhat down-regulated by tumors as 
part of a strategy to inhibit immuno-surveillance, the use of CARs in the treatment of 
cancer may be more favorable (Bridgeman et al. 2010).  
T-Cell activation usually requires two signals. One is delivered by the TCR-
CD3 complex which interacts with the MHC-antigen complex. The other is delivered 
by co-stimulatory domain CD28 when it interacts with the co-stimulatory molecules 
(such as CD80 or CD86) found on the antigen presenting cells. Other co-stimulatory 
domains, such as CD137 or CD134 may also be necessary.  
The optimal construction of CARs has been explored during the past two 
decades (Eshhar et al. 2001).  Naturally, the precise design would depend on the 
target antigen and efficacy of the CAR. As illustrated in Figure 1, first generation 
CARs consist of the single-chain variable fragment (scFv) of an immunoglobulin 
specific for antigen (usually a tumor antigen), bound to a hinge region that crosses the 
cell membrane. The hinge region is attached only to the CD3- ! chain of the TCR-CD3 
complex which plunges into the cytoplasm and acts as the signaling domain.  
To enhance effectiveness, second generation CARs have a co-stimulatory 
signaling domain, such as CD28, CD137 (4-1 BB), or OX40, inserted between the 
hinge region and the CD3- ! chain (Urba and Longo 2011). For example, inclusion of 
a CD137 co-stimulatory signaling domain significantly enhanced in vivo persistence of 
CARs and antitumor activity in preclinical trials (Kalos et al. 2011, as described in 
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June et al. 2009). Third generation CARs incorporate various combinations of co-
stimulatory domains (Urba and Longo 2011).  
!
Figure 1: T-Cell Activation.  
“Optimal T-cell activation requires a minimum of two signals. Signal 1 is delivered by the TCR–CD3 
complex through interaction of the T-cell receptor (TCR) alpha and beta chains as they recognize 
peptide presented by a class I (CD8 T cells) or class II (CD4 T cells) major histocompatibility 
complex (MHC) molecule. Signal 2 is most commonly provided by the engagement of CD28 on the 
T cell with the costimulatory molecule CD80 or CD86 on the antigen-presenting cell. CD137 (4-
1BB) and CD134 (OX40) also provide costimulation to T cells. The optimal combination of effector 
function, proliferation, and survival requires both signals. Delivery of signal 1 without costimulation, 
which often occurs for tumor-infiltrating lymphocytes and transgenic T cells encountering antigen 
on a solid tumor devoid of costimulatory molecules, leads to anergy and apoptosis, thereby limiting 
the antitumor response. The first-generation chimeric antigen receptors usually comprise of a single-
chain variable fragment of an antibody specific for tumor antigen, linked to the transmembrane and 
intracellular signaling domain of CD3-zeta. Second-generation chimeric antigen receptors were 
developed to incorporate the signaling domain of a costimulatory molecule to improve T-cell 
activation and expansion. Third-generation chimeric antigen receptors include combinations of 
costimulatory domains.” (Data are from Keith Bahjat, Ph.D.) Source: Urba and Longo 2011 
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Currently, expression of CARs on non T-cells is limited due to difficulties in 
transfection, although developments are underway. Furthermore, CARs only target 
molecules expressed on cell surfaces. Thus, intracellular tumor specific antigens would 
require a different approach (Bridgeman et al. 2010).  
HIV-1 BASED LENTIVIRAL VECTORS 
A key factor in effectively transducing T-cells, as in any other aspect of gene 
therapy, is choice of the vector. Safety; long-term stability; versatility; and, sometimes, 
the ability to transduce non-dividing cells are all taken into account (Lu et al. 2004). In 
the UP trial, an HIV-1 based lentiviral vector was used. Lentiviruses (lenti is the Latin 
word for “slow”) are thus named because of the long incubation period between 
infection and the onset of disease. What makes lentiviruses unique among retroviruses 
is their ability to infect non-dividing cells (Durand and Cimarelli 2011). Typically, a 
retrovirus must wait until the S phase of the cell cycle when it is afforded the 
opportunity of penetrating the nuclear membrane. Thus, it cannot infect the cell unless 
the cell is dividing. However, lentiviruses have the ability to integrate into the host’s 
genome by penetrating the nuclear membrane on their own (Lu et al. 2004). This 
makes them highly useful in gene therapy whose main targets include the brain, lungs, 
liver, muscles, and hematopoietic system (Zufferey et al. 1998). In addition, 
transcriptional silencing has been observed in the use of onco-retroviral vectors and 
not in the use of lentiviral vectors. In fact, lentiviral vectors have successfully 
integrated into a variety of tissues (Vigna and Naldini 2000). Furthermore, these 
vectors are capable of carrying large transgenes of up to 18,000 bases (Coleman et al. 
2003). One drawback of lentiviral vectors is that they integrate into the host’s genome 
at random locations. Sometimes, this may activate nearby oncogenes. A number of 
patients in a clinical trial undergoing gene therapy for SCID – "C (severe combined 
immunodeficiency) syndrome developed leukemia as a result of the use of lentiviruses 
(Durand and Cimarelli 2011). Only one virus is known to incorporate itself at a 
specific site in the human genome—the adeno-associated virus that partially integrates 
into the human chromosome 19q13.42. Scientists are attempting to find a way to 
transpose the site-specificity of the adeno-associated virus to lentiviruses (Durand and 
Cimarelli 2011).      
HIV STRUCTURE 
The HIV virus (Figure 
2) contains two copies of a 
single-stranded RNA 
measuring 9,749 nucleotides 
long enclosed in a capsid. 
Bound to the RNA are 
nucleocapsid proteins p6 and 
p7 (which prevent the RNA 
from digestion by nucleases) 
and enzymes such as reverse 
transcriptase and integrase. 
These enzymes allow the virus 
to transcribe DNA off its 
RNA and then integrate into Figure 2: HIV Structure. Source: Henderson C. 
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the host’s genetic material, respectively (Kuiken et al. 2008). Along the viral envelope 
are protein units that aid in attachment to the host cell. Each unit consists of three 
transmembrane subunits of glycoprotein 41 attached to three external subunits of 
glycoprotein 120 (Chan et al. 1997). Surrounding the capsid and anchoring these 
glycoproteins into the envelope is a matrix composed of the protein p17 (Kuiken et al. 
2008).  
HIV GENOME 
The typical HIV genome contains nine genes flanked by LTRs (long terminal 
repeats). The gag, pol, and env genes code for viral structural proteins. Gag codes for a 
p17 presursor, capsid protein p24, necleocapsid proteins p6 and p7, and spacer 
peptides. Pol codes for HIV protease, integrase, and reverse transcriptase. The env 
(envelope) gene codes for glycoprotein 160, a precursor to gp41 and gp 120 which are 
necessary for viral attachment to the host cell (Watts et al. 2009). 
Tat and rev are two regulatory genes. Tat activates expression of the viral RNA, 
and rev promotes cytoplasmic export of gag, pol, and env transcripts. Vif, nef, vpu, and vpr 
are accessory genes critical for 
pathogenesis but not for 
replication (Vigna and Naldini 
2000). 
CONSTRUCTION OF 
SAFE HIV-1 BASED 
VECTORS  
Constructing safe 
vectors presents many 
challenges. The virus must 
retain those genes necessary 
for efficient transduction of 
target cells. At the same time, 
genes that would enable the 
virus to reproduce and infect 
other cells following 
transduction must be 
eliminated.    
Effective transduction 
using the two-plasmid 
production approach involves 
the introduction of two 
genomic constructs into the 
target cell: a transfer vector 
construct (Figure 3) and a 
packaging construct, also 
known as the helper plasmid 
(Figure 4). The transfer vector 
construct contains cis- acting 
sequences that are vital for the 
transfer and integration of the 
Figure 3: Various HIV-1 derived transfer vector constructs. 
Source: Vigna and Naldini 2000 
 
Figure 4: Various HIV-1 derived packaging 
constructs/helper plasmids. Source: Vigna and Naldini 2000 
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viral genome into a host’s genome. The transgene is hooked onto the transfer vector 
construct. The packaging construct contains trans-acting genes that code for the 
essential viral proteins. When both constructs are introduced into the same cell, they 
express proteins necessary for encapsulation and integration of the transfer vector. As 
these vectors are carefully engineered to adhere to the highest standards of biosafety, 
this infectious process happens only once. This is due to efficient removal of genetic 
material that would enable the virus to proliferate and infect other cells.   
In first generation HIV-1 derived packaging constructs, all genes necessary for 
the production of structural and accessory proteins are maintained; only env is 
eliminated. In second-generation constructs, the accessory genes, vif, nef, vpu, and vpr 
are also absent. In the third generation, tat and rev are eliminated as well, although rev 
is expressed by a separate construct that is flanked by a rous sarcoma virus promoter 
and a polyadenylation signal. Thus, only three out of the original nine genes are 
expressed.  
Transfer vectors house the transgene as well as GA and RRE, which are placed 
adjacently between an LTR and the internal promoter. GA is a derivative of the gag 
gene, while RRE (rev-responsive element) is a portion of the env gene (Vigna and 
Naldini 2000). 
Elimination of most viral genes is necessary in order to avoid RCR (replication 
competent recombinants), which can happen if the trans-acting viral genes in the 
packaging constructs merge with the cis-acting sequences in the transfer vector. In 
fact, the biosafety of a vector depends on the extent of successful separation between 
the functions of the cis-acting and trans-acting viral genomes that comprise the transfer 
vector construct and packaging construct, respectively.  
To avoid the emergence of RCR, self-inactivating (SIN) transfer vectors have 
been designed. In a wild-type LTR transfer vector (non-SIN), the LTRs are 
maintained. In the SIN transfer vector, there is a large deletion in the U3 region of the 
3’ LTR. Upon transduction, this deletion is duplicated upstream, resulting in 
inactivation of both LTRs (Vigna and Naldini 2000). Thus, during reverse 
transcription, the deletion is transferred to the proviral DNA, resulting in ineffective 
transcription of the LTRs. This avoids the hazardous production of complete vector 
RNA, since the LTRs contain promoter and enhancer sequences. In addition, sabotage 
of the LTRs prevents aberrant expression of sequences in the host’s genome that are 
adjacent to the vector integration site. Transcription of the transgene is, instead, driven 
by an internal promoter that is nestled safely away from the cell’s native genome 
(Zufferey et al. 1998). 
The improved SIN transfer vector has some additional constituents. The 
central polypurine tract (cPPT) sequence (which provides increased transduction 
efficiency and transgene expression) of the pol gene is inserted just before the internal 
promoter in order to improve gene transfer performance. The post-transcriptional 
regulatory element of the woodchuck hepatitis virus (Wpre), which improves the 
performance of vectors, is inserted just after the transgene to enhance its expression 
(Vigna and Naldini 2000).!  
Lentiviral vectors, as observed by stable expression of marker genes in vivo, can 
successfully transduce a spectrum of cells. Neurons of adult rat brains were the first 
cells in which stable expression of lentiviral tranduction was observed (Vigna and 
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Naldini 2000, as described in Verma et al. 1996). Other cells that have been 
successfully transduced with lentiviral vectors include cells of the retina, liver cells of 
rodents (Miyoshi et al. 1997), human dendritic cells and  macrophages (Schroers et al. 
2000), and human CD34+ and CD38- hematopoietic cells (Case et al. 1999).  
FIRST LENTIVIRAL VECTOR EVALUATED IN HUMAN CELLS, 
VRX494 and its sister VRX496 were the first lentiviral vectors to be evaluated 
in human cells. The trial was conducted by Xiaobin Lu and his colleagues at the 
Sydney Kimmel Comprehensive Cancer Center of the John Hopkins School of 
Medicine. The HIV env gene is not eliminated from VRX494 and 496; instead, these 
vectors express a 937-base antisense to silence the gene. VRX496 contains a 186-base 
sequence that acts as a molecular marker and is derived from the Green Fluorescence 
Protein (GFP) gene. VRX494 has an enhanced GFP gene.  
The cells transduced in this experiment were human CD4+ T lymphocytes. 
Human blood was obtained, and CD4+ cells were isolated with the magnetic activated 
cell-sorting system. Flow cytometry indicated a purity >95%. The cells were then 
cultured in X-vivo 15 media containing 10% human serum and the antibiotic 
gentamycin. In preparation for transduction, the cells were plated in a 24-well plate at 
1 x 106 cells per well.  VRX494 was added to the cells at 20 tranducing units per cell. 
Concurrently, to ensure activation and expansion of the cells, immobilized anti-
CD3/CD28 (iCD3/28) antibodies were added at a ratio of three beads per cell as well 
as 100 U/ml of interleukin 2. The cells were then cultured for three days during which 
they were washed three times to remove the vector. The iCD3/28 beads were removed 
four days later. Finally, the lymphocytes were replated at half a million cells per ml. At 
this point, the culture was able to be maintained for a significant amount of time.  
After seven days in culture, the tranduced cells were assessed for GFP 
expression which would indicate successful integration. Flow cytometry indicated that 
99.4% of tranduced cells were positive for vector gene expression, while 99.9% of the 
control cells were negative.  
To measure stability of transduction, another batch of CD4+ T lymphocytes 
were transduced at 20 TU/cell as well. The cells were allowed to expand 1.5-million-
fold over 36 days during which GFP expression was monitored.  GFP expression 
remained stable throughout the entire culture period, demonstrating consistent vector 
payload expression. To date, no RCR generation has been reported in the use of 
VRX494 and VRX496 (Lu et al. 2004).  
CHIMERIC ANTIGEN RECEPTORS AND LENTIVIRAL VECTORS IN THE 
TREATMENT OF CANCER  
The recent pilot study conducted by Dr. Carl June and his colleagues at UP 
involved three patients with chemotherapy-resistant CLL. Two of them had p53-
deficient CLL, a 17p deletion that usually indicates poor response to conventional 
treatment. Before enrollment in the study, all the patients underwent standard 
therapies, such as rituximab, fludarabine and bendamustine. Nevertheless, all had 
significant tumor burdens right before the trial, including bone marrow infiltration and 
lymphoadenopathy. One patient also had peripheral lymphocytosis.  
The lentiviral vector used, GeMCRIS 0607-793 (Figure 5), was produced by 
Lentigen Corp. using a three-plasmid approach. It contained the transgene CD-19-
BB- ! which coded for a second-generation chimeric antigen receptor (Kalos et al. 
8 Efrat Bruck 
2011).  The receptor was comprised of the 
single-chain variable fragment (scFv) from 
the  human CD19-specific murine antibody 
(FMC63), a human CD8# hinge region, a 
human 4-1BB (CD137) co-stimulatory 
signaling domain, and a human CD3-! 
signaling domain (June et al. 2011). As 
previously mentioned, the inclusion of the 
4-1BB signaling domain considerably 
enhanced anti-tumor activity and in vivo 
persistence of CARs in preclinical trials. 
This effectiveness was also observed in the 
clinical trial.  
The patients’ cells were obtained via 
leukapheresis. Anti-CD3/CD28 mAB-
coated paramagnetic beads were used to 
positively select and activate T cells while 
remaining leukemic cells were depleted.  
GeMCRIS 0607-793, the lentiviral vector 
housing the transgene, was added to the 
culture and washed out three days later. 
The transduced cells were then allowed to 
expand for eight to ten days. Finally, the magnetic beads were removed by passing 
them through a magnetic field. The CART19 cells were collected, washed, 
concentrated, and cryopreserved in infusible medium (Kalos et al. 2011).   
PATIENTS’ RESPONSES 
One to four days preceding the infusion of tranduced T-cells, all the patients 
underwent a round of lymphodepleting chemotherapy.  Subsequently, each patient 
was infused intravenously with the transduced T cells over a three-day period as 
follows: 10%, 30%, and 60% of the dosage was infused on days one, two, and three, 
respectively. Patient UPN 03, the focus of this paper, began to have low-grade fevers 
associated with grade-2 fatigue two weeks after the infusion. Over the next few days, 
his temperature increased. Other symptoms, such as diarrhea, nausea, anorexia, and 
diaphoresis, were also observed. On day 22, he was diagnosed with tumor lysis 
syndrome, a metabolic complication that results when the kidneys are overburdened 
with a large load of destroyed tumor cells. The patient’s uric acid and lactate 
dehydrogenase levels were above normal at 10.6 mg/dL and 1130 U/L, respectively. A 
creatinine level of 2.6 mg/dL indicated acute kidney injury.  The patient was 
hospitalized and treated. His uric acid level returned to normal within 24 hours and 
the creatinine level within three days. He was discharged on the fourth day, and lactate 
dehydrogenase levels gradually decreased and returned to normal within a month.  
On day 23 after infusion of the CART19 cells, CLL was absent from the bone 
marrow (BM) of UPN 03. By day 28, adenopathy was not palpable, and on day 31, 
CT scanning showed its resolution. In 198 out of 200 cells examined, FISH testing was 
negative for the p53 deletion. Flow cytometry indicated B-cell aplasia and no residual 
CLL. Three months later, CT scanning showed sustained remission. In addition, at 
Figure 5: Lentiviral transfer vector construct 
used in the UP trial. The major functional 
elements of the transgene (represented by the 
sectional arrow labeled CD19BB !) are 
outlined in the bar at the bottom of Figure 5.  
Source: June et al. 2011 
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three and six months after infusion, studies of BM indicated no evidence of CLL as 
well as normal B cells (Figure 6). As of the publication of the study, remission has 
been sustained for ten months (June et al. 2011).   
Patient UPN 02 also developed fevers and was hospitalized after CART19 
infusion. Adenopathy was reduced somewhat, and p53 deficient CLL cells were 
eradicated from peripheral blood (PB). However, one month later, his BM was still 
infiltrated extensively with CLL cells. Thus, he had only sustained partial remission. !
Patient UPN 01 also developed symptoms upon infusion. No CLL cells were 
detected in his blood one and sixth months later. BM studies were performed one, 
three, and six months after infusion and indicated total absence of CLL cells. 
Adenopathy was resolved as observed by CT scans one and three months after 
infusion. He remained in remission for over ten months as of the publication of the 
study (Kalos et al. 2011).  
CART19 EFFECTOR-TO-CLL TARGET CELL RATIO 
In preclinical trials involving humanized mice, 2.2 x 107 CAR T cells were able 
to destroy tumors containing 1 x 109 cells (Kalos et al. 2011, as discussed in June et al. 
2009).  However, these calculations did not take into account in vivo expansion of the T 
cells. In the aforementioned UP trial, the three patients had their tumor loads 
estimated before infusion of the CAR T cells. This was done by calculating CLL cells 
in blood, bone marrow, and secondary lymphoid tissue. Patient UPN 03 had an 
estimated 8.8 x 1011 CLL cells in his bone marrow and 4.4 x 1011 CLL cells in 
secondary lymphoid tissue, totaling approximately 1.3 x 1012 tumor cells. His infusion 
contained only 1.4 x 107 CART19 cells. An astounding effector-to-target (E/T) ratio of 
1:93,000 resulted in complete elimination of CLL cells. The overwhelming 
effectiveness of the CART19 cells is most likely due, in part, to their in vivo expansion.  
The E/T ratios observed in patients UPN 01 and UPN 02 were 1:2200 and 1:1000, 
respectively (Kalos et al. 2011).  
SAFETY OF CART19 CELLS 
No long-term toxicity, other than B cell aplasia, was observed as a result of 
CART19 infusion. The patients did, however, develop transient febrile reactions and 
other short-term symptoms indicative of a serious immune response that coincided 
with tumor destruction (June et al. 2011). 
Figure 6: Bone marrow specimens of patient UPN 03. “The baseline specimen shows hypercellular bone 
marrow (60%) with trilineage hematopoiesis, infiltrated by predominantly interstitial aggregates of small, 
mature lymphocytes that account for 40% of total cellularity. The specimen obtained on day 23 shows 
residual lymphoid aggregates (10%) that were negative for chronic lymphoid leukemia (CLL), with a mixture 
of T cells and CD5-negative B cells. The specimen obtained 6 months after infusion shows trilineage 
hematopoiesis, without lymphoid aggregates and continued absence of CLL.” Source: June et al. 2001  
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CYTOKINES 
The patients’ immune responses were accompanied by sharp increases in 
cytokines. Peripheral blood and bone marrow samples were analyzed and significant 
increases in interleukin-6, (IL-6), IL-8, IL-10, and interferon-" (IFN- ") were 
observed in patients UPN 01 and 02. Levels of chemokines, such as CXCL9 and 
CXCL10, also rose. Cytokine and CART19 cell levels both peaked at the same time, 
coinciding with the patients’ clinical symptoms and eradication of tumor cells.  
The chimeric antigen receptor used in this trial contained a 4-1BB signaling 
domain as opposed to CD28. CARs containing a CD28 signaling domain are 
associated with increased levels of IL-2 and tumor necrosis factor-# both of which are 
undesirable. Previous studies have shown that high levels of IL-2 suppress CAR T 
cells, and TNF-# is associated with cytokine-storm effects. Levels of IL-2 and TNF-# 
did not rise in any of the patients (Kalos et al. 2011).  
IN VIVO EXPANSION, PERSISTANCE, AND BONE MARROW 
TRAFFICKING  
On the first day after infusion, real-time PCR detected expression of the anti-
CD19 CARs in patient UPN 03. The doubling time of CART19 cells was 
approximately 1.2 days. By day 21, a 3-log expansion of the cells was observed. 
CART19 cells comprised over 20% of circulating lymphocytes at peak levels, 
coinciding with the elevated levels of serum cytokines and the tumor lysis syndrome. 
Six months after infusion, CART19 levels were still significantly high, although they 
decreased by a factor of ten.  The elimination half-life of the cells was 31 days. 
CART19 cells were also detected in the bone marrow beginning on day 23 and 
remained there for at least six months. Their half-life in the BM was 34 days, slightly 
longer than those in circulation. Three months after treatment, no CD19 or normal B 
cells were detected (June et al. 2011).  Interestingly, none of the patients had an 
immune response targeting the CART19 cells even though they contained murine-
derived segments. This may be due to the patients’ severely compromised immune 
systems resulting from heavy pretreatment of CLL (Kalos et al. 2011).  
LONG-TERM EXPRESSION AND ESTABLISHMENT OF MEMORY 
In previous studies that have been conducted, CART cells have not been 
effective for prolonged periods of time. The long-term success of CART19 cells in the 
UP trial may be due to improved construction of the CAR. Several months after 
infusion, the values obtained by PCR for the prevalence of the CAR transgene closely 
matched those obtained by flow cytometry for the frequency of circulating CART19 
cells.  Blood and BM samples of UPN 03 that were analyzed by flow cytometry 169 
days after infusion indicated the presence of CART19 cells and complete absence of B 
cells. In all three patients, PCR indicated that CART19 cells persisted for at least four 
months. At 71 days after infusion, 5.7% of the T cells in the blood of patient UPN 01 
expressed CARs, and on day 286, 1.7% expressed CARs. Although small, these 
percentages indicate long-term expression of a CART19 population, possibly 
indicating long-term immunity too. 
Polychromatic flow cytometry was also performed to study the function and 
phenotype of CART19 cells in patient UPN 03. On day 56, CART19 CD8+ cells 
expressed an effector memory phenotype which is normally stimulated by prolonged 
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exposure to an antigen. By day 169, some of the CART19 CD4+ cells expressed a 
central memory phenotype, as indicated by CCR7 and CD127 expression, both of 
which are associated with memory T cells. B cell progenitors in the BM could ensure 
that CART19 cells maintain a memory population, thereby providing long-term 
immunity to CLL with the use of CART19 cells (June et al. 2011).  
CONCLUSION 
Decades of research in genetics, immunology, and molecular biology have 
culminated in the ability of medical scientists to treat patients with CLL with 
autologous T cells. In the UP trial of Dr. Carl June and his colleagues, two out of 
three patients enrolled in the study have reached total remission, and one achieved 
partial remission. The engineering of chimeric antigen receptors, the ability to use 
lentiviral vectors to transduce T cells to express them, and the in vivo expansion and 
persistence of these CAR cells all represent monumental breakthroughs that will, 
hopefully, be transposed to other areas of medicine as well.   
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INTRODUCTION 
Parkinson’s disease was first described and named Paralysis Agitans in 1817 by 
British physician James Parkinson (Lieberman 2004). Later on, it took on its current 
name after Dr. Parkinson. Parkinson’s disease (PD) is a neurological disorder for 
which the cause is yet to be discovered. Like many other diseases, PD has numerous 
facets. Throughout all of its different stages, it presents with motor, as well as non-
motor, symptoms (Simuni et al. 2009). Though estimates of people affected by PD are 
constantly being made, it is difficult to determine a precise and accurate number. This 
difficulty arises since symptoms are often mistaken for other diseases of the nervous 
system (jointly known as Parkinsonism) or are mistakenly attributed to the normal 
aging process. It is estimated that over 1 million people in North America are affected 
by this degenerative disorder. As life expectancy increases, incidence of the disease 
rises (Lang and Lozano 1998). 
The mortality rate of PD patients is 2-5 times greater than age-matched 
controls; this alone indicates the significance of its impact. It is predicted that, by the 
year 2040, Parkinson’s disease will surpass cancer as the second leading cause of death 
among the aged (Bennett et al. 1996). 
NEUROPATHOLOGY 
Parkinson’s disease is characterized by slow movement, rigidity, and 
involuntary movement, which occur because of death to dopamine-producing neurons. 
Dopamine is the main neurotransmitter to be affected by the disease, although it is not 
the only one; serotonin, acetylcholine, and norepinephrine are other affected 
neurotransmitters.  However, their contribution to clinical symptoms is unknown.  
The striatonigral complex is the region of the brain that is the source for the 
majority of the brain’s dopamine.  It includes the putamen, caudate, and substantia 
nigra; the substantia nigra is the main source of dopamine in the region. There are 5 
dopamine receptors (D1-D5) found in various brain regions that include the cortex, 
striatum, and limbic system (Macphee and Stewart 2007).  Three of the receptors (D1, 
D2, and D3) are present in the basal ganglia. D1 and D2 receptors are known to 
promote voluntary movement; D3’s function is unknown. The limbic system, which 
controls emotion, contains D3, D4, and D5 receptors; thus, the dopamine deficiency of 
PD leads to the cognitive and emotional impairments associated with PD (Rezak 
2007).  
The basal ganglia have a circuit that enables voluntary and involuntary 
movement (Macphee and Stewart 2007). Nigral cells have axons that extend into the 
putamen and caudate nucleus. The globus pallidus located near this complex regularly 
inhibits movement by releasing the neurotransmitter gamma amino butyric acid 
(GABA), an inhibitory neurotransmitter, to the thalamus, which prevents the motor 
cortex from being excited. The substantia nigra excites the caudate and putamen via 
the transmission of dopamine, which then informs the globus pallidus as to which 
forms of movement it should stop inhibiting. Thus, dopamine is necessary for motor 
output and decreased stimulation by dopamine causes decreased motor output (Kalat 
2009). 
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The distinguishing characteristic of Parkinson’s disease was once thought to be 
the presence of Lewy bodies. However, not all forms of the disease have this 
pathological feature. For example, those that are classified as autosomal recessive cases 
do not have Lewy bodies. In autosomal dominant cases, however, Lewy bodies are 
seen (Macphee and Stewart 2007). Lewy bodies are spherically shaped protein masses 
and contain transparent cytoplasmic centers with halos surrounding them. The center 
consists of neurofilaments and other proteins accountable for proteolysis (protein 
breakdown) including parkin, ubiquitin, and alpha synuclein. In those patients who 
experience Lewy bodies, Lewy bodies appear in all affected areas of the brain (Dauer 
and Przedborski 2003). The mechanism of formation of Lewy bodies and their 
function in the pathology of the disease is not yet known (Lang and Lozano 1998). 
Many areas of the brain are affected by the disease. The most significant 
damage occurs in the pars compacta, the posterior part of the substantia nigra 
(Macphee and Stewart 2007). This region is located in the midbrain, midway between 
the cerebral cortex and the spinal cord (Lieberman 2004). Most of the motor 
symptoms associated with the disease occur because of damage to this area. Motor 
symptoms begin to appear after the majority of the cells in this area are lost. Damage 
to the nucleus basalis, an area of the brain that produces an abundance of the 
neurotransmitter acetylcholine, is correlated with impaired memory and cognitive 
function in PD patients (Macphee and Stewart 2007). 
The pars compacta has both anterior and posterior parts to it. The posterior 
part is pigmented with neuromelanin, whereas the anterior is considerably lighter, as it 
lacks this pigment. Normal aging is consistent with cell loss in the posterior region. 
PD, on the other hand, impairs the anterior region. This shows that Parkinson’s 
disease is not an effect of advanced aging (Macphee and Stewart 2007). 
Studies show that neurological symptoms of Parkinson’s disease develop in an 
upward manner. The disease starts with damage to the brainstem and advances 
upward to the cerebral cortex. The disease can be divided into six stages, each 
associated with the onset of specific neurological symptoms (Macphee and Stewart 
2007). In the first two stages, symptoms are not apparent (Davie 2008). 
CAUSES 
GENETIC CAUSES 
Most incidences of PD occur sporadically, rather than from genetic causes 
(Wood-Kaczmar et al. 2006). Onset generally occurs at younger ages in genetic forms 
of the disease and pathological symptoms are different (Vila and Przedborski 2004). 
Genetic inheritance of PD occurs in both autosomal dominant and autosomal recessive 
forms (Wood-Kaczmar et al. 2006). Dominantly inherited Parkinson’s was first 
discovered in the 1990s upon studying a familial case. Alpha-synuclein was the gene 
identified as causing PD (Cordato and Chan 2004). Several other genes involved in 
the onset of the disease have been located since that initial discovery (Vila and 
Przedborski 2004). 
ALPHA SYNUCLEIN 
A mutated SNCA gene, which encodes the alpha synuclein protein, has an 
altered sequence of nucleotides (Vila and Przedborski 2004) and therefore codes for a 
different protein product (Klug et al. 2006). Three types of mutations were found that 
link this gene to Parkinson’s disease. These genetic mutations are only associated with 
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dominant inheritance (Wood-Kaczmar et al. 2006).  Mutations in SNCA are thought to 
account for a small percentage of Parkinson’s disease since it was found in a small 
number of studied hereditary cases (Lang, and Lozano 1998). 
Alpha synuclein is made up of 140 amino acids and is present in several 
locations of the brain. It is found in the highest concentrations in the cortex, 
hippocampus (Wood-Kaczmar et al. 2006), hypothalamus, olfactory neurons, and 
substantia nigra. Neural and glial cells produce this protein, which is mainly found at 
pre-synapses. Alpha synuclein has the shape of an alpha helix and is found in vesicles 
that transport lipids.  
Studies were done on mice by transferring a gene from another organism to 
replace the gene that encodes for alpha synuclein, in order to test its function in living 
organisms. Absence of alpha synuclein showed fewer proteins at synapses and fewer 
vesicles available for transport (Cordato and Chan 2004). Its function is not well 
understood, although it is thought to play a role in transmission of chemical messages, 
learning, and neuroplasticity (the ability for neurons to adapt to environmental stimuli) 
(Wood-Kaczmar et al. 2006).  
Alpha synuclein can also be harmful.  In high concentrations, these proteins 
cluster together to form polypeptides that are associated with various diseases. These 
unwanted protein accumulations are normally broken down by enzymes that specialize 
in getting rid of harmful material to the cell. Toxicity to neurons can happen if mutated 
SNCA produces alpha synuclein proteins that are more likely to clump together or are 
folded in such a way that makes it difficult for enzymes to break them down. These 
proteins are part of Lewy body formation and are thought to cause cell death by 
breaking down the proteins of neurons (Cordato and Chan 2004).  
LEUCINE-RICH REPEAT KINASE 2 
A number of mutations in the gene that encodes for leucine-rich repeat kinase 2 
(LLRK2) have been located in late-onset dominantly inherited PD. The most common 
one is substitution of the G2019S gene. This mutation generally accounts for a small 
percentage of genetically inherited PD. It contributes to a significantly greater 
percentage of PD in North African Arabs and Ashkenazic Jews. The role of this 
protein and its contribution to the disease is not yet understood (Wood-Kaczmar et al. 
2006).  
PARKIN 
Parkin is made up of 465 amino acids. It is one of many proteins that have a 
ring finger domain. Proteins that have this characteristic are able to act as ubiquitin 
ligases by breaking down harmful protein buildup, such as buildup of alpha synuclein. 
Mutations in the gene that encodes for parkin, PARK2, are due to recessive inheritance 
and are consistent with early-onset PD (Cordato and Chan 2004). Mutations of 
PARK2 and alterations in parkin’s post-translational state cause parkin’s inability to 
target certain forms of alpha synuclein for breakdown, which can lead to build-up of 
alpha synuclein and toxicity to neurons (Vila and Przedborski 2004). In addition, 
mutations in other proteins do not permit parkin to carry out its job properly, resulting 
in toxic accumulation (Wood-Kaczmar et al. 2006).  PARK2 mutations cause death to 
cells of the substantia nigra and locus ceruleus (Cordato and Chan 2004).  
Parkin functions as an ubiquitin enzyme marking its target cell for destruction. 
Lewy bodies form when a sequence of ubiquitin enzymes binds to a target protein and 
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is unable to break it down. In its mutated forms, parkin cannot bind to its target 
proteins; thus, Lewy bodies are not seen in this instance (Cordato and Chan 2004).   
The two types of mutations (Wood-Kaczmar et al. 2006) in the PARK2 gene 
(missense and nonsense mutations) cause very similar symptoms, such as early onset 
(usually occurring before age 30) (Cordato and Chan 2004; Vila and Przedborski 
2004), degeneration at a slower pace, receptiveness to levodopa (a medication used to 
treat motor symptoms of PD) (Macphee and Stewart 2007), and susceptibility to side 
effects of levodopa early on (Cordato and Chan 2004). Mutations in the PARK2 gene 
account for 50 percent of early-onset familial PD and for 77 percent of early-onset 
sporadic cases (Wood-Kaczmar et al. 2006). 
PARK7  
The gene PARK7 codes for DJ-1, a protein with many functions. It is found 
scattered in many areas of the brain. Several recessive mutations link this protein to 
PD. Compared to mutations in PARK2, mutations in DJ-1 account for a small amount 
of early onset PD. Mutations occur in various areas of the gene, yet they cause the 
same symptoms (Vila and Przedborski 2004). The normal function of DJ-1 is to 
stabilize proteins, while protecting them from damage by free radicals. Studies on mice 
that lack DJ-1 have shown dysfunction of dopamine pathways, causing motor 
disability (Wood-Kaczmar et al. 2006).  
ENVIRONMENTAL CAUSES 
The development of PD in a group of drug users was linked to the intake of a 
drug containing methyl-phenyl-tetrahydropyridine (MPTP). MPTP has been shown 
to cause degeneration specifically in the nigral cells, by decreasing complex 1 (the first 
enzyme of the respiratory chain leading to the production of ATP) activity of the 
mitochondria. The discovery that environmental toxins can lead to the onset of PD has 
led researchers to extend their studies to pesticides and herbicides to test their 
contribution to the disease (de Lau and Breteler 2006). Rotenone is an agent 
commonly used by gardeners to prevent unwanted plant growth. Repeated exposure to 
this chemical in low doses has also been shown to cause degeneration specific to nigral 
cells. Studies show that exposure to this pesticide is linked to the formation of Lewy 
bodies, a major component of the PD, whereas exposure to MPTP has not yielded 
such results (Jenner 2001). It has been hypothesized that exposure and accumulation 
of heavy metals, such as aluminum, amalgam, copper, iron, manganese, zinc, etc., in 
the substantia nigra may cause an increased risk of PD by causing oxidative damage 
(de Lau and Breteler 2006).  
SYMPTOMS 
MOTOR SYMPTOMS 
A number of motor features, including bradykinesia (slow movement), a resting 
tremor, muscle rigidity, and postural instability, distinguish PD from Parkinsonism. 
There are several scales to assess the rate of decline in PD patients. Two widely used 
scales are the Hoehn and Yahr, and the Unified Parkinson’s disease rating scale 
(UPDRS). The Hoehn and Yahr, a scale that ranges from 0 (no symptoms) to 5 
(bedridden) evaluates how far the disease has progressed. The UPDRS, on the other 
hand, is used to determine speed of progression of the disease. This scale is currently 
being modified to include non-motor symptoms of PD (Jankovic 2007). 
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The most apparent symptom of the disease is bradykinesia, or decreased 
movement. Bradykinesia adds difficulty to daily activity management, leading to an 
inability to initiate, plan, multitask, and/or carry out tasks in a consecutive order. Slow 
movement affects fine motor function such as buttoning a garment and handling 
utensils. Spontaneous movement, such as blinking, facial expressions, and arm 
swaying while walking, is also impaired. These hindrances are due to reduced 
dopamine activity, which causes a decrease in motor output (Jankovic 2007).  
Slowness of movement is related to the patient’s emotional state, not their motor 
abilities.  Thus, when an external stimulus, such as a yell of “Fire” or a signal telling 
them to beware of an obstacle, informs them of the need for quick movement, they 
regain the ability to move quickly (Jankovic 2007). 
According to studies (Gelb et al. 1999), the most common symptom of PD 
(Jankovic 2007), which occurs in 79-90 percent of patients, is a resting tremor. Hand 
tremors begin on one side of the body and spread to the other. It is noticeable on the 
lateral parts of the hand or leg. Tremors may also affect the chin, jaw, lips, and legs. 
Tremors are not apparent while sleeping or in the course of action (Jankovic 2007).  
Another feature seen in PD is stiffness, which can occur in several areas, such 
as the ankles, hips, neck, shoulders, and wrist. Stiffness can be accompanied by pain. A 
study found that rigidity, along with tremor and imbalance, was associated with an 
increased risk of PD in individuals who initially showed no signs of Parkinsonism 
(Jankovic 2007). 
 Rigidity can also cause bending of the elbows, knees, neck, and/or trunk. It can 
also lead to striatal hand or foot, which occurs when the thumb or big toe is extended 
while the joint by the knuckles and other toes are bent. These abnormalities usually 
occur later on in the disease and are generally associated with early onset of the disease 
(Jankovic 2007).  
Postural instability usually arises in later stages of the disease. This symptom is 
the source for many falls that often cause hip fractures. One study indicated a wait of 
nine years for patients to experience their first fall. Interestingly, patients who fear 
falling show an increased incidence of falling. Unlike other symptoms, postural 
imbalance is generally untreatable by therapy (Jankovic 2007).  
NON-MOTOR SYMPTOMS 
Non-motor aspects of PD are currently receiving increased attention, since 
they affect the quality of life of patients significantly (Macphee and Stewart 2007). 
Non-motor features consist of autonomic dysfunction, sleep disorders, and impaired 
cognitive function (Jankovic 2007).  
Autonomic dysfunction includes sweating, constipation, erectile dysfunction, 
orthostatic hypotension (a sudden decrease in blood pressure when the patient stands 
up) (Jankovic 2007), and reduced olfaction (Chaudhuri et al. 2006). Constipation is a 
common symptom that can serve as a precursor to PD. A study done over a period of 
24 years showed that men who originally had constipation were three times more likely 
to develop PD, following a 10 year interval. Both elevated and decreased sex drive 
were reported by patients.  Ninety percent of PD patients develop problems with their 
sense of smell. A number of studies concluded that decreased sense of smell is an early 
sign of motor symptoms in PD. Many relatives of patients who reported reduced 
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olfaction but did not report any other symptoms of PD were later diagnosed with PD 
(Chaudhuri et al. 2006).  
Sleep disruption was once thought to be a side effect of treatment for 
Parkinson’s. Several doctors now believe that it is a component of the disease. About 
one third of PD patients have rapid eye movement sleep behavior disorder where a 
dream accompanies dramatic motor movement. Insomnia occurs in over 50 percent of 
patients (Jankovic 2007). Sleepiness during daytime hours is common and may result 
from sleep disruption at night or as an outcome of treatment (Macphee and Stewart 
2007).  Degeneration of neurons in the brain’s sleep regulation centers in the 
thalamocortical pathway and brainstem contribute to sleep disorders (Chaudhuri et al. 
2006).  
Studies have found decreased cognitive ability in nearly 85 percent of PD 
patients, while close to half of them developed dementia. Dementia in PD patients 
usually accompanies neuropsychiatric disorders. A study comprising 537 PD patients 
showed that close to 50 percent experienced anxiety, apathy, depression, and 
hallucinations. Other studies reveal that many patients display various forms of 
impulsive behavior, such as cravings, hypersexuality, obsession with shopping, 
pathological gambling, etc. These behaviors develop as a result of taking levodopa 
(Jankovic 2007), a medication used to treat PD (Macphee and Stewart 2007).  
PREVENTION 
Several case-control and population-based studies from numerous countries 
showed a significantly decreased risk for PD among cigarette smokers. The 
mechanism of cigarette smoking decreasing the risk of PD is not well understood. It is 
possible that nicotine in cigarettes stimulates dopamine release.  
Several studies also found consumption of coffee to be consistent with a 
reduced risk for PD. The effective component in coffee is perhaps caffeine, because 
other studies showed a decreased risk for PD from taking in other sources of caffeine. 
According to studies, caffeine has a greater protective effect on men than woman (de 
Lau and Breteler 2006).  
A third factor that may reduce risk of PD is alcohol consumption.  Some 
studies found a decreased risk with alcohol consumption.  Others, though, found no 
association (de Lau and Breteler 2006). 
DIAGNOSIS 
The main symptoms of PD at the time of diagnosis include rigidity, 
bradykinesia, and a resting tremor (Davie 2008). Postural instability is usually not 
present during diagnosis since it typically manifests itself later on in the disease 
(Jankovic 2007). Symptomatic features are generally not present on both sides of the 
body. Handwriting change and decreased facial expressions can be detected. 
Decreased olfaction can be reported since it is usually an early symptom of PD. Post-
mortem studies showed that diagnosis of PD by a neurologist reflected a 25 percent 
misdiagnosis rate. Patients who were diagnosed in a clinic that specialized in 
movement disorders indicated less diagnostic inaccuracy. It is thus important to see an 
expert in the field to ensure proper diagnosis (Davie 2008).  
There are several Parkinsonism disorders that can easily be mixed up with PD.  
Diagnosis of PD normally takes place in a clinical setting. Sometimes brain images 
using magnetic resonance imaging (MRI) and computed tomography (CT) are 
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necessary to rule out other Parkinsonism diseases.  Using single emission 
computerized tomography (SPECT), other conditions can be ruled out (Davie 2008).  
TREATMENT OF MOTOR SYMPTOMS 
LEVODOPA 
Each patient requires treatment dedicated to his or her specific symptoms and 
needs (Rezak 2007). Since the 1960s, levodopa has been the main drug used in 
treatment of PD (Schapira et al. 2006). Levodopa greatly reduces symptoms of rigidity 
and bradykinesia, but has a lesser effect on tremors (Macphee and Stewart 2007). 
Levodopa is currently the most effective drug on the market. However, since 
levodopa’s effectiveness lasts for about ten years (Rezak 2007), it is held back from 
patients or given at low doses until it is absolutely necessary.  
In order to reduce its side effects, levodopa may be combined with other drugs.  
Levodopa, a dopamine precursor, is usually combined with a decarboxylase inhibitor 
(Macphee and Stewart 2007), such as carbidopa or benserazide. These inhibitors 
occupy receptors on the enzyme dopa decarboxylase, thus preventing levodopa’s 
conversion to dopamine before it reaches the brain. Decarboxylase inhibitors help 
alleviate side effects that accompany levodopa such as excessive sweating, low blood 
pressure, and nausea. Another drug that may be combined with levodopa and 
carbidopa is entacapone. This drug inhibits catechol-o-methyl-transferase, an enzyme 
that breaks down neurotransmitters, causing increased uptake of levodopa in the 
intestines.  
Even when combined with other drugs, there are possible side effects that 
accompany levodopa (Rezak 2007). After five years of taking levodopa, 50 percent of 
patients may develop (Lieberman 2004) dyskinesia, motor fluctuations, hallucinations, 
sleepiness, nausea, and/or low blood pressure (Rao et al. 2006). Levodopa induced 
motor fluctuations can range between wearing off of dosage and unsystematic severe 
on and off motor functioning. Levodopa’s half-life of 60-90 minutes causes a spurt of 
dopamine receptor activation. The occurrence of continuous abrupt spurts of 
dopamine receptor activation at the same time as the constant death of dopamine-
producing cells causes abnormal receptor activation known as the “on-off” 
phenomenon. Initially, levodopa is prescribed very sparingly in order to protect 
patients from its adverse side effects (Rezak 2007). 
DOPAMINE AGONISTS 
Dopamine agonists activate dopamine receptors by mimicking the actions of 
dopamine (Lieberman 2004). They include bromocriptine, cabergoline, lisuride, 
pergolide, pramipexole, ropinerole, and rotigotine (Macphee and Stewart 2007). 
Dopamine agonists, which have been previously prescribed together with levodopa, 
are currently being given alone as an early PD treatment, thereby delaying the 
administration of levodopa. Pramipexole, ropinerole (Rezak 2007), and rotigotine are 
currently the most prescribed dopamine agonists (Davie 2008). Studies comparing the 
effects of pramipexole and ropinerole against levodopa have shown a decreased rate of 
progression of PD with levodopa use. The dopamine agonists, however, showed less 
motor complications (Rao et al. 2006). With advancement of the disease, dopamine 
receptor agonists are commonly taken with levodopa/carbidopa to reduce levodopa’s 
accompanied motor complications (Lieberman 2004). Possible side effects of 
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pramipexole and ropinerole can include low blood pressure, dyskinesia, abnormal 
sleep patterns, impulsive behavior, and cognitive/psychiatric impairments. Unlike the 
other dopamine agonists, rotigotine is administered through a transdermal patch and is 
absorbed over a 24-hour period, thereby continuously stimulating dopamine receptors. 
Pergolide, bromocriptine (Rezak 2007), cabergoline, and lisuride are not prescribed 
that often since they cause cardiac valve degeneration (Davie 2008). 
MONOAMINE OXIDASE-B INHIBITORS (MAO-B) 
The enzyme monoamine oxidase-B (MAO-B) is responsible for degrading most 
of the dopamine in the basal ganglia. Selegiline and rasagiline are two drugs that 
inhibit this enzyme causing increased levels of available dopamine (Rezak 2007). Like 
dopamine agonists, selegiline can either be used alone to treat symptoms while 
delaying levodopa therapy or be joined with levodopa to reduce motor fluctuations 
(Macphee and Stewart 2007). Insomnia and nausea are potential side effects of this 
drug (Rao et al. 2006). Rasagiline is a newer and more powerful MAO-B inhibitor 
than selegiline. Rasagiline is an effective monotherapy in early PD as well as a 
preventer of motor fluctuations when taken with levodopa later on in the disease’s 
progression (Rezak 2007). Compared to a placebo, when taken with levodopa, 
rasagiline has shown to decrease motor fluctuations by one more hour per day 
(Macphee and Stewart 2007).   
CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT-I) 
Catechol-O-methyltransferase is an enzyme present in several locations, 
including the intestines, liver, kidneys, neural cells and glial cells. The goal of 
tolcapone and entacapone, the two catechol-O-methyltransferase inhibitors (COMT-
I), is to prevent motor fluctuations resulting from the wearing off of levodopa's effects 
between doses (Macphee and Stewart 2007). These drugs can improve symptoms and 
effectively reduce the dose of levodopa (Rao et al. 2006). COMT-I drugs inhibit 
metabolism of levodopa by COMT in the gastrointestinal tract, thus increasing the 
amount of levodopa reaching the substantia nigra and thereby enabling levodopa’s 
conversion to dopamine. In addition to increasing the availability of levodopa to the 
brain, tolcapone and entacapone also prolong the duration of levodopa's metabolism. 
COMT inhibitors can be good treatments for early Parkinson's disease. They delay the 
onset of levodopa's motor complications by stabilizing the blood concentration of 
levodopa and effectively decreasing peak dosage, via the increase of levodopa's half-life 
(Rezak 2007).  
COMT-I drugs can have negative effects as well.  Diarrhea can occur as a side 
effect (Rao et al. 2006), necessitating discontinuation of the drug. The addition of 
COMT inhibitors to levodopa therapy causes increased dopaminergic stimulation, 
possibly resulting in dyskinesia. Such cases may call for decreased dosage. Since 
tolcapone has been shown to cause hepatotoxicity, the FDA requires patients' liver 
enzymes to be monitored (Rezak 2007); it is thus given only when entacapone proves 
to be ineffective (Macphee and Stewart 2007). Although it has a shorter half-life and is 
less effective, entacapone is still more frequently used (Rezak 2007).  
AMANTADINE 
 Amantadine, initially an antiviral drug, was discovered to be useful in 
PD treatment (Lieberman 2004) by improving dopamine release from presynaptic 
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terminals (Rezak 2007) and acting as an anticholinergic agent, which prevents 
glutamate activation of N-methyl-D-aspartate (NMDA) receptors (Lieberman 2004). 
Overstimulation of NMDA receptors are linked to dopaminergic death in PD. 
Amantadine’s impact on treating symptoms is greatest for tremor and it has its greatest 
effects in the early PD stages. It has also shown to reduce dyskinesia associated with 
levodopa (Rezak 2007). Side effects of this drug may include hallucinations, confusion, 
hypotension, nausea, and edema (Rao et al. 2006).  
Source: Cordato and Chan 2004 
Table 1: FDA Approved Medications for Parkinson’s Disease 
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ANTICHOLINERGICS 
Anticholinergic drugs also treat tremor in PD. Trihexyphenidyl, benztropine, 
and procyclidine, are the most commonly used anticholinergic drugs. Due to their 
adverse effects, they should not be given to the elderly. Side effects of anticholinergic 
drugs can include blurred vision (Rezak 2007), dry mouth, hypotension, constipation 
and cognitive impairment (Rao et al. 2006). 
SURGERY 
Brain surgery used to be a common method for treating tremor and rigidity in 
Parkinson patients, although success rates varied and detrimental risk factors such as 
death were involved. However, with the advent of levodopa in the 1960s, which 
proved to be a safer and more effective option for treatment, the idea of surgery 
diminished. With advances in neuroimaging, surgery has regained popularity as a 
treatment for PD among those who do not respond to drug therapy anymore 
(Lieberman 2004). 
With greater understanding of the neuropathology involved in PD, two 
ablative procedures are renewably performed (Arle and Alterman 1999) to help 
control symptoms of PD (Lieberman 2004). A thalamotomy involves destroying part 
of the ventrolateral thalamus, a brain region involved in transmitting signals that 
control movement. This procedure significantly reduces tremor but shows little 
improvement to symptoms of rigidity and bradykinesia. Death rates are less than 1 
percent due to better targeting and lesion technique. Since thalamotomy does not 
significantly improve many symptoms of PD, it is less favored than pallidotomy (Arle 
and Alterman 1999). 
In a pallidotomy, the globus pallidus, a brain area responsible for involuntary 
intermittent movements in PD patients, is targeted (Lieberman 2004).  Pallidotomy 
has been shown to greatly reduce rigidity, bradykinesia, and tremor. Patients taking 
levodopa can also benefit from this procedure because it decreases the "off" period in 
their motor fluctuations. Better UPDRS scores were reported for up to 2 years 
following this procedure (Arle and Alterman 1999). 
Deep brain stimulation has become more common now because of its 
effectiveness. The head of the patient is placed in a stereotaxic frame, a halo-like 
device. Surgeons can spot the thalamus, globus pallidus, or the subthalamic nucleus 
through MRI on the brain. The skull is pierced, using a drill, and a probe is placed 
deep inside the brain to reach the target tissue. The probe transmits a burst of 
electricity, which causes the brain region’s electrical activity to normalize reversing PD 
symptoms. This is a safe surgery and results can be seen immediately (Lieberman 
2004).  
STEM CELL THERAPY 
Currently there is no cure for PD. Embryonic stem cells and stem cells that 
come from fetal brains and adult bone marrow have been successfully transformed into 
functioning dopamine producing cells. However, there are several setbacks. Use of 
embryonic stem cells is controversial (Arias-Carrion and Yuan 2009) as many people 
believe that fetal tissue should not be used for research as a fetus is unable to consent 
(McLaren 2001). Many believe that adult stem cells have much to offer for future 
treatment of degenerative diseases such as PD. Previously, adult stem cells have been 
scarce, but recent progress enables their use in large quantities. Adult stem cells can be 
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implanted into the brain where it can differentiate into neural cells. With a better 
understanding of the immune system and successful transplantation, the use of stem 
cells is under serious consideration for treating the various dimensions of PD. It is 
hypothesized that stem cells should come from the very same patient who will derive 
benefit from it; however, not much is known about this type of implantation. The 
current goal under study is to test the use of autologous stem cell transplant in animals, 
and further the findings to clinical studies (Arias-Carrion and Yuan 2009). 
CONCLUSION 
Parkinson's disease is a multi-dimensional disease for which there is currently 
no cure. Much advancement has been made in the treatment of PD symptoms as 
opposed to curing it. Current research is giving increased attention to treatment of 
non-motor symptoms since it greatly affects the quality of life of patients. Additionally, 
increasing focus is being given to stem cell research as a potential cure for Parkinson’s 
disease by using the patient’s own stem cells to repair their damaged dopaminergic 
tissue. 
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HOW ARE DRUG THERAPEUTIC LEVELS MAINTAINED WHILE 
AVOIDING DANGEROUS SIDE EFFECTS ASSOCIATED WITH 
CONVENTIONAL IMMEDIATE-RELEASE DOSAGES? 
Chedva Farkas 
INTRODUCTION 
Ever since the discovery of bacteria and their role in the disease process in the 
mid-1800s, scientists have been heavily involved in the discovery and development of 
drug therapies and their mechanism of action in the human body.  Shortly after the 
initial discovery came the era of drug discovery of the late 1800s-early 1900s, also 
known as the “drug revolution” (Dash and Cudworth 1998).  Although the drug 
revolution led to the rapid discovery of many new drugs, pharmacological factors such 
as dosage forms, drug delivery systems, plasma drug levels, and how all these factors 
contribute to the efficacy of a drug were poorly understood.  It wasn’t until the mid- 
1900s that these factors were identified (Dash and Cudworth 1998).  One particular 
factor which, once discovered, turned into a main focus in pharmacological research 
and lead to improvements in drug efficacy is centered on the importance of 
maintaining a steady therapeutic drug concentration level in the plasma.   
The most conventional method for drug administration has always been 
through the use of oral products, such as tablets and capsules.  These conventional oral 
drug products are formulated to release the active drug immediately after oral 
administration to obtain complete and rapid drug absorption in the body and 
immediate therapeutic effects (Shargel et al. 2004).  However, once the body fully 
absorbs the drug, plasma drug concentration levels decline precipitously, possibly 
falling below the minimum effective plasma concentration (MEC), resulting in a loss of 
therapeutic activity.  Before falling below MEC, the patient must be administered 
another dosage to maintain therapeutic effects (Shargel et al. 2004).  Clearly, the 
conventional dosage form leads to a peak-and-valley curve of drug plasma levels 
versus time.  This peak-and-valley pattern can have adverse effects since peaks, high 
plasma concentration of drugs (a result of frequent dosing), can cause toxicity, and 
valleys, low drug concentration in the plasma, may lead to sub-therapeutic levels and a 
possible buildup of drug resistance by the body’s immune system (Dash and Cudworth 
1998).  How are drug therapeutic levels maintained while avoiding dangerous peak-
and-valley side effects that often occur after the administration of conventional 
immediate-release dosage forms? 
In order to maximize the therapeutic effectiveness of a drug while avoiding 
potential side effects that result from large fluctuations in drug blood levels, optimal 
concentration of drug in blood plasma must be sustained continuously (Breimer et al. 
1984).  In the past, the only known way to maintain a steady concentration of a drug’s 
level in the plasma was through intravenous (IV) administration of the drug at a 
constant rate.  Although steady IV administration is effective, it generally requires a 
health care professional to monitor the plasma drug concentration and cannot be 
performed at home (Dash and Cudworth 1998).  In recent years, continued advances 
in pharmaceutical sciences have given rise to modern technological processes which 
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provide alternate drug delivery systems that can maintain a steady therapeutic drug-
plasma level while avoiding the inconveniences of IV administration and the possible 
dangers of frequent oral dosing (Chen et al. 2010).  “Modified-release drug products” 
is the general term used by the US Pharmacopeia (USP) to describe products that 
“alter the timing and/or rate of release of the drug product to accomplish constant 
therapeutic levels not offered by conventional immediate release products” (Chen et al. 
2010).   
A major subdivision of modified-release products includes drug products with 
extended-release (also referred to as controlled-release) characteristics.  Examples of 
extended-release drug products primarily include prolonged-action drug products and 
sustained-release drug products.  Prolonged-action drug products are designed to 
slowly release the active drug substance in a way that provides a continuous supply 
over a period of time, 
thereby avoiding rapid 
and peak drug 
absorption in the 
plasma.  Sustained-
release drug products 
are designed to deliver 
an initial therapeutic 
dose followed by a 
slower steady release 
of drug that equals the 
rate of drug elimination 
from the body, 
resulting in minimal 
plasma drug 
concentration 
fluctuations (Shargel et 
al. 2004).  Figure 1 
portrays a plasma drug 
concentration versus 
time profile for both oral and sustained release delivery systems.  This graph proves 
the value of an extended-release drug delivery system over the conventional frequent 
oral dosage since the sustained-release delivery system clearly stays in the desirable 
therapeutic and relatively homeostatic level while the oral immediate-release pill 
fluctuates between toxic and ineffective levels (Dash and Cudworth 1998).  Currently, 
extended-release drug products encompass a wide range of products ranging from 
extended-release oral products, transdermal patches, and even implantable drug 
systems.   
Before investigating the actual pharmaceutical applications used to create 
extended-release drug products, it is important to understand the possible 
biopharmaceutical factors that determine how a drug works in the gastrointestinal 
tract and the various pharmacokinetic properties that determine a drug’s rate of 
absorption and release in the human body.      
Figure 1: plasma drug concentration versus time profile for both oral and 
sustained release delivery systems. Source: Dash and Cudworth 1998 
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DRUG- ABSORPTION 
As mentioned above, modified-release pharmaceutical preparations are 
generally designed to produce drugs with slow and uniform in-vivo absorption.  In 
view of the fact that many of these oral modified release drugs are designed to remain 
intact in the gastrointestinal (GI) tract longer than the original immediate-release 
drugs, the anatomy and physiology of the GI tract plays a key role in the dosage and 
absorption of these drug products (Shargel et al. 2004).  There are a number of 
physiological factors along the GI tract that affect drug release rate and uptake from 
the modified-release product. They include variations in pH, GI motility phases, 
presence of food, gastric emptying, presence of bacteria, enzymatic activities, varying 
permeability along the GI tract, volume of intestinal juice, and other factors as well 
(Lobenberg et al. 2000).  Clearly, in-vivo behavior of modified-release oral drugs can 
be extremely complex considering all of the interacting mechanisms and changes 
occurring at every second in the gut (Varum et al. 2010).  Researchers have, therefore, 
studied gut physiology and the mechanisms of digestion extensively with the hope that 
they can get a grasp on the in-vivo mechanisms and thereby produce maximally 
effective modified-release drugs.   
The stomach is the first organ along the gastrointestinal track that a drug 
reaches.  The general role of the stomach in the digestive system is to mix entering 
foodstuffs with digestive juices and then empty this mixture periodically into the small 
intestine (Shargel et al. 2004).     Although this may seem to be a simple and 
predictable cycle, the movement of food and drugs through the stomach is greatly 
affected by the physiological state of the stomach, thereby affecting the time and 
location of the release of a drug from its dosage form (Shargel et al. 2004 and Varum et 
al. 2010).  One particularly significant physiological factor which affects the ultimate 
time a drug is released from its dosage form depends upon the presence or absence of 
food in the stomach at the time of drug intake.   
FACTORS THAT INFLUENCE ABSORPTION 
The presence or absence of food has a major role in gastric emptying and 
gastric retention (Varum et al. 2010).  In the presence of food, the stomach is 
considered to be in a digestive phase, whereas when lacking food, the stomach is 
considered to be in an interdigestive phase (Shargel et al. 2004).  In the interdigestive 
phase, also known as the fasted state, gastric motility is under the control of a series of 
cyclical fluctuations in contractile activity commonly referred to as the migrating 
motility complex (MMC) (Higaki et al. 2008).  The MMC is composed of four phases 
and can take up to about 30-40 minutes to be completed.  Phase I is characterized by a 
total lack of activity.  Phase II follows with an increase in the number and intensity of 
contractions.  Phase III is characterized by large-amplitude peristaltic contractions 
that end with a strong “housekeeper contraction” which causes a massive gastric 
emptying of everything left in the stomach.  Phase IV is an intermediate phase and acts 
as a transition period between the strong contractions of Phase III and Phase I of the 
next MMC cycle (Higaki et al. 2008 and Shargel et al. 2004).  In the presence of food, 
on the other hand, MMC is basically abolished and low-amplitude peristaltic 
contractions take over, enabling gastric emptying of only small molecules into the 
duodenum (Higaki et al. 2008).  Food particles larger than 2mm are retained in the 
stomach during the digestive phase (Shargel et al. 2004).  Clearly, gastric emptying of 
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drugs (particularly tablets larger than 2mm) occurs mainly during Phases II and III of 
MMC in the fasted state (Higaki et al. 2008).  Therefore, drugs larger than 2mm that 
are administered during a fasted state will be emptied out of the stomach fairly quickly, 
leading to a faster release of the drug into the patient’s plasma.  However, if the same 
large drug is administered in the digestive stage, it may remain in the stomach for a few 
hours until Phase II/III of the next MMC occurs.   
Another factor that is known to have an important effect on gastric emptying 
and gastric retention is the caloric content of meals eaten around the time of drug 
administration.  High caloric content meals generally show a delay in gastric emptying 
of both food and drug.  In one particular study, a multiple-unit dose failed to empty for 
up to ten hours post-dosing in volunteers who consumed a high caloric meal (Varum et 
al. 2010).  If, for example, a certain drug is modified to be released a few hours after 
administration with the intent that, at that time, the drug will be in the small intestine, 
a highly caloric meal might retain the drug in the stomach for too long and lead to a 
release of the drug in the stomach instead of the small intestine.  Clearly, researchers 
can greatly benefit from knowledge of factors affecting gastric retention and emptying 
when formulating modified-release dosages. 
Many studies were done to determine the effects of the fed/fasted state along 
with the caloric content of a meal on gastric emptying of a modified- release drug.  One 
experiment in particular hypothesized that gastric emptying of different-sized enteric-
coated pellets (enteric coating of pellets is a modified-release formulation characteristic 
that prevents dissolution in the stomach but allows rapid dissolution in the small 
intestine) would occur at different rates with the smaller pellets emptying in the fed 
state and the larger pellets emptying in the fasted state (Rhie et al. 1998).  In this 
experiment, 12 healthy individuals were each given 0.7mm caffeine (CAFF) and 
3.6mm acetaminophen (APAP) along with a viscous caloric meal at levels of 4000, 
6000, and 8000 cP.  The CAFF and APAP pellets were both enteric-coated spherical 
pellets formulated with sucrose nonpareils as the core which was coated with several 
suspension layers of the active ingredient, thereby achieving a target diameter, drug 
potency, and enteric coat level to aid in the release of the drug at a specific location.  
Gastric motility patterns were recorded using the monometric catheter, a technological 
device where the peaks on the machine represent the start and end of the different 
stages, such as Phases II and III of the MMC cycle.  Blood samples were also obtained 
throughout the experiment in order to assess the plasma profiles of the drug, focusing 
specifically on the time when the drug was first detected in the plasma.  Plasma results 
demonstrated that CAFF from the 0.7mm enteric-coated pellets were consistently 
(with all the different caloric level meals) measured in the plasma before the APAP 
from the 3.6mm enteric-coated pellets.  Additionally, upon observing the timing of the 
release of the pellet dose, the results indicated that plasma profiles were strikingly 
superimposable upon the gastric motility patterns noted by the monometric catheter 
(especially with the 4000 cP meal); the time that CAFF from the smaller pellet was 
detected in the plasma correlated with the spikes on the monometric catheter which 
represented a fed state phase, backing up the assumption that small pellets are released 
from the stomach during the digestive phase.  In contrast, APAP pellets were first 
observed in the plasma at the same time as the onset of the fasted contractile activity 
(Phases II and III).  Overall, the meal viscosity levels in this experiment did not 
significantly affect the rate of drug absorption (Rhie et al. 1998).  Knowledge of how 
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factors of gastric emptying affect the release of a drug assists in the development of 
modified release drugs that can take advantage of these factors.  
It is important to note that, although most studies prove that a larger dosage 
form results in longer gastric retention, there have been studies that proved that 
different size dosages had no effect on the timing of gastric emptying.  Clearly, more 
research should be done on this complex issue.  Perhaps one of the many other 
physiological factors in the stomach, such as a pH level of 1-2 in the presence of food 
and 3-5 in the absence of food, can alter gastric emptying times if the experiment is not 
properly controlled.  
The stomach empties its contents into the small intestine which provides a large 
surface area for drug absorption and where transit time of solids takes approximately 
3-5 hours (Varum et al. 2010).  Data obtained from various research projects is too 
varying to make conclusions on the effects fed and fasted states have on the transition 
of dosage forms along the small intestine.  However, it was observed in numerous 
studies that the administration of modified-release multiple-unit enteric-coated dosage 
forms before eating resulted in a faster small intestinal transit time compared with the 
transit time of the drug in a fasted state (Varum et al. 2010).  This information is 
extremely valuable.  For example, if a drug is meant to be absorbed in the proximal 
small intestine, such a drug should be administered in pre-fed patients, resulting in 
modified-release of the drug in the upper GI tract.  Administration of the drug in a 
fasted state might give the drug enough time to travel as far as to the colon where 
colonic conditions may make it impossible to be absorbed.  Additionally, the presence 
of bacteria in the terminal part of the small intestine and its pH level of about 6 may 
also affect drug release in the small intestine.   
The large intestine is the next and last step for a drug to be absorbed in the GI 
tract.  A lack of fluids in the colon, besides for in the rectum, makes it difficult to 
absorb drugs passing through.  The presence of bacteria in the colon can perhaps 
affect the absorption of modified-release drugs in the colon as well (Shargel et al. 
2004).   
The high variability in GI transit presents significant implications for the in-
vivo performance of drugs in modified-release systems that are intended to delay or 
sustain release of drugs (Varum et al. 2010).  The following studies represent how 
modified-release drug products can take advantage of the physiological conditions of 
the GI tract.  Scientists do numerous studies on the gastrointestinal effects on a drug 
before creating a modified-release version of the drug.  The majority of these 
experiments use the novel technique of pharmaco-scintography to assess regional drug 
absorption in humans.  This technique works by co-administering a radiolabeled 
placebo pellet along with the coated modified-release drug of choice.  The radiolabeled 
pellet’s gastrointestinal transit is then monitored through a gamma camera.  Blood 
samples are also generally collected periodically to assess plasma concentration of the 
drug in question and then compared to the scintigraphic results to help determine the 
exact time and gastrointestinal location of drug release (Basit et al. 2004).   
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One specific study was performed to evaluate the GI transit, release, and 
absorption of budesonide, a drug used for the treatment of inflammatory bowel disease 
(IBD), from its mutimatrix MMX® formulation. Budesonide’s MMX formulation is 
designed to release the drug throughout the entire colon at a controlled rate (Brunner 
et al. 2006).  Previously, budesonide had only been formulated to treat IBD in the 
right-sided colonic region in Chron’s disease, and in left-sided ulcerative colitis.  
Therefore, in order to orally treat distally located IBD, gastric- resistant, extended-
release budesonide tablets characterized by a multimatrix structure have been 
developed to allow a prolonged and steady release of budesonide along the entire colon 
at a controlled rate.  This experiment 
tested the efficacy of the drug’s 
prolonged-release characteristics on 
twelve healthy males.  The volunteers 
were administered the budenoside 
multimatrix tablets, along with a 152Sm-
oxide tablet that was transformed into a "-
ray-emitting compound to be used for 
scintigraphy.  Scintigraphic scans and 
blood samples were taken and compared 
periodically.  MMX®-budesonide tablets 
were detected by scintigraphic imaging in 
the ascending colon between 4 and more 
than 24 hours after dosing, as is depicted 
in 2, and the drug left the descending 
colon at 12 to more than 24 hours post-
dosing. 
An estimated 96% of the 
budesonide was absorbed in the target region (between the ascending and descending 
colon) as was calculated by the area under the curve (AUC), represented by the 
AUCtarget/AUC24 ratio where the AUCtarget represented the plasma AUC where 
radioactivity was detectible in the target region, and the AUC24 was attained from the 
plasma AUC values of budesonide observed over the entire 24-hour period (Brunner 
et al. 2006). Clearly, this modified budenoside formulation was successful in delivering 
its active drug throughout the entire colon.  Additionally, although budesonide plasma 
concentrations were first observed after 6.8 ± 3.2 h, maximum plasma concentrations 
were reached about seven hours later.  The time difference between the initial 
detection of budesonide in the plasma and budesonide’s time of max concentration 
(tmax) verifies the sustained-drug release characteristics of the budesonide MMX® 
tablets.   
Phase two of this experiment tested the effect of food on budesonide 
pharmacokinetics.  Plasma samples taken after the administration of a highly caloric 
and fatty meal reflected the fact that budesonide absorption decreased by 30% in 
relation to those who took the pill under fasted conditions (Brunner et al. 2006).  This 
decrease of drug absorption may justify the administration of this drug with a meal to 
limit its potency and thereby improve the safety profile as a drug.  Conclusively, the 
formulation of  MMX®-budesonide tablets have clearly utilized knowledge of 
gastrointestinal transit as an aid in producing a sustained-release drug suitable for 
Figure 2: Scintigraphic imaging of the colon. 
Source: Brunner et al. 2006   
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targeted drug-delivery to the colon.  However, further research should be done on this 
subject, since colonic infected individuals, for whom this drug is meant, may react 
differently to the drug than healthy individuals on whom the experiment was done.   
Another study evaluated the absorption of the drug Ipsapirone along the 
human GI tract.  In man, Ipsiparone, an anti-depressant, has an absorption half-life of 
less than 0.25 hours and an elimination half-life of about 1-3 h.  This noticeably rapid 
absorption leads to a rapid peak in plasma concentration of the drug which often 
causes vertigo, dizziness, and dysphoria (Fuhr et al. 1994).  Researchers have, 
therefore, studied the bioavailability (a term used to describe the fraction of an 
administered dose of unchanged drug that reaches the systemic circulation) of 
Ipsapirone after its administration at different regions of the GI tract to help develop 
an effective and safe modified-release drug.  Researchers hoped that a modified-release 
version of Ipsapirone would reduce unwanted side effects since the modified-release 
dosage form does not release its entire dose in one region, thereby avoiding a rapid 
plasma peak of the drug.  Ipsapirone-HCl was administered to four healthy males 
orally, rectally, and locally in different locations along the GI tract by a remote control 
drug delivery device.  Plasma results indicated that there was a 2-3-fold increase in the 
bioavailability of the drug administered directly into the colon than when the drug was 
administered into the upper GI tract.  This 2-3-fold increase indicates an equivalence 
of a 5 mg dose of ipsapirone-HCl released in the colon with a 10-15 mg dose given 
orally.  Oral doses of this size (10-15 mg) were tolerated, and administration of 5 mg 
ipsapirone into the colon was deemed safe.  These results fulfill the criteria for the 
development of a prolonged-release preparation with 5 mg ipsapirone-HCl.  Through 
modifications of the drug’s coating, the drug could be modified to be released only in 
the colon; such a modification makes it unnecessary to administer a full 10-15 mg 
immediate-release dose which loses most of the drug by the time it reaches the colon.  
Considering the fact that this was a small sample of only four males, further research 
should be done to test if rectal administration of this drug to the colon really equals 
oral prolonged-release administration (Fuhr et al. 1994). 
An example of a new oral modified-release drug that was formulated based on 
knowledge and applications of the varying characteristics of the GI tract is Rifamycin 
SV MMX (Di Stefano et al. 2011).  Rifamycin SV is an oral, non-absorbable antibiotic 
which can be used in the treatment of colonic bacterial infections.  These tablets are 
formulated using a multimatrix structure which, like budesonide, delivers the active 
drug ingredient (200mg of sodium rifamicyn SV) directly to the colon.  In immediate-
release drugs, the active ingredient would be released immediately upon 
administration, and maximum bioavailability in the colon would not be achieved (Di 
Stefano et al. 2011). With the modified-release tablets, however, the maximum 
bioavailability of the active ingredient is achieved, and the biological effect is optimized 
at the target region, the colon.   
The Rifamicyn SV MMX tablet contains a double-matrix system.  
Microparticles of the active ingredient are dispersed in a lipophilic matrix which is in 
turn dispersed in a hydrophilic matrix.  The hydrophilic coating inhibits the 
penetrations of fluids into the tablet, thereby lowering the rate of drug dissolution in 
the upper GI tract.  The tablet is coated with a pH dependent, gastro-resistant polymer 
film which also inhibits dissolution of the tablet in the upper GI tract.  This MMX 
tablet begins to disintegrate when the pH is %7.  With the pH-sensitive and hydrophilic 
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coating, the tablet reaches the cecum intact and it is there that the release of the drug 
begins.  The pH-sensitive coating disintegrates, and the intestinal fluids interact with 
the hydrophilic coating which forms an outer gel mass that slows diffusion of the 
antibiotic into the colonic lumen (Di Stefano et al. 2011).  As the tablet progresses 
towards the rectum, debris of the gel mass disaggregates and releases the antibiotic 
directly near the mucosa of the rectum.  Studies done through pharmaco-scintigraphic 
investigations clearly demonstrate an effective colonic delivery of this drug, supporting 
the production of rifamycin in a modified-release formulation.  
These studies all give us valuable insight into the natural absorption of different 
drugs. Using this knowledge allows for the creation of drugs specially suited for 
different releases.  
PHARMACOKINETICS  
Pharmacokinetics is the study of the time-course of drug concentrations in the 
body, based on various characteristics of drug absorption, distribution, metabolism, 
and excretion (Mager 2006). As stated above, conventional drug delivery systems very 
often rely on frequent dosing in order to attain a therapeutic level, which leads to large 
fluctuations in drug blood levels.  The frequency at which a conventional dosage must 
be given is dependent on two pharmacokinetic properties: elimination half-life (t1/2) 
and therapeutic index (TI) (Sood and Panchagnula 2003).  Half-life is the time 
interval in which half of the active drug in a system is lost, and therapeutic index is the 
concentration range in which a drug works (Sahin and Benet 2008).  Knowing the 
half-life of a drug assists pharmaceutical companies in setting dosage frequency 
intervals so that the right amount of active drug will be in circulation at all times, since 
the dosing interval directly influences the ratio of maximum (Cmax) to minimum (Cmin) 
blood drug concentrations.  Although this seems quite simple, it should be noted that 
there are many other factors involved in half-life and other pharmacokinetic properties 
and equations which are beyond the scope of this paper.  Obviously, drugs with 
shorter half-lives require a more frequent administration in order to keep blood-drug 
concentration levels within the therapeutic index.  The goal of controlled-release drugs 
is to release the active drug ingredient at a sufficient rate, frequency, and dose so that 
the ratio Cmax/Cmin is maintained at an effective steady state throughout the therapy 
without having to be so dependent on half-life and therapeutic indexes which often 
leads to the necessity of frequent dosing (Sood and Panchagnula 2003).  Drugs with 
zero-order kinetics are generally the easiest to deal with when producing controlled-
release dosage forms because they are predictable.  They release the active ingredient 
at a constant rate that is independent of the concentration of the reactants; it is much 
easier to create a modified-release formulation when the drug’s exact rate of release is 
already known.     
RELEASE CONTROL MECHANISM  
The knowledge of the gastrointestinal and pharmacokinetic implications on a 
drug’s efficacy aided researchers in manufacturing extended-release drugs which can 
help in lowering the fluctuations in blood-drug levels.  Most extended-release drugs 
are manufactured through the use of a matrix structure.  The drug is suspended or 
dissolved within the matrix and/or within a rate-controlling membrane through which 
the drug diffuses (Shargel et al. 2004).  In this context, the matrix refers to an inert 
solid in which the drug is suspended throughout and diffuses out of quite slowly.  
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There are basically three different types of modified release matrix mechanisms.  In the 
first type, the drug is dissolved in a matrix material that is coated with a soluble 
coating. In such a case, the rate of drug release depends entirely on the matrix 
material; a porous matrix will lead to a fast absorption of water, resulting in rapid drug 
release from the matrix material, whereas a less porous matrix will not absorb much 
water right away and will, therefore, cause a slower and lengthier drug release.  The 
second system is that of a matrix with an insoluble membrane.  When a drug is 
prepared in such a manner, its release is not only dependent on the permeability of the 
matrix; it is dependent on the membrane’s permeability as well.  The third system is a 
matrix tablet with a combined membrane where the membrane becomes porous after 
dissolving the soluble part of the membrane in water.  Aside from matrix and 
membrane factors in creating extended-release products, most extended-release drugs 
release their drug product as a result of a combination of processes including 
dissolution, permeation, and diffusion.  Water permeation is probably the most 
important factor that drug manufacturers consider since, as the influx of water into the 
product is controlled, the rate at which the drug dissolves is essentially controlled.  
Once the drug dissolves, drug diffusion out of the tablet/capsule is further controlled 
by the permeability of the membrane (Shargel et al. 2004). All of these factors are 
considered and used to aid in the development of modified-release drugs.   
ORAL EXTENDED-RELEASE 
Of all the different kinds of extended-release products, oral extended-release 
products prove to be the simplest and easiest to manufacture, lowest cost, high level of 
reproducibility, and stability (Siddique et al. 2010).  The following examples touch the 
surface of the numerous kinds of applications that can modify the release of oral drugs 
to maintain homeostatic conditions in the human body.   
GUM-TYPE MATRIX TABLETS 
Gum-type matrix tablets are manufactured with a matrix that swells in the 
presence of water to form a gel-like consistency.  This gel is generally very thick and, 
therefore, provides a barrier for drug diffusion out of the tablet.  Such a matrix is 
commonly formed with excipients (carrier of active drugs) such as methylcellulose, 
gum tragacanth, Veegum, and alginic acid.  The thickness of the gel caused by these 
excipients provides controlled-release results in that they prevent drug dissolution 
until the gel-like matrix breaks up and the drug completely dissolves and gradually 
diffuses into the intestinal fluid (Shargel et al. 2004).   
Diazepam, a benzodiazepine drug used for acute management of severe 
seizures, is an example of a drug that has been manufactured in a gum-type matrix 
tablet, thereby providing sustained-release of this drug for hours (Shargel et al. 2004).  
A study was done on Diazepam which investigated the feasibility of incorporating 
Diazepam, a poorly water-soluble drug, into solid-lipid nanoparticles (such as a gum-
type matrix) that can offer rapid onset (for early termination of seizures) and 
prolonged-release of the drug for long-acting protection against further seizures.  The 
particular characteristics of the solid-lipid nanoparticles (SLNs) used (such as the 
SLN’s biocompatible lipid core but ampiphillic outer shell in this case) allowed for 
immediate and prolonged release which, in essence, is the main characteristic of a 
sustained release drug system.  Different SLN formulations were then tested to see 
which combination of lipid matrices and surfactant would result in the best prolonged-
34 Chedva Farkas 
release results.  (SLN formulations composed of Tween 80 as a surfactant and lipid 
matrix of 5% Compritol ATO 888 and 5% Imwitor 900k provided the best in vitro 
prolonged-release effects for diazepam (Abdelbary and Fahmy 2009).)   
Clearly, a gum-type/lipid matrix is one effective manner of prolonging the 
release of a drug, thereby preventing the need of frequent dosing and dangerous 
fluctuations of blood drug levels.  However, it should be noted that since this 
experiment tested results in vitro, more research should be done to obtain in vivo 
results which would be more beneficial in determining the actual effects of such drugs 
in the human body.                   
POLYMERIC MATRIX TABLETS 
Of recent, drug manufacturers have been very interested in using polymeric 
material in the matrix to prolong the rate of drug release.  The significance of 
polymeric matrix tablets over other kind of matrix tablets is that polymeric matrix 
tablets can prolong the release of a drug to last for days or even weeks (Shargel et al. 
2004).  The polymers that are available for drug formulation include hydrophilic 
polymers, such as polylactic acid and polyglycolic acid, and hydrophobic polymers, 
such as ethylene-vinyl acetate copolymer (EVA).  The hydrophilic polymers release 
the drug gradually while the hydrophobic polymers release the drug over a much 
longer period of time because of its hydrophobic characteristic which blocks water 
from entering and causing drug dissolution.  Additionally, the rate of drug release can 
be further controlled by combining different polymers, such as adding a hydrophobic 
polymer to a hydrophilic one to decrease the rate of the drug’s release.  Light, heat, 
and other factors may also be administered to change the properties of the polymers 
being used (Shargel et al. 2004). 
One particular study investigated the influence of polymer level and type of 
some hydrophobic polymers including hydrogenated castor oil; Eudragit RS100; 
Eudragit L100; and some fillers, mainly mannitol; dibasic calcium phosphate 
dihydrate; and anhydrous dibasic calcium phosphate on the release rate and 
mechanism of the drug baclofen.  Results showed that a high polymeric content (40%) 
in the matrix lowered the release rate of baclofen, whereas a low polymeric content 
(20%) elevated the rate of drug release from the matrix.  Additionally, hydrogenated 
castor oil was proven to be the polymer that caused the strongest retardation of drug 
release (Abdelkader et al. 2008).  Thus, in addition to knowing the kinetics and half-
life of a particular drug, the correct combination of polymers can be formulated to 
bring about the perfect amount and rate of drug release.   
MULTIPLE UNIT PELLETS 
Modified-release dosage forms which have been proven to control the release of 
the active drug, thereby reducing the side effects associated with peak and trough drug 
plasma levels, have been improved upon in the development of modified-release 
multiple unit pellets.  Whereas single-unit formulations contain the active ingredient 
within one single tablet or capsule, multiple-unit dosages are manufactured so that a 
number of discrete particles are combined into one dosage form.  These particles could 
come in the form of pellets, granules, sugar seed (non-pareils), mini-tablets, or 
powders which contain within them the active ingredient.  One advantage of multiple 
unit pellets over single unit pellets is that when taken orally, multiple unit pellets 
spread over a large surface in the GI tract, and the particles behave like liquids that 
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can leave the stomach shortly after entering 
without waiting for the series of waves to 
push them along the GI tract (Abdul et al. 
2010).  In addition, the fact that the pellets 
disperse throughout the GI tract improves 
the drug’s bioavailability and can reduce 
drug concentration in a specific location 
which might otherwise have lead to toxicity.  
Additionally, sometimes if a drug is released 
too early along the GI tract, it can irritate the 
gastric mucosa.  Multiple unit pellets 
definitely reduce the risks associated with 
premature drug release because of the rapid 
transition of smaller enteric-coated pellets 
along the GI tract.  Failure of some of these 
units from reaching their target will also not 
be as consequential as the failure of a single-
unit dose.  Theophylline (Gyrocap) is an 
early example of a beaded form extended-
release pellet (Shargel et al. 2004).  The frequency of adverse reactions such as nausea, 
headache, and vertigo, were greatly reduced after the administration of Theophylline 
in pellet form as opposed to a liquid form.  The reduction of side effects in multiple 
pellet dosage forms comes from the fact that, unlike liquid, the multiple pellet dosage 
allows drugs to be absorbed gradually instead of rapidly (Shargel et al. 2004). 
Because it is difficult to compact the multiple pellets into one system, there are 
currently only a few multiple-unit tablet 
products available.  They include Beloc® 
ZOK, Antra® MUPS, and Prevacid® 
SoluTbTM.  The difficulties in compaction 
arise when trying to fuse the pellets 
together without fusing them mistakenly 
into non-disintegrating matrixes.  If the 
pellets are fused into a non-disintegrating 
matrix, they can no longer provide the 
benefits of a multiple-unit pellet system 
that disintegrates into individual pellets 
in the GI fluids leading to a more 
uniform concentration of active drug in 
the body (Abdul et al. 2010).  Scientists 
should, therefore, develop safe ways to 
compact pellets so that the maximum 
benefits of multiple-unit pellets can be 
available to the world of modified-release 
drugs.   
 
Figure 3: MUPS.  Source: Abdul et al. 2010   
Figure 4: Factors influencing design of MUPS. 
Source: Abdul et al. 2010 
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 TRANSDERMAL DRUGS   
Transdermal drug delivery systems have recently turned into a promising field 
of study for scientists involved in the production of extended-release drug products.  
The transdermal drug delivery system, generally in the form of a patch, is designed to 
deliver the active medication across the skin in a controlled rate over an extended 
period of time (Shargel et al. 2004).  Transdermal drug delivery systems obviously 
provide benefits over immediate-release oral dosages since the controlled rate of drug 
delivery eliminates frequent dosing which leads to dangerous plasma level peaks and 
valleys.  Transdermal drugs also seem to have added benefits over the oral modified-
release drugs.  One major benefit is that drugs administered transdermally avoid 
hepatic first-pass metabolism.  Such a feature can greatly benefit individuals who are 
hepato-compromised, since the drug avoids the liver altogether.  Transdermal delivery 
routes also completely avoid passage through the GI tract.  In this case, poorly 
bioavailable drugs can clearly take advantage of avoiding the GI tract through a 
transdermal route (Paudel et al. 2010).   
Although transdermal patches may vary, most designs store the active drug in a 
reservoir that is enclosed on one side with an impermeable backing and with an 
adhesive on the other side that contacts the skin (Prausnitz and Langer 2008).  There 
are generally four layers in a patch: an impermeable backing membrane, a drug 
reservoir, a semi-permeable membrane that may serve as a rate-limiting barrier, and an 
adhesive layer.  Nitroglycerin is a drug that is commonly administered transdermally 
and formulated in the described manner (with the four layers).  Nitroglycerin 
delivered transdermally may provide protection against angina (chest pains that results 
from a lack of oxygen-rich blood reaching heart muscles) for hours whereas as 
sublingual (oral) tablets only provide relief for a few minutes (Shargel et al. 2004).   
Although transdermal drugs do seem to be a fantastic way to administer drugs 
at a controlled rate while avoiding possible complications that arise along the GI tract, 
they have not yet taken over the controlled-release drug market because of several 
limitations.  One such limitation is that the skin, the most important natural barrier 
against the efficacy of transdermal drugs, only allows moderately lipophilic and low 
molecular weight drugs to cross over transdermally (Paudel et al. 2010).  The 
solubility of the drug across the skin rather than the concentration of the drug in the 
patch is the most important of the rate-controlling factors of a transdermal drug 
(Shargel et al. 2004).  Therefore, overcoming low skin permeability through different 
chemical and physical means has become an active field of research in order to allow 
many more pharmaceutical products entrance into the world of transdermal drugs 
(Paudel et al. 2010).  Other factors such as humidity and temperature can also affect 
the rate of absorption across the skin (Shargel et al. 2004).   
Interestingly enough, transdermal drug delivery has been proven to provide an 
even more stable blood level of drug than provided by oral dosages (Shargel et al. 
2004).    Thus, if the drug is found to be successful against transdermal barriers, 
scientists will probably be interested in manufacturing the drug almost exclusively as a 
patch because of the stable blood levels, avoidance of GI tract, and other benefits of 
transdermal drugs over oral modified-release dosages.  Many experiments have, 
therefore, been done to compare the effects of transdermal versus oral dosage forms.  
For example, a series of experiments were done to determine the dose-response effects 
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of oral versus transdermal selegiline on anti-depressant-like activity in rats.  Rats 
received selegiline orally by gavage (0-100 mg/kg) or via transdermal patches (0-4.8 
cm2; 0-8.7 mg/kg) daily for seven days.  Antidepressant-like activity was then 
determined in two ways.  The first was through the forced-swim test in which 
immobility and latency times during a five-minute forced swim test were measured.  
The latency time, which is the measurement of the swimming time from the beginning 
of the trial until the onset of immobility, increases under therapeutically effective anti-
depressants.  The second way through which anti-depressant activity was assessed was 
through assaying the cerebral cortices of the rats after day seven for MAO-A and 
MAO-B activities, since inhibition of MAO-A is an indication and requirement for 
clinical improvements in depressed patients.  Results demonstrated that selegiline is an 
effective anti-depressant, as represented in the forced-swim test after both oral and 
transdermal delivery, that the anti-depressant-like effect of selegiline requires greater 
than 70% inhibition of MAO-A activity, and that the transdermal delivery of slelgiline 
is 10-20 times more potent than the oral selegiline in producing both its anti-
depressant-like effects and in inhibiting cortical MAO-A (Gordon et al. 1999).  
Clearly, transdermal administration of selegiline, which bypasses first-pass 
metabolism, allows for the usage of lower doses than in oral administration.   
Scientists have also put massive focus on the development of a transdermal 
treatment for menopausal syndromes.  One particular experiment was done to 
determine the efficacy of Busipirone hydrochloride (BH) administration in animal 
models in the treatment of the main menopausal syndromes of hot flushes and anxiety 
(Shumilov and Touitou 2010).  With oral administration, BH is rapidly absorbed in 
the GI tract and undergoes extensive first-pass metabolism, so it has a very short 
elimination half-life.  Because of the short half-life elimination, efficient oral treatment 
requires frequent dosing.  Scientists hypothesized that administering this drug 
transdermally would avoid the drawbacks of oral treatment.  This study was therefore 
done to test the efficacy of the BH transdermal system using ethosomes (vesicular 
carriers that enhance permeation through the skin).  Figure 5 represents the plasma 
drug concentration profiles following transdermal administration of 15 mg/kg BH from 
a formulation containing 30 mg/g drug and a single dose of 3 mg/kg oral administration 
of aqueous drug solution.   
Clearly, when administered 
transdermally, the drug was 
present in rat plasma for a much 
longer period compared to the oral 
administration, 12 hours versus 4 
hours, respectively.  The 
continuous delivery of BH into the 
bloodstream under transdermal 
administration can offer sustained 
efficacy with reduced side effects, a 
huge benefit in the world of modified-release drugs.  Additionally, the application of 
BH ethosomal system on the skin of rats caused a decrease in the temperature at three 
hours after administration and continued for a total period of 6 hours, proving that 
transdermal BH could be effective against hot flushes. This should, therefore, be 
further researched in humans (Shumilov and Touitou 2010).   
Figure 5: Plasma drug concentration profile following 
transdermal versus oral administration of BH. 
Source: Shumilov and Touitou 2010 
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Another study was done to compare the efficacy of the Lidocaine Patch 5%, a 
transdermal, noninvasive treatment, versus Naproxen 500 mg two times daily for the 
treatment of Carpal Tunnel Syndrome.  Results of this experiment proved that 
Lidocaine Patch 5% provided a comparable level of pain relief to the oral alternative 
while avoiding risk factors associated with systemic and invasive treatments 
(Nalamachu et al. 2006).   
Transdermal delivery definitely presents an attractive alternative to the oral 
delivery of drugs.  Transdermal delivery has provides an advantage for poorly 
bioavailable drugs in that it avoids hepatic first-pass metabolism (which can 
prematurely metabolize drugs) and the GI tract (Prausnitz and Langer 2008 and 
Gordon et al. 1999).  Transdermal delivery of drugs also eliminates frequent dosing 
and allows for steady, controlled delivery which lowers plasma level peaks and valleys 
(Paudel et al. 2010).  Transdermal drugs are also non-invasive and can generally be 
self-administered—a big advantage for patients requiring long-term treatment (Paudel 
et al. 2010).  The advantages of the transdermal route over the conventional oral route 
have led to much interest in producing modified-release drugs through a transdermal 
route.  Eventually, when transdermal challenges, such as permeation of the 
hydrophobic skin barrier and possible skin irritation from patches, are eliminated, 
transdermal drugs may become a popular choice on the modified-release drug market.   
IMPLANTABLE DRUG DELIVERY SYSTEMS 
In the late 1930s, Deasby and Parkes began researching sustained release 
implantable drug delivery systems as a possible solution to the problem of high plasma 
concentrations of drugs that may lead to toxicity or low drug levels that may cause 
sub-therapeutic levels found with immediate-release products (Dash and Cudworth 
1998).  This relatively novel idea involves implanting a drug delivery system that has 
been previously modified to release the active drug in a controlled manner into the 
human body at a specific location.  Implantable systems are geared specifically to 
deliver drugs to a specific site, thereby reducing the amount of drug necessary and 
limiting its side effects, since the drug does not have to travel throughout the body 
before reaching its target.  Pharmaceutical literature has shown that when the drug 
used is selective to its site of action, fewer drugs need to be administered.  In this 
manner, drugs which were previously too unstable to administer in-vivo because of 
bodily temperature and pH conditions that may diminish the drug’s efficacy can now 
be administered directly to the site requiring treatment.  Another advantage of 
implantable drug delivery systems over conventional oral dosages is that while an oral 
dose may need to be administered one, two, or even multiple times daily, some of the 
implantable systems have been developed to last as long as five years with minimal 
monitoring as opposed to administering the oral dose one, two, or even multiple times 
daily (Dash and Cudworth 1998).  These advantages notwithstanding, since the 
system is to be implanted, care must be taken that it be biocompatible with the human 
environment.  All materials used must be chemically inert, non-carcinogenic, 
hypoallergenic, and mechanically stable so that the human body does not reject the 
implantable system.   
There are two main classes of implantable drug delivery: drug implants and 
implantable pumps containing the drug (Dash and Cudworth 1998).  The class of drug 
implants can be further divided into non-degradable and biodegradable implant 
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systems.  One common form of the non-degradable implant system is the matrix 
system. In this system, the drug is dispersed inside the matrix material, and slow 
diffusion of the drug out of the matrix provides sustained release of the drug.  
However, the kinetic release of the drug is not at a constant (zero-order) rate since it 
depends on the volume fraction of the drug ingredient in the matrix.  A non-zero order 
release rate can be hard to handle in sustained-release drugs since it is difficult to 
predict its rate of release.  A second common form is the reservoir-type system which 
contains a compact drug core within a permeable non-degradable membrane.  The 
permeability and thickness of this membrane controls the rate of diffusion of the drug 
into the body.  This type of system generally releases its drug at a constant zero-order 
kinetic release rate because the drug is released based on the properties of diffusion; as 
soon as some drug is swept away by the surrounding material in the body, more drug 
diffuses out of the reservoir, leading to the constant rate of diffusion (Dash and 
Cudworth 1998).  Levonorgesterol (LNG), a sustained-release birth control, is the 
most commonly used reservoir system.  In this system, the hormone LNG is 
encapsulated in a silicone membrane and is implanted on the underside of the upper 
arm.  This LNG system has been proven to effectively provide sustained-release of 
LNG for up to five years.   
However, there are still some problems with non-degradable implants that 
prevent such a system from being an extremely popular sustained-release route.  One 
issue is that minor surgery is required to insert and remove the implant system, 
especially with non-degradable systems because they do not disintegrate in the body.  
Additionally, there is also the fear that the membrane will rupture and lead to “drug 
dumping,” causing drug-plasma concentration to exceed maximum safety levels and 
have toxic side effects.  This fear is especially relevant with reservoir systems because 
the membrane is the only barrier blocking the drug from diffusing throughout the 
body, unlike the matrix systems in which the drug must first dissolve out of the matrix 
and then out of the membrane.  Therefore, although implantable systems do seem like 
a fantastic approach to modified-release drugs, there are clearly some factors that 
make scientists wary of its use.  Biodegradable drug implant systems improve a bit 
upon non-degradable drugs since the polymers used in biodegradable systems are 
eventually absorbed or excreted by the body.  Surgery to remove the system is 
avoided, so patients are more accepting to the idea of an implantable drug.  However, 
since the polymers in such a system are biodegradable, many added factors have to be 
considered.  For example, in order to maintain the sustained-release characteristics of 
the drug in-vivo, the degradation rate of the polymer must be maintained at a constant 
rate as well as the drug, since the release kinetics, solubility, and diffusion of the drug 
depend upon the degradation of the polymer (Dash and Cudworth 1998).  Factors 
such as pH, temperature, and increased surface area can lead to early erosion of the 
degradable system.  All of these factors, therefore, become a major challenge when 
developing a biodegradable system with extended-release goals.  The reservoir and 
matrix systems of biodegradable implants are similar to the non-degradable systems 
except for the fact that the material used in biodegradable implants is degraded in-vivo 
at a controlled rate as the drug is released.   
The second major class of implantable drug delivery systems is the implantable 
pump containing the drug.  Implantable pumps provide precise control of delivery rate 
that biodegradable and non-degradable systems cannot provide. Pump systems have 
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been made possible through advances in micro technology which developed small 
enough pumps that release drugs at a controlled rate as result of an electronically 
generated pressure difference gradient (Dash and Cudworth 1998).  Implantable drug 
delivery systems have definitely created a breakthrough in sustained-release drug 
therapy.  However, the limitations mentioned above, such as possible dose dumping 
and the need for surgery, along with the costliness of these products limits the use of 
implantable systems.  Hopefully, the future will bring possible methods to lower the 
cost of these products so that implantable drug delivery systems can be used as 
standard therapeutic practice. 
CONCLUSION 
Oral, transdermal, and implantable extended-release drug products definitely 
offer many important advantages over immediate-release dosage forms.  The most 
important advantage is that extended-release characteristics allow for a sustained 
therapeutic drug-blood level, providing a clinical response in patients that lasts much 
longer and steadier than with immediate-release products.  This sustained therapeutic 
level also reduces fluctuations between a drug-plasma minimum and maximum that 
comes from a multiple dose regimen of an immediate-release product.  In this manner, 
the side effects that come as result of the highly fluctuating drug-blood concentrations, 
such as toxicity and sub-therapeutic levels, are basically eliminated.  Another 
advantage of extended-release products is that such products generally lead to better 
patient compliance, because taking an extended-release oral dosage once a day, 
applying a patch once a week, or inserting a pump that lasts five years, is much more 
convenient than having to remember to take the dosage multiple times a day to 
maintain a therapeutic level.  Clearly, drugs with a short half-life, which under 
immediate-release characteristics would need to be given frequently, will greatly 
benefit from an extended-release formulation that can lower dosage frequency and 
maintain efficacy over a longer duration of time.   
One major concern that came with the introduction of extended-release drugs 
was that although extended-release products would lower fluctuations, they would not 
provide the same effective therapeutic levels as the immediate-release counterpart.  
However, all of the studies mentioned in this paper show that the extended-release 
products do provide the same effective therapeutic effects along with the benefit of 
lowering fluctuations of the blood-drug levels.   
However, some concerns have yet to be resolved. One such concern is the 
possibility of dose dumping and the difficulty of removing the spilled drug from the 
body.  Immediate-release products definitely have the benefit over extended-release 
products in this case since it is a much smaller dosage that is causing the adverse 
reaction and is, therefore, not as toxic, and it is also easier to remove.  Another concern 
is the lack of in-vivo testing conducted on human models.  In-vivo testing on human 
models is crucial since different gastro-intestinal factors and in-vivo characteristics can 
perhaps interact with the different formulations in possibly destructive ways.  Ideally, 
the study should be done on patients with the disease the drug is meant to treat in 
order to see if and how the disease affects the release rate and/or efficacy of the drug.  
Sometimes, slight differences between different individuals, such as caloric content of a 
meal, body temperature, and weight, can also affect drug release and must, therefore, 
be taken into account.  It may not either be worthwhile to formulate an oral extended-
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release drug for products that are administered at high dosages for the practical reason 
that the size of the pill will be too large to swallow. Therefore, all these factors must 
been studied extensively to determine the cost/benefit ratio of the extended-release 
drug.     
Clearly, there are a couple of considerations that must be acknowledged when 
dealing with extended-release products. More research should be done in-vivo to 
determine if the disadvantages of the extended-release products can be reduced, 
thereby providing the benefits of lowering fluctuations in blood-drug plasma and 
maintaining a homeostatic profile without the added disadvantages.  For example, 
further research should determine whether products demonstrate sustained-release 
characteristics without dose dumping and if products are consistent with minimum 
patient-patient variations.  Further research should also definitely be done on 
transdermal and implantable drugs since they have the benefit of completely avoiding 
the intricacies of the gastro-intestinal tract.  Perhaps the transdermal and implantable 
methods can be applied to many more drug products, thereby benefitting patients in 
the long run.  
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EPIGENETICS: A POSSIBLE MECHANISM OF MEMORY 
Aliza Grossman Rubenstein 
INTRODUCTION 
The mind-body connection has fascinated philosophers and scientists for 
centuries.  How is it possible that consciousness arises from a lump of matter known as 
the brain?  How does neurons’ firing affect choice and beliefs?  How do the 
electrochemical properties of the brain allow for the memory of events long after 
they’ve occurred?  One of the most studied of these areas is that of memory.  
Researchers seek to understand the biological basis behind memory and how that 
biology is affected in individuals suffering from memory disorders.   
Why is memory so difficult to comprehend from a biological standpoint?  There 
are several facets of memory that must be satisfied by its biological mechanism: 
acquisition, consolidation, and extinction.  To acquire a memory, the brain must first 
be stimulated by the environment.  The outside world must be able to influence the 
biology behind memory.  Once acquired, the memory must have the ability to become 
permanent, or consolidated, to accommodate long-term memory.  The biological 
mechanism must be switched on by the environment, and remain on.  Last, once 
memories are present, there must be a mechanism that allows them to be forgotten 
(otherwise known as extinction).  These three requirements must be found in any 
biological mechanism that seeks to explain memory. 
Recently, researchers have begun exploring the field of epigenetics in relation 
to memory.  Epigenetics (literally “over genetics”) is a term coined by Conrad H. 
Waddington to describe regulation of genetic expression by modifications of the 
genome that are independent of DNA sequence (Reichenberg et al. 2009; Sananbenesi 
and Fischer 2009).  Originally, epigenetics was only used to describe stable, heritable 
modifications.  Today, though, this distinction has blurred with the realization that 
epigenetic factors can be both transient and dynamic, occurring fleetingly in response 
to environmental factors (Day and Sweatt 2011).  This is especially true in the field of 
cognitive epigenetics, as it is this flexibility of epigenetics that enables it to act in 
cognition. 
Epigenetics is well suited as a candidate mechanism to explain memory as it 
satisfies the three requirements of the biological mechanism of memory.  The 
epigenome is dynamic and can change in response to environment, allowing the 
encoding of a memory in response to a stimulus.  Once activated, it may be relatively 
stable, thereby storing the memory across time (Day and Sweatt 2011).  Despite its 
relative stability, its dynamic nature does allow for change, thus ensuring the 
possibility of extinction of the memory.  Epigenetics, therefore, may be able to encode, 
store, and allow for extinction of memory. 
EPIGENETICS  
Epigenetics encompasses several processes, which may be present separately or 
may interact to express complex phenotypes.  The two factors that have garnered the 
most research in the field of memory are DNA methylation and histone modifications.  
Both factors modify the genome, influencing transcription. 
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CHROMATIN 
In order to adequately discuss DNA methylation and histone modifications, it is 
necessary to first examine the organization of the genetic code.  The genome consists of 
three levels of organization: the actual DNA sequence, the histones around which 
DNA is wrapped, and the chromatin, the highest level. Changes at both the DNA level 
and the histone level may influence the transcription of the chromatin.  Chromatin is 
divided into two categories, according to its degree of transcription: euchromatin and 
heterochromatin.  Euchromatin is more open and transcriptionally active while 
heterochromatin is less accessible to transcriptional machinery and is, therefore, 
transcriptionally silenced (Nelson and Monteggia 2011; Sananbenesi and Fischer 
2009).  Epigenetic changes at either the DNA level or histone level can alter 
heterochromatin to become transcriptionally active, or euchromatin to become 
transcriptionally silenced. 
DNA METHYLATION 
The two major pre-transcriptional epigenetic modifications are those that occur 
at the DNA level, such as DNA methylation, and those that occur at the histone level, 
such as histone modification.  DNA methylation consists of adding a methyl group to 
the 5’ carbon of cytosine within CpG sequences (sequences of cytosine-guanine 
nucleotides).  These CpG sequences often repeat within the genome, especially within 
the promoter regions of genes, and are then known as CpG islands (Lubin 2011).  
METHYLATION AND DEMETHYLATION: MECHANISMS  
DNA methylation is 
catalyzed by DNA 
methyltransferases (DNMTs), 
which transfer a methyl group from 
S-adenosylmethionine to the 5’ 
carbon of cytosine (Lubin 2011). 
There are three distinct DNMTs in 
humans: DNMT1, which is 
primarily involved in ensuring that 
the methylation pattern of DNA is 
conserved during DNA replication, 
and DNMT3a and DNMT3b, 
which are able to methylate DNA de 
novo, at a previously unmethylated 
position (see Figure 1) (Nelson and 
Monteggia 2011). DNMTs are 
selective in their methylation, only 
methylating specific cytosines.  One 
possible selectivity mechanism is 
that DNMT1s are targeted towards 
hemimethylated CpG islands, or 
islands that have methyl groups 
attached on one side.  A second 
targeting technique is that of 
histone modification marks, which 
Figure 1: De novo methylation occurs via DNMT3a 
and DNMT3b, while maintenance replication occurs 
via DNMT1, which targets hemimethylated DNA. 
Source: Yu et al. 2011 
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will be discussed shortly.  Yet a third possibility involves small non-coding RNAs, 
although this has not been described yet in mammals (Yu et al. 2011).  This selectivity 
of DNMTs facilitates the creation of a methylation pattern that can be tissue-specific 
and event-dependent. 
Methylation via DNMTs is a clear and well-known process; however, scientists 
are still investigating whether that process is reversible, allowing demethylation to 
occur (see Figure 2).  While passive demethylation (i.e. demethylation due to a lack of 
DNMT activity) is widely accepted, active demethylation remains a puzzle.  
Methylation creates a covalent bond; as such, it is considered the most stable 
epigenetic mark (Yu et al. 2011).  Over the past decade, though, there have been 
several reports of active demethylation.   
Two candidate mechanisms for active demethylation exist.  One is an excision 
repair-based mechanism involving growth arrest and DNA damage-inducible 
(Gadd45# and Gadd45&) proteins.  A recent study found that overexpression of 
Gadd45 proteins was correlated with global DNA demethylation while Gadd45 
knockdown was correlated with hypermethylation.  Presumably, Gadd45 proteins 
recruit DNA damage repair machinery, which replaces the methylated cytosine with 
an unmethylated cytosine (Barreto et al. 2007).  A second possibility is that ten-eleven 
translocation 1 protein causes demethylation by converting 5-methylcytosine to 5-
hydroxymethylcytosine, which leads to demethylation (Yu et al. 2011).  Although it 
appears that active demethylation occurs, further research is required to elucidate its 
exact mechanism. 
REGULATION OF METHYLATION 
Methylation is regulated by DNMTs; however, how are DNMTs regulated?  
The exact mechanisms that regulate the expression of DNMTs are currently unclear 
(Nelson and Monteggia 2011).  It is known, however, that DNMTs are actively 
regulated across different regions of the body and across a lifetime.  Both DNMT1 and 
DNMT3a are expressed differentially in cortical neurons, especially in interneurons, in 
the brain of human adults.  Fascinatingly, the expression of DNMT3a is greater 
during embryogenesis and then declines into adulthood while the expression of 
DNMT3b increases into adulthood (Lubin 2011).  This active regulation of DNMTs 
indicates the dynamic nature of DNA methylation.  
Figure 2: Cytosine group is methylated by DNMT1 and DNMT3a, as well as DNMT3b (not 
shown in figure) and demethylated by an unknown mechanism, although there are some 
possible explanations for this mechanism. Source: Korzus 2010 
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IMPACT OF METHYLATION 
DNA methylation generally causes transcriptional repression through two 
possible mechanisms (see Figure 3).  First, it can act as a docking site for proteins that 
contain a methyl-binding domain, such as the methyl-CpG binding protein2 (MeCP2).  
These proteins, especially MeCP2, can recruit histone-modifying enzymes that aid in 
the formation of heterochromatin (Nelson and Monteggia 2011).  Second, the 
methylated cytosine residues hinder transcription by repelling transcriptional 
activators (Yu et al. 2011).  The usual result of DNA methylation is, therefore, 
transcriptional repression. 
 HISTONE MODIFICATIONS 
The second major pre-transcriptional epigenetic regulation occurs at the 
histones, through histone modification.  Before examining histone modifications, 
further explanation regarding the nature of a histone is necessary.  A histone is a small, 
highly basic protein consisting of a globular domain and a flexible N-terminus.   The 
histone binds DNA, which is wrapped around it.  Eight histones, linked as an octamer, 
form a nucleosome, which consists of two molecules of each core histone: H2A, H2B, 
H3, and H4.  The N-termini of the histones protrude from the nucleosome and are 
referred to as “histone-tails” (Sananbenesi and Fischer 2009).  It is these histone tails 
that can be modified by the addition of one of several molecular groups: acetyl, methyl, 
phosphate, SUMO, or ubiquitin.  Each of these molecular groups influences 
transcription differently (Mikaelsson and Miller 2011).  
MODIFICATION: MECHANISM 
The modification of the 
histone tail by each group is 
catalyzed by a different group of 
enzymes.  The only class of 
enzymes that is explored in 
much detail in terms of memory 
is that of the acetyl group. The 
acetyl group consists of histone 
acetyltransferases (HATs), 
which add the acetyl group, and 
histone deacetyltransferases 
(HDACs), which remove an 
acetyl group (see Figure 4) 
(Nelson and Monteggia 2011).  
HDACs form a significant part 
Figure 3: DNA methylation causes MeCP2 to bind to DNA, which recruits repressor enzymes, 
suppressing transcription. Source: Lubin 2011 
Figure 4: Acetylation of histone tails occurs via HATs, and 
deacetylation occurs through HDACs. Source: Korzus 2010 
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of cognitive epigenetics.  Two classes of HDACs are Class I HDACs (HDACs 1, 2, 3, 
8) and Class II HDACs, which can be further divided into Class IIa (4, 5, 7, 9) and 
Class IIb (6, 10).   Class I HDACs are generally localized to the nucleus, although 
HDAC3 can be found in both the cytoplasm and the nucleus.  These HDACs are 
highly expressed in the mature neuron, with HDAC3 having the highest expression 
levels in the hippocampus, cortex, and cerebellum (Haggarty and Tsai 2011; 
McQuown and Wood 2011).  Class II HDACs shuttle between the nucleus and 
cytoplasm in response to phosphorylation signals and are more specifically expressed 
(Nelson and Monteggia 2011).  Much interaction occurs between HDACs.  HDAC3, 
for instance, can interact with HDACs 4, 5, 7, and 10 (Haggarty and Tsai 2011). 
HDACs can be inhibited using small molecule probes called HDAC inhibitors, 
or HDACis.  These probes inhibit histone deacetylase activity, thus increasing histone 
acetylation and generally increasing gene upregulation.  Three classes of probes that 
have been explored in terms of memory are carboxylic acids (e.g. butyrate and 
valproate), hydroxamic acids (e.g. trichostatin A and suberoylanilide hydroxamic 
acid), and ortho-aminoanilines (e.g. MS-275) (Haggarty and Tsai 2011).  Potentially, 
HDACis can be administered therapeutically to change the histone acetylation level. 
IMPACT OF MODIFICATION 
Each group has a different effect on transcription.  Acetyl and phosphate 
groups, which are negatively charged, reduce the affinity of the histone tail for the 
negatively charged DNA backbone, so the DNA has a more “open” conformation and 
is more easily transcribed (Lubin 2011). Additionally, acetyl groups facilitate 
recruitment of bromo-domain coactivators, such as chromatin-associated proteins and 
histone acetyltransferases, which bind the acetyl-lysine motifs and promote 
transcription (McQuown and Wood 2011). SUMOylation and ubiquitination have the 
opposite effect on transcription (Lubin 2011).  Methylation, on the other hand, can 
activate or repress transcription depending on the methylation site and the number of 
methyl groups that are added.  It influences transcription by serving as a docking site 
for activator/repressor proteins to restructure chromatin, not through its electrical 
charge (Lubin 2011).  The varied effects of the groups on transcription allow for a 
large degree of precision in epigenetic regulation. 
CROSS-TALK BETWEEN DNA METHYLATION AND HISTONE 
MODIFICATION 
DNA methylations and histone modifications often interact, producing 
interesting results.  First, DNA methylation may change the pattern of histone 
modifications.  Methylated CpG islands recruit proteins that interact with HDACs to 
mediate repression of target groups.  Second, histone marks can target DNMTs to 
specific DNA sequences.  This effect is demonstrated at the unmethylated histone 
H3K4, which becomes a docking site for DNMTs, resulting in de novo DNA 
methylation and transcriptional repression (Lubin 2011).  Third, histone modifications 
are often interdependent.  A hypoacetylated H3 tail is targeted in phosphorylation of 
H3S10 residues, and the phosphorylation of H3S28, methylation of H4K20, and 
dimethylation of H3K4 are interdependent on HDAC3 (McQuown and Wood 2011). 
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MEMORY AND SYNAPTIC PLASTICITY 
Even with an understanding of epigenetics, an understanding of memory is still 
required.  Memory on a cellular and molecular level is a much studied but little 
understood phenomenon.  The accepted model of memory claims that memories are 
encoded as connections between neurons.  In this model, neuronal connections are 
altered as new memories are encoded, either by growing new dendrites or altering 
synaptic strength (Squire 2011).  This model is known as synaptic plasticity. 
Long-term potentiation (LTP) and long-term depression (LTD) are two 
examples of synaptic plasticity.  LTP refers to the enhanced synaptic transmission 
between two neurons, resulting from a short burst of high-frequency stimulation of the 
presynaptic fibers.  LTD can be seen as the opposite of LTP; it involves decreased 
synaptic transmission due to low-frequency stimulation of the presynaptic fibers 
(Squire 2011).  Both phenomena are persistent, lasting for hours or even weeks, yet 
they are triggered by a transient stimulus (Squire 2011).  LTP, LTD, and long-term 
memory (LTM) share this feature of a short stimulus affecting long-term neuronal 
change, as well as input specificity and an inability to be maintained in the presence of 
protein synthesis inhibitors (Day and Sweatt 2011).  Interestingly, enhancements or 
impairments in spatial memory are demonstrated in animals that have increases or 
decreases in hippocampal LTP, respectively (Nelson and Monteggia 2011).  These 
shared features strongly suggest that LTP is involved in memory formation. 
The next question that scientists ask involves the molecular changes that occur 
with LTP and LTM.  The rapid turnover of proteins within a cell belies the long-term 
effects of LTP (Day and Sweatt 2011).  There must be some kind of maintenance 
molecule to overcome the loss of acquired changes (Yu et al. 2011).  Crick postulated 
in 1984 that this maintenance molecule would form multimers or at least dimers, with 
each monomer able to exist in a modified (+) or unmodified (-) mode.  If a monomer is 
(+), then even if molecular turnover causes a newly synthesized linked monomer to be 
(-), the maintenance enzyme would alter it to become (+) (Yu et al. 2011).  This 
feature matches the activity of DNMTs in methylation of hemimethylated DNA 
perfectly (see above). Additionally, since both LTP and LTM cannot be maintained in 
the presence of protein synthesis inhibitors, it seems that changes in gene expression 
are a necessary component of memory formation (Day and Sweatt 2011; Nelson and 
Monteggia 2011).  Together, these features suggest that epigenetic regulation may act 
to mediate LTP, and through LTP, memory formation. 
EPIGENETICS AND MEMORY 
EVIDENCE OF EPIGENETIC CHANGES WITH LEARNING 
THE GLOBAL EPIGENOME 
In the past decade, much evidence has shown that the epigenome changes in 
response to learning or memory events.  The DNA methylation status of the genome 
changes drastically.  According to Sananbenesi, exposing rats to fear conditioning 
causes a brief rise in the hippocampal levels of DNMT3a and DNMT3b, presumably 
changing DNA methylation levels (Sananbenesi and Fischer 2009).  This was found to 
be true in a study performed by Feng and his colleagues that found a global 20% 
demethylation in DNMT1 and DNMT3a conditional double knockout mice that 
exhibited memory impairments.  That study also demonstrated that 84 genes were 
upregulated more than 1.5-fold and 7 genes were downregulated more than 1.5-fold in 
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these double knockout mice (Feng et al. 2010).  It has been shown that contextual fear 
conditioning triggers de novo DNMT gene expression in the adult hippocampus (Lubin 
2011).  DNA methylation appears to be affected in learning and memory. 
Besides causing changes in DNA methylation, learning and memory events 
appear to alter histone modifications.  According to Mikaelsson, novel taste learning in 
rats resulted in heightened acetylation of histone H2A and H4 in the insular cortex 
(Mikaelsson and Miller 2011).   Rats displayed a transient increase in histone 
acetylation 1 hour after exposure to fear conditioning (Mikaelsson and Miller 2011; 
Sananbenesi and Fischer 2009).  Correspondingly, HAT activity, which serves to 
acetylate histones, increased in the amygdala following cued fear conditioning, an 
amygdala- and hippocampal-dependent form of associative learning (Nelson and 
Monteggia 2011).  Learning and memory events appear to cause increased histone 
acetylation.   
Other histone modifications altered by learning include phosphorylation and 
methylation.  Increased histone H3 phosphorylation occurs at Ser10 residue in 
hippocampal area CA1 during the formation of contextual fear memory (Mikaelsson 
and Miller 2011).  Contextual fear conditioning also increases histone H3 
phosphoacetylation, H3K4 trimethylation, and H3K9 dimethylation in the 
hippocampus (Nelson and Monteggia 2011).  Thus, increases in histone 
phosphorylation and methylation are involved in learning and memory formation. 
BEHAVIORAL PHENOTYPE OF EPIGENETIC CHANGES 
Behaviorally, learning and memory appear to be dependent on DNA 
methylation and histone modifications changes.  In the aforementioned study by Feng 
and his colleagues (2010), it was shown that the DNMT double knockout mice, which 
had lost much of their ability to dynamically regulate DNA methylation levels, 
performed poorly in the Morris water-maze task, a hippocampus-dependent learning 
and memory task.  Generally, DNMT double knockout mice had impaired spatial 
learning and memory ability.  Other studies sought to determine the effect of the 
blockade of DNMT activity using DNA methylation inhibitors as opposed to mutated 
mice.  It was found that inhibition of DNA methylation by intrahippocampal injections 
of 5-aza or zebularine (two DNMT inhibitors) severely impaired memory 
consolidation (Sananbenesi and Fischer 2009).  These studies seem to prove DNMTs 
are necessary for long-term memory (LTM) formation. 
A second vital epigenetic change in memory and learning is that of histone 
modifications. HATs, which act to acetylate histones, include the cAMP response 
element-binding (CREB)-binding protein (CBP) and P300.  Both are necessary for 
hippocampal synaptic plasticity and long-term memory formation in both novel objects 
and contextual fear conditioning paradigms (Mikaelsson and Miller 2011; Sananbenesi 
and Fischer 2009).  In fact, mouse models that lack CBP and its HAT function 
demonstrate attenuated histone acetylation as well as impaired LTM (McQuown and 
Wood 2011).  LTM is seemingly dependent on HATs. 
Since HATs appear to be necessary for LTM, one would expect HDACs to be 
negative regulators of LTM; this has been shown to be true in mutant mouse models.  
Mice deficient in HDAC5 show enhanced learning in cocaine conditioned place 
preference, while mice that overexpressed HDAC4 or HDAC5 demonstrated a 
weakened expression of cocaine conditioned place preference (McQuown and Wood 
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2011).  Additionally, HDAC2 deficient mice experienced enhanced memory formation 
and synaptic plasticity while forebrain overexpression of HDAC2 (but not HDAC1) 
caused impaired memory formation and synapse formation (Nelson and Monteggia 
2011).  A study undertaken by McQuown and her colleagues demonstrated that 
HDAC3 deficiency enhanced LTM formation to such a degree that HDAC3 deficient 
mice that received subthreshold training (3 minutes) in a novel object recognition test 
did experience LTM formation, and those mice that had completely lost HDAC3 
function retained this memory for seven days, which is longer than the normal 
retention of object memory (2011).  It seems that HDACs negatively regulate LTM. 
Several studies have sought to confirm that HDACs negatively regulate LTM 
by examining the effect of HDAC inhibitors (HDACis) in wild-type mice.  The 
previously mentioned study by McQuown and her colleagues also found enhanced 
learning in wild-type mice that were injected with an HDACi, RGFP136 (2011).  
These mice experienced LTM even with subthreshold training conditions.  A second 
study, performed by Vecsey and his colleagues (2007), proved that HDAC inhibition 
in the hippocampus enhances memory consolidation for hippocampus-dependent 
learning by microinjecting mice with trichostatin A (TSA), an HDACi, directly after 
conditioning, and measuring their level of freezing when exposed again to the 
conditioned context.  Mice injected with TSA showed a notable enhancement in 
memory as compared to control groups.  This study also ruled out HDACi inhibition 
enhancement of memory retrieval, as opposed to consolidation, by microinjecting the 
mice with TSA four hours before re-exposure to the conditioned context: results were 
comparable for experimental and cued conditioning (Vecsey et al. 2007).  Additionally, 
the study repeated the protocol using non-hippocampal dependent conditioning in 
order to prove that the memory enhancement is due to the microinjections into the 
hippocampus; again, no differences were found between the TSA- and control-treated 
mice (Vecsey et al. 2007).  It appears that HDACis do enhance LTM formation in 
wild-type mice. 
HDACis have also been found to ameliorate loss of other epigenetic functions, 
such as those caused by inhibition of DNMTs or loss of HATs.  DNMT inhibitors 
impair memory, but this effect appears to be reversed by administration of TSA, an 
HDACi, prior to the test (Day and Sweatt 2011).  Loss of CBP, as mentioned above, 
impairs LTM, but not short-term memory, in a number of learning and memory tests.  
Administration of HDACis to Cbp mutant mice restores their memory function, 
probably because some CBP HAT activity remained active (Nelson and Monteggia 
2011). Oddly enough, when the same HDACis were administered to CBP conditional 
knockout mice, which lacked any expression of CBP in excitatory neurons of the 
forebrain, no restoration of memory function was observed; this was most probably 
due to the complete deficiency of CBP (Nelson and Monteggia 2011).  A similar effect 
was observed in the aforementioned study by Vecsey and his colleagues (2007).  
Memory enhancement was observed in CREB+/+ mice that were injected with TSA but 
not in the CREB#' (CREB-deficient) mice that were injected with it.  It appears that 
HDACis can act in a limited capacity to reverse memory impairment caused by 
deficiencies in other epigenetic functions. 
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EFFECT OF EPIGENETIC CHANGES ON LTP AND LTD 
After concluding that epigenetic changes heavily influence memory formation, 
the question is whether they influence synaptic plasticity (e.g. LTP and LTD).  DNA 
methylation does appear to play a role in both LTP and LTD.  A number of studies in 
mutant mouse models demonstrate that DNA methylation is necessary for LTM 
formation.  In a study performed by Feng and his colleagues (2010), the mice that 
were deficient in DNMT1 and DNMT3a, showed attenuation of LTP and enhanced 
induction of LTD.  Importantly, DNMT KO mice show no LTP after 1-2 hours, but 
the base response is still there, so the DNMTs must be acting in memory acquisition, 
not in initial synaptic transmission (Day and Sweatt 2011).  One explanation of why 
DNA methylation is so significant in LTP focuses on MeCP2, one of the mechanisms 
by which DNA methylation acts to repress transcription.  MeCP2 mutant mice show 
impairments in hippocampal LTP, hippocampal LTD, and cortical LTP, while MeCP2 
overexpressing mice show enhanced hippocampal LTP. Apparently, DNA methylation 
may mediate LTP through MeCP2. 
Other studies have sought to confirm that DNA methylation influences 
synaptic plasticity by examining the results of treatment with DNMT inhibitors.  
Brain slices treated with DNMT inhibitors show no LTP after 1-2 hours, but the base 
response is still there, so the DNMTs  must not be influencing the synaptic 
transmission itself (Day and Sweatt 2011).  Specifically, the LTP in hippocampal slices 
that were treated with the DNMT inhibitors zebularine and 5-aza was shown to be 
reduced in magnitude (Nelson and Monteggia 2011).   DNA methylation is significant 
to synaptic plasticity. 
Histone acetylation, as well, appears to play a role in synaptic plasticity, as 
studies using mutant mice models demonstrate.  HDAC2 overexpressing mice showed 
impaired hippocampal LTP (Nelson and Monteggia 2011) as well as decreased 
dendritic spine density and synapse number (Haggarty and Tsai 2011), while HDAC2 
forebrain-specific KO mice showed enhanced LTP (Nelson and Monteggia 2011) and 
increased synapse number (Haggarty and Tsai 2011).  Additionally, heterozygous Cbp 
mutant mice showed impaired hippocampal late-phase LTP with a normal stimulation 
protocol; however, with a stronger stimulation protocol, no impairment was observed.  
Histone acetylation is crucial for synaptic plasticity. 
Several studies have sought to confirm the involvement of epigenetic changes in 
synaptic plasticity, using the effects of HDACis on wild-type mice.  The study 
performed by Vecsey and his colleagues (see above) demonstrated that HDACis 
enhanced LTP in hippocampal slices from wild-type mice (Vecsey et al. 2007).  Their 
controls included mice that were injected with TSA and actinomysin D, a substance 
that prevents transcription, to prove that HDACis act through transcription-
dependent mechanism.  Most HDACis appear to have this effect on LTP.  Treatment 
of hippocampal slices with TSA and sodium butyrate, an HDACi, resulted in 
enhanced LTP induction at Schaffer-collateral synapses, while treatment of amygdala-
containing slices with TSA resulted in enhancement of forskolin-induced LTP (Nelson 
and Monteggia 2011).  Last, treatment of hippocampal slices with suberoylanilide 
hydroxamic acid enhanced late-phase LTP in wild-type mice but had no effect on 
HDAC2 KO mice, showing that HDACis are effective due to their effect on HDACs 
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(Nelson and Monteggia 2011).  HDACis do enhance LTP in wild-type mice, 
confirming a role for histone acetylation in LTP. 
Other studies examined the ability of HDACis to compensate for the effects of 
other epigenetic deficiencies.  HDACis compensate for the loss of DNMT activity 
through DNMT inhibitors; treatment with TSA prior to testing reverses the effect of 
DNMT inhibitors on LTP (Day and Sweatt 2011).  Additionally, HDACis can 
somewhat attenuate the effects of a loss of CBP function.  The treatment of 
hippocampal slices with suberoylanilide hydroxamic acid does ameliorate the LTP 
deficit generally observed in Cbp+/- mice (Nelson and Monteggia 2011).  However, 
TSA treatment of CREB#' mice and mice with a genetic disruption between CREB 
and CBP did not enhance LTP.  Apparently, HDACis can compensate somewhat for 
the loss of other epigenetic changes. 
MECHANISM OF EPIGENETIC CHANGES AND MEMORY 
Now that it is clear that epigenetic changes are involved in memory, the next 
step is to determine how they influence memory.  Intriguingly, as explained above, 
memory appears to be dependent on both histone acetylation and DNA methylation 
(see Figure 5).  This is rather incongruous as histone acetylation increases 
transcription while DNA methylation decreases transcription.  The apparent 
inconsistency can be explained by viewing these epigenetic modifications as gene-
specific, so that histone acetylation upregulates some genes whereas DNA methylation 
downregulates other genes. There are many genes, as well as some non-histone 
substrates of histone-modifying enzymes, that are regulated by these epigenetic 
changes. 
Figure 5: Histone acetylation and DNA methylation are necessary for memory formation and LTP.  Histone 
deacetylation and DNA demethylation impair memory formation and LTP. Source: Nelson and Monteggia 2011 
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EPIGENETIC PROTEINS 
Interestingly, several enzymes that are instrumental in epigenetics are 
themselves regulated by epigenetics.  First, DNMT1, the enzyme that methylates 
DNA, is itself a target of histone methylation enzymes (Lubin 2011).  Second, 
HDAC1, which acts to deacetylate histones, is a substrate of histone acetylation 
enzymes (Lubin 2011). Third, the HATs p300, CBP, and p300/CBP-associated 
protein, are their own targets; each can act to acetylate itself, a process known as auto-
acetylation (Lubin 2011).  They can also be deacetylated by HDAC3, in combination 
with a corepressor known as nuclear receptor co-repressor 1 (McQuown and Wood 
2011).  Histone-modifying enzymes modify both DNA methylation enzymes and other 
histone-modifying enzymes. 
MEMORY GENES 
Several genes that are known to be involved in memory are regulated via 
epigenetics.  The promoter of reelin, which enhances LTP, shows a robust response 
when exposed to DNMT inhibitors while learning (Mikaelsson and Miller 2011).  
DNMT inhibitors also modify DNA methylation in the adult brain at the promoter of 
bdnf, a gene that is crucial for memory (Day and Sweatt 2011).  Electroconvulsive 
treatment, which causes LTP, decreases the methylation level of specific regulatory 
regions of bdnf (Yu et al. 2011).  Interestingly, bdnf promoters are differentially 
methylated in memory.  Bdnf exon I promoter is demethylated by chronic network 
activity caused by picrotoxin treatment of cultured neurons, as well as contextual 
exposure to living animals; the methylation level of this promoter is correlated with 
object recognition memory task performance (Yu et al. 2011).  Bdnf exon IV promoter, 
which is generally basally-repressed by MeCP2, becomes demethylated and, thereby, 
expressed following high potassium induced neuronal depolarization in rodent primary 
neuron culture (Yu et al. 2011).  Interestingly, bdnf demethylation may be active, 
caused by Gadd45&, as discussed above, since Gadd45&-KO mice displayed no 
significant demethylation at regulatory region of bdnf exon IX in response to 
electroconvulsive treatment, thus downregulating bdnf expression (Lubin 2011).  Both 
reelin and bdnf are regulated by DNA methylation. 
Bdnf is also regulated by histone modifications.  Fear conditioning causes the 
upregulation of bdnf exons I and IV, which is associated with increased histone 
acetylation and phosphorylation at those promoters.  Additionally, extinction of fear 
conditioning in mice is associated with an increase in histone H4 acetylation around 
the promoter of bdnf exon IV.  Bdnf is regulated epigenetically to influence LTM 
formation. 
Two memory suppressor genes, Re1n and Pp1 are also regulated by DNA 
methylation.  Interestingly, although DNMT inhibitors upregulate Re1N and Pp1, 
DNMT1 and DNMT3a conditional double knockout mice have normal expression of 
both genes (Feng et al. 2010; Nelson and Monteggia 2011).  PP1 may actually 
participate in regulating other epigenetic modifications at the promoters of Creb and 
nuclear factor-kappa B (NF-!B).  Pp1 and Re1N may be epigenetically modified during 
memory formation. 
TRANSCRIPTION GENES 
Several genes that are involved in transcription experience epigenetic 
modification during memory formation.  Nr4a1 and Nr4a2, which are both immediate 
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early genes (IEGs), acting to transcribe other genes, are regulated by histone 
acetylation.  After TSA-induced memory enhancement, CBP-dependent expression of 
Nr4a1 and Nr4a2 occurred (Vecsey et al. 2007).  Additionally, increased Nr4a2 
expression was observed in the area of focal HDAC3 deletion in the dorsal 
hippocampus two hours after subthreshold training (McQuown and Wood 2011).  
Remarkably, the silencing of Nr4a2 through small interfering RNA attenuates the 
memory enhancing effects of HDAC3 deficiency in novel object memory (Haggarty 
and Tsai 2011), indicating that Nr4a2 may interact with CBP and/or HDAC3 in their 
epigenetic roles, besides for being regulated by them. 
A second IEG is Egr1, which is also influenced by histone acetylation.  Egr1 is 
upregulated in the hippocampus by associative learning.  This appears to be mediated 
by BDNF, which causes HDAC2 to leave chromatin.  H3 and H4 in the Egr1promoter 
are thereby acetylated, causing transcription.   The expression of Egr1 is affected by 
histone acetylation. 
A third transcription factor is NF-!B, previously discussed in the context of 
PP1, which may act to regulate it.  The promoter of NF-!B experiences reduced 
phosphorylation during novel object recognition (Mikaelsson and Miller 2011).  NF-
!B itself has been implicated in the induction of synaptic plasticity and initial 
formation of LTM.  One of its subunits, p65/Re1A, is actually activated as one of the 
non-histone substrates of histone-modifying enzymes.  It is the target of both histone 
methylation and histone acetylation enzymes (Lubin 2011).  HDAC2 acts to negatively 
regulate it, and treatment with TSA results in prolonged p65 acetylation with a 
resulting increase in NF-!B DNA binding activity as well as enhanced memory 
formation.  This enhancement in memory is attenuated by inhibitors of NF-!B DNA 
binding activity, indicating that this may be a mechanism whereby HDACis cause 
enhanced memory formation (Lubin 2011).  NF-!B is regulated epigenetically to 
influence memory formation. 
Other IEGs and transcription factors include c-Fos, transcription factor p53, 
and MEF2.  Increased c-Fos expression was noted in the area of focal HDAC3 deletion 
in the dorsal hippocampus two hours after subthreshold training (McQuown and 
Wood 2011).  Transcription factor p53 is a non-histone substrate of histone-
methylating and histone-acetylating enzymes (Lubin 2011).  MEF2, a transcription 
factor important for regulation of structural plasticity genes, can be deacetylated by 
HDAC3, thus terminating the transcription of plasticity genes. 
IMMUNE FUNCTION GENES 
Interestingly, several genes that are involved in immune function may be 
involved in memory as well, including MHC 1, Stat1, and calcineurin.  MHC 1 is highly 
upregulated in DNMT double knockout mice (Feng et al. 2010).  Stat1, which is 
important for synaptic function in CNS and learning/memory, is also highly 
upregulated in neuronal cells of DNMT double knockout mice (Feng et al. 2010).  
Calcineurin is regulated by a methylation change that occurs in contextual fear 
conditioning (Yu et al. 2011).  These genes may be involved in signaling pathways that 
influence memory formation. 
 Epigenetics: a Possible Mechanism of Memory 55 
 
OTHER NON-HISTONE TARGETS OF EPIGENETIC ENZYMES 
There are several other non-histone substrates of chromatin-modifying 
enzymes.  The estrogen receptor alpha is targeted by both histone methylation and 
histone acetylation enzymes.  Both tubulin and the glucocorticoid receptor are 
substrates of histone-acetylating enzymes.  The function of these proteins in memory is 
unclear. 
REGULATION OF EPIGENETIC CHANGES IN MEMORY 
Epigenetics clearly influences memory via regulation of genetic transcription.  
How, though, is epigenetics itself modulated by the physical cause of memory, 
neuronal stimulation?  Clearly, increased synaptic activity triggers DNA methylation 
changes and histone modification changes.  N-methyl-D-aspartate receptor activation 
is a crucial part of the signaling pathway.  It activates MAPK signaling which is 
instrumental in hippocampal H3 acetylation (Sananbenesi and Fischer 2009).  The 
ERK/MAPK pathway is crucial for heightened acetylation of H2A and H4 in insular 
cortex due to novel taste learning in rats, histone acetylation associated with 
hippocampus-dependent fear memory, and histone H3 phosphorylation during 
formation of contextual fear memory (Mikaelsson and Miller 2011).   Additionally, N-
methyl-D-aspartate receptor activation is actually linked to both bdnf DNA 
methylation and changes in the levels of histone H3K4me3 at the bdnf promoter IV in 
response to contextual fear conditioning (Lubin 2011).  Other pathways that may be 
involved in DNA methylation mediation are the protein kinase C and NF-!B 
pathways (Lubin 2011).  Synaptic activity may act through N-methyl-D-aspartate 
receptor activation to initiate signaling cascades that cause epigenetic modifications to 
occur. 
FUTURE DIRECTIONS 
Although it is clear that epigenetics is heavily involved in memory formation, 
there are still many questions that must be clarified.  These questions can be classified 
into three categories: those regarding memory alone, those involving epigenetic 
changes and memory, and those investigating therapeutic potential of epigenetics.  
According to Haggarty (2011), it is crucial to understand the roles of the individual 
genes implicated in memory in order to comprehend the ways in which epigenetic 
modifications affect them.  Before understanding memory, it is unfeasible to 
understand how epigenetics affects memory. 
A second direction is to examine the ways in which epigenetic modifications 
affect memory.  One problem involved is that of cross-talk between epigenetic 
modifications (e.g. histone acetylation affecting DNA methylation, etc.).  Researchers 
should undertake to study the epigenome and neuron as a whole, investigating all 
aspects of memory formation in order to understand how they interact (Haggarty and 
Tsai 2011).  Another part of epigenetic modification that must be clarified is that of 
how a cell-wide modification affects synapse selectivity.  Although there are several 
theories that attempt to explain this, no studies have examined it in depth (Day and 
Sweatt 2011).  A third difficulty is that of differentiating between epigenetic 
modifications that are transient and activity-induced and can therefore be implicated in 
acquisition, and those that are more stable and likely involved in consolidation (Yu et 
al. 2011).  Answering these puzzles is a significant step in understanding epigenetics. 
56 Aliza Grossman Rubenstein 
The last class is that of examining the potential of HDACi as a therapeutic 
drug.  The memory enhancement ability of HDACi seems to indicate its utility as a 
therapeutic drug for cognitive diseases such as Alzheimer’s disease and Huntington’s 
disease.  Several questions must be answered, though, before it can be used clinically.  
First, the selectivity of different HDACis must be determined.  Since non-histone 
substrates and histone substrates are involved, it is necessary to determine how 
different HDACis will affect each of them.  Currently, most HDACis affect all 
HDACs, which may be too general for therapeutic utility.  More research should be 
undertaken to find other, more specific, HDACis (Haggarty and Tsai 2011).  
Additionally, the absorption, distribution, metabolism, excretion, and 
pharmacokinetics of HDACis must be studied (Haggarty and Tsai 2011).  Although 
HDACis have great potential, much must be answered before they can be used. 
CONCLUSION 
Epigenetic modifications play a large role in memory formation. They modify 
genetic expression of many genes and proteins that are involved in transcription and 
memory formation.  Although it is still unclear how exactly epigenetics fulfills the 
requirements of a molecular mechanism of memory formation, it definitely holds much 
potential for future research and investigation of its role.  The mind-body connection 
may be elucidated after all. 
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IMATINIB RESISTANCE IN PHILADELPHIA 
CHROMOSOME-POSITIVE CHRONIC MYELOID 
LEUKEMIA 
Rivky Kops 
Chronic myeloid leukemia (CML) is a disorder of blood stem cells in bone 
marrow, which leads to a rapid production of white blood cells. Of the patients 
diagnosed with CML, 95% have the Philadelphia (Ph) chromosome, which means that 
chromosome 22 is smaller than regular (22 q-).  Historically, the median survival time 
for chronic phase CML patients was four to five years, while the accelerated and blast 
(profusion of immature red blood cells in circulation) phases had a much shorter 
survival time.  Recently, due to the revolutionary new drug imatinib, CML patients 
diagnosed early have a higher survival rate.  Nevertheless, some patients may show 
resistance to imatinib, and alternative treatments must be considered (Hochhaus and 
La Rosée 2004).   
CHRONIC MYELOID LEUKEMIA 
Chronic myeloid leukemia originates in a single pluripotent bone marrow stem 
cell.  It accounts for approximately 15% of all leukemia cases (Liesveld and Lichtman 
2011).  As shown in Figure 1 below, the long (“q”) arms of chromosome 9 and 22 swap 
DNA, resulting in a longer chromosome 9 (9q+) and shorter chromosome 22 (22q-). 
Chromosome 22q- is known as the Philadelphia chromosome and is the 
identifying characteristic of CML in over 90% of cases.  It occurs when the Abelson 
oncogene (ABL) of chromosome 9 at 9q34 fuses with the breakpoint cluster region 
(BCR) of chromosome 22 at 22q11.  BCR is a multiplier gene, and ABL codes for a 
tyrosine kinase which is heavily suppressed in healthy cells (Encyclopedia of the 
Human Genome).  The resulting BCR-ABL gene codes for a constitutively active 
tyrosine kinase which induces rapid stem cell differentiation by inducing cell growth 
and bypassing signals that block cell mitosis.  These new BCR-ABL+ stem cells have 
Figure 1: Normal chromosomes 9 and 22, and 9q+ and 22q- resulting 
from the reciprocal BCR-ABL translocation. Source: Litzow 2006 
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lower proliferation capacities compared to normal stem cells, but the tremendous 
increase in stem cells results in a net increase in leukocytes .  Granulocytes, and often 
megakaryocytes, are the main cells arising from the malignant stem cells.  However, 
studies have also found erythroblasts and macrophages with the Philadelphia 
chromosome, leading to the belief that CML arises in a pluripotent stem cell (Liesveld 
and Lichtman 2011).   
Early stage chronic myeloid leukemia is asymptomatic; the abnormally high 
percentage of white blood cells compared to red blood cells is frequently only detected 
as part of a routine complete blood count. Common CML symptoms are anemia; 
extreme blood granulocytosis; splenomegaly; early satiety and unintentional weight 
loss; and, seldom, thrombocytosis.  A chronic phase is usually followed by an 
accelerated phase, which is characterized by blasts making up 15% of the red blood 
cells circulating in the bloodstream.  Historically, median survival rate in the 
accelerated phase has been one to two years, with many dying before reaching blast 
crisis.  Blast phase, characterized by 30% immature cells, had a median survival of 
three to six months.  Ninety percent of patients are diagnosed in the chronic stage. In 
the chronic stage, survival rates and remission rates are more optimistic compared to 
the accelerated and blast phases (Pemmaraju et al. 2011). 
There are three markers of remission: hematological, cytogenetic, and 
molecular response.  Complete hematological remission is marked by white blood cell 
counts returning to normal levels of less than 10 x 109/L and the disappearance of 
CML symptoms.  However, while quality of life is much improved with the 
normalization of white blood cell counts, hematological remission is a poor indicator of 
long-term survival.  Cytogenetic response means that cells bearing the Ph chromosome 
are not being produced.  Partial cytogenetic response is defined as 1 to 35% of 
metaphases remaining Ph positive, while complete cytogenetic response means that no 
mature cells bear the Ph chromosome.  Complete molecular response means that there 
are no detectable BCR-ABL transcripts (Pemmaraju et al. 2011).  In an IRIS 
(International Randomized Study of Interferon and STI-571) trial, which compared 
the efficacy of drugs targeting CML, achieving a complete cytogenetic response was 
determined to be the most important factor in long-term survival.  Of the patients 
achieving complete cytogenetic response but incomplete molecular response, the five-
year survival rate was 98% (Wetzler et al. 2012).  Therefore, achieving a complete 
cytogenetic response was established as the goal of treatment (Pemmaraju et al. 2011).  
Progression-free survival, which means that patients have not progressed from the 
chronic phase to a more advanced state, is also used as a benchmark of successful 
therapy, since patients in the chronic phase usually experience few side effects and 
have a higher quality of life. 
Because the vast majority of CML patients display the Ph chromosome, the 
BCR-ABL fusion is the best target for therapy to treat CML.  Imatinib is the first truly 
targeted drug to inhibit a tyrosine kinase (Marx 2001), and it has granted CML 
patients a hopeful prognosis. 
IMATINIB 
Imatinib, a highly targeted tyrosine kinase inhibitor, uses hydrogen bonding to 
bind to the contact site in the inactive configuration of the BCR-ABL kinase. This 
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hinders the ATP binding site so that the affected cell has no source of energy for 
proliferation and survival. This process is shown in Figure 2. 
Imatinib also induces apoptosis in 
Philadelphia-chromosome-positive cells without 
affecting Ph negative cells (Moen et al. 2007).  It has 
a very high success rate, and patients diagnosed in the 
early chronic phase now have an estimated survival of 
20 to 30 years.  The rate of complete cytogenetic 
response for early chronic phase is about 80%, and 
five-year progression-free survival is 96.7%.  Imatinib 
is well tolerated, with less than 3% of patients 
showing resistance to it (Pemmaraju et al. 2011).  The 
structure of imatinib is shown in Figure 3. 
Prior to the introduction of imatinib, patients were treated with interferon 
(IFN-#), which treated CML more effectively than standard chemotherapy.  IFN-# 
was successful in achieving a complete cytogenetic response in 5 to 25% of patients.  
Combining IFN-# with cytarabine yielded better results and a greater probability of 
survival.  In an IRIS trial, patients were randomly chosen for either IFN-# with 
cytarabine or imatinib.  Imatinib showed significantly higher rates of complete 
cytogenetic response and lower toxicity levels than IFN-# with cytarabine.  At 19 
months, the percent of imatinib-treated patients achieving complete cytogenetic 
remission was 79%, compared to 11% achieved in patients treated with IFN-# with 
cytarabine. At the five-year follow-up, the percent of complete cytogenetic remission 
from imatinib had increased to 82%. There are no five-year follow-up data for the 
group taking IFN-# because most of that group switched to imatinib treatment.  
Additionally, health-related quality of life was maintained among the patients on 
imatinib, while those receiving IFN-# with cytarabine experienced a deterioration in 
Figure 2: Imatinib (STI571) filling ATP binding site of BCR-ABL tyrosine kinase. Source: Feng 
et al. 2010 
 
Figure 3: Structure of imatinib. 
Source: Chabner et al. 2011. 
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quality of life.  Imatinib was therefore established as the primary therapy for chronic 
myeloid leukemia (Moen et al. 2007). 
The standard dose for imatinib is 400 mg/day, with doses under 300 mg/day 
yielding unsatisfactory results.  The TOPS (Tyrosine Kinase Inhibitor Optimization 
and Selectivity) trial investigated the possible benefit of doubling imatinib dose to 800 
mg/day.  While patients taking 800 mg/day initially fared better, the percentages of 
complete cytogenetic responses over a longer period were nearly equal: 64% for 800 
mg/day and 58% for 400 mg/day. Since long-term toxicity levels have not been 
assessed for the higher dose, the standard dose is currently 400 mg/day (Pemmaraju et 
al. 2011). 
Imatinib, unlike previous treatments for CML, is unique in that it can effect a 
hematological remission for patients in the accelerated and blast phases (Marx 2001). 
However, 4-5% of patients on imatinib, particularly those who have progressed past 
the chronic stage, become resistant to the drug and relapse (Biotech Business Week 
2006), including 80% of patients in blast crisis (Marx 2001).  Others may never 
achieve remission with imatinib. 
IMATINIB RESISTANCE 
Imatinib resistance results from BCR-ABL gene amplification and point 
mutations.  Some causes of resistance can be countered by dose escalation, while 
others render imatinib useless. 
Some patients relapse due to gene amplification, which leads to increased 
kinase activity.  The BCR-ABL gene produces more tyrosine kinase than standard 
dose imatinib (400 mg/day) can counter.  The tyrosine kinase produced by BCR-ABL 
overexpression causes too many leukemia cells to be produced. While imatinib still 
functions properly, the leukemia cells proliferate at an even faster rate than usual.  If 
the patient has not become imatinib resistant, an increased dosage of 600 or 800 
mg/day may overcome the rapid proliferation of cells and bring about a remission.  In 
particular, patients who achieved a complete cytogenetic remission and then lost the 
remission benefit from increased dosage (Pemmaraju et al. 2011). 
Some patients are completely resistant to imatinib. Imatinib resistance is 
categorized as either primary or acquired.  Primary resistance means that the patient 
never responds to the medication.  Acquired resistance means a loss of imatinib-benefit 
after previously benefiting from it, which can be on a hematological, cytogenetic, or 
molecular level (Hochhaus and La Rosée 2004). 
Point mutations, individual changes in gene sequencing, often confer drug 
resistance. They are thought to occur due to the inherent genetic instability of 
cancerous cells (Marx 2001). The dominant mechanism of imatinib resistance is 
genetic mutation in the kinase domain (ABL portion) of BCR-ABL.  The mutated Ph 
chromosome contains an amino acid residue different than the regular BCR-ABL 
oncogene, coding for a slightly different tyrosine kinase.  Since imatinib competitively 
inhibits the BCR-ABL tyrosine kinase by snugly fitting into the contact site, any 
change in the binding site can prevent it from binding effectively.  Additionally, 
mutations often lock the protein in its active configuration, and imatinib binds only to 
the inactive configuration.  Imatinib’s pronounced specificity in binding makes 
resistance common (Liesveld and Lichtman 2011).  
 Imatinib Resistance 61 
 
There are four main regions of the protein that are prone to resistance-
conferring mutations:  the ATP binding loop, or P-loop; the imatinib contact site; the 
catalytic domain; and the activation loop, which controls catalytic activity and changes 
conformation depending on protein activation (Litzow 2006).  Although over 40 point 
mutations have been identified, 85% of mutations occur at seven amino acid residues: 
M244V, G250E, Y253F/H, and E255K/V in the P-loop; T315I at the contact site; 
M351T and F359V in the catalytic domain (Cang and Liu 2008).  Usually only a single 
point mutation is detected in an imatinib-resistant patient, but occasionally patients 
have multiple mutations (Hochhaus and La Rosée 2004).  
P-loop mutations account for 36-48% of all mutations (Cang and Liu 2008).  
The tyrosine kinase is composed of two flexible loops: the P-loop and the activation 
loop (An et al. 2010).  When a mutation occurs in the P-loop, the configuration 
changes, causing the activation loop to fold outward into the active configuration and 
remain that way.  Imatinib binds only to the inactive form of BCR-ABL and is, 
therefore, ineffective against most forms of P-loop mutations (Litzow 2006). 
Contact site mutations confer high levels of resistance as well.  The 315th amino 
acid of the tyrosine kinase serves as a contact point for imatinib.  The threonine 
present at 315 forms a hydrogen bond with imatinib, a step that is crucial in order for 
imatinib to fill the ATP binding pocket (Hochhaus and La Rosée 2004).  The switch of 
threonine to an isoleucine residue confers resistance in two ways.  First, isoleucine 
does not form a hydrogen bond with imatinib like threonine does, so imatinib cannot 
form the bond critical for the drug’s inhibitory effect on tyrosine kinase.  Second, 
isoleucine is bulkier than threonine, so it acts as a “gatekeeper” by adding residue to 
the contact site, sterically hindering imatinib (Tanaka et al. 2010).  In fact, the T315I 
mutation confers resistance to all second-generation tyrosine kinase inhibitors as well, 
as will be expounded upon later.  
According to the MD Anderson algorithm for treating CML, if a patient has 
not achieved a complete hematological response within three months from the start of 
treatment, the patient is deemed imatinib resistant and switched to a different 
treatment method.  Likewise, a patient who has not achieved a complete cytogenetic 
remission at 18 months is switched to a different therapy.  If at any point in imatinib 
treatment, a patient relapses and loses a level of remission, it indicates a need for 
alternative treatment (Pemmaraju et al. 2011).  The MD Anderson algorithm for CML 
treatment is shown in Figure 4. 
ALTERNATIVES 
Several alternative forms of treatment have been suggested for patients not 
responding satisfactorily to imatinib.  They include allogeneic stem cell transplantation, 
novel tyrosine kinase inhibitors, aurora kinase inhibitors, and reactive oxygen species 
generators. 
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Allogeneic stem cell transplantation (SCT) is currently the only potentially 
curative treatment for CML (Linker and Damon 2011).  All other therapies control 
the BCR-ABL oncogene expression; allogeneic SCT destroys the stem cells bearing 
the gene (Pemmaraju et al. 2011).  SCT involves heavy chemotherapy and/or radiation 
regimens to destroy the diseased cells, ridding the body of the disease, and the 
transplant of healthy stem cells to the patient’s bone marrow to replenish the cells 
destroyed by chemotherapy.  Autologous SCT, in which healthy stem cells are 
extracted from the patient prior to chemotherapy and reintroduced afterwards, is 
sometimes used (Liesveld and Lichtman 2011).  However, autologous SCT is 
associated with high morbidity levels due to the high-dose chemotherapy preparatory 
regimen.  Allogeneic SCT uses stem cells from a well-matched donor which are infused 
Figure 4: The MD Anderson algorithm for treatment of CML. Patients who fail to achieve the desired 
remission level within the specified timeframe or relapse are switched to a different therapy. Source: 
Pemmaraju et al. 2011 
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with mature donor leukocytes.  This is more effective than autologous SCT because 
the grafted leukocytes recognize any remaining cancerous stem cells as foreign and 
attack them.  This graft-versus-malignancy effect successfully eradicates malignant 
stem cells not destroyed by the preparatory regimen.  Therefore, the pre-transplant 
regimen does not need to be as rigorous, making allogeneic SCT therapy an option for 
older patients (ages 60-75) who cannot tolerate standard high-dose chemotherapy 
(Linker and Damon 2011).  Prior to the introduction of imatinib, allogeneic SCT was 
the treatment of choice for younger patients with a well-matched donor.  However, 
allogeneic SCT has high morbidity levels due to incidence of graft-versus-host, in 
which the donor’s cells attack the host.  Therefore, with the introduction of imatinib, 
allogeneic SCT is no longer first-line therapy for chronic phase CML.  However, it still 
remains useful for treating patients with poor response to imatinib and in patients with 
the T315I mutation (Liesveld and Lichtman 2011). 
Following the success, and mindful of the flaws, of imatinib, several second-
generation tyrosine kinase inhibitors (TKI) were created.  These TKIs counter 
different imatinib resistance-conferring mutations.  The three second-generation TKIs 
that are currently available are dasatinib, nilotinib, and bosutinib.  Each has a distinct 
advantage over imatinib. 
Dasatinib is a powerful TKI that inhibits many tyrosine kinases.  It exhibits 300 
times greater potency against the unmutated form of BCR-ABL than imatinib.  Unlike 
imatinib, it binds to both the active and inactive forms of BCR-ABL and is, thus, 
unaffected by P-loop mutations (Cang and Liu 2008).  Although effective against most 
mutations, it is ineffective against T315I, V299L, F317L, and a few others.  Dasatinib 
has impressive results; over 50% of patients in chronic phase who failed imatinib 
therapy achieved a complete cytogenetic response with dasatinib.  The standard dose 
for dasatinib is 100 mg daily, based on minimal toxicity levels and maximum 
performance.  Dasatinib has few side effects and is overall well tolerated (Pemmaraju 
et al. 2011).   
Based on dasatinib’s effectiveness 
against imatinib-resistant CML, a study 
was conducted using dasatinib as front-line 
therapy in newly diagnosed chronic phase 
CML.  Results were impressive and swift.  
Within six months, 90% of patients 
achieved complete cytogenetic remission 
(compared to historical records of (80% 
with imatinib); within 12 months, 45% of 
patients had further improved to major 
molecular remission; and within 24 months, 71% achieved major molecular remission 
(Pemmaraju et al. 2011).  The structure of dasatinib is shown in Figure 5. 
Nilotinib is structurally similar to imatinib but modified to increase drug 
potency and selectivity.  Like imatinib, it binds to the inactive configuration of BCR-
ABL, locking the activation loop in the closed form to block the ATP binding site.  
Unlike imatinib, however, nilotinib forms hydrogen bonds with the amino acids at 286 
and 381, two residues not prone to mutation (Chabner et. al. 2011).  In a study of 321 
chronic phase CML patients who failed imatinib treatment, 46% achieved a complete 
cytogenetic response with nilotinib.  Nilotinib has an advantage over imatinib because 
Figure 5: Molecular formula for dasatinib.  
Dasatinib binds both the active and inactive 
configurations of ABL-BCR tyrosine kinase. 
Source: Chabner et al. 2011 
 
64 Rivky Kops 
it is effective against nearly all mutations, with the exception of T315I (Pemmaraju et 
al. 2011).  Some P-loop mutations have shown in-vitro resistance to nilotinib, so 
patients with P-loop mutations might benefit more from dasatinib (Cang and Liu 
2008).  Nilotinib is approved at 400 mg twice daily and is well tolerated (Pemmaraju et 
al. 2011). 
Due to nilotinib’s high success rate in 
imatinib-resistant patients, studies were conducted 
using nilotinib as the initial therapy for early chronic 
phase CML.  Over 90% of patients achieved a 
complete cytogenetic response within six months, 
and an astounding near 80% of patients achieved a 
major molecular remission by 12 months.  More 
significantly, one study showed that by 12 months, 
less than 1% of patients had progressed to the 
accelerated or blast phases, compared to 4% in 
patients receiving imatinib (Pemmaraju et al. 2011).  
The structure of nilotinib is shown in Figure 6. 
Bosutinib is another potent TKI currently in 
development.  It is 30-50 times stronger than 
imatinib against unmutated CML and is active 
against almost all BCR-ABL mutations.  Bosutinib has success rates similar to the 
other second-generation TKIs; over 40% of chronic phase CML patients who switch to 
bosutinib because of imatinib resistance achieve a complete cytogenetic response.  
Bosutinib has an advantage over other TKIs due to its greater selectivity.  Unlike the 
other TKIs, bosutinib has less off-target outcomes, which is theorized to reduce 
toxicity associated with other TKIs.  Unfortunately, though, as with the other TKIs, 
bosutinib is ineffective against the T315I mutation (Cang and Liu 2008). 
The efficacies of the three second-generation TKI’s, dasatinib, nilotinib, and 
bosutinib, are summarized in Table 1. 
Despite the efficacy of second-generation TKIs, none are successful in 
combating the T315I, and alternate therapies are necessary. 
Aurora kinase inhibitors are a new class of CML therapy.  Aurora kinases have 
been implicated in intensifying certain cancers, so combatting aurora kinases with 
aurora kinase inhibitors holds promise for controlling CML (Tanaka et al. 2010).  
MK-0457 was the first aurora kinase inhibitor to show activity against T315I.  It binds 
to the amino acid at 381, and not at 315, thereby avoiding the steric clash with 
isoleucine (Quintas-Cardama and Cortes 2008).  However, despite the promising 
results of MK-0457, trials were stopped due to concerns of cardiotoxicity (Cang and 
Liu 2008).  Other aurora kinase inhibitors, like XL228, PHA-739358, KW-2449, and 
AT9238, are in various stages of clinical trials (Quintas-Cardama and Cortes 2008).  
Though the introduction of aurora kinase inhibitors in T315I+ CML is recent, results 
of early trials look promising since aurora kinase inhibitors do not bind to T315 and, 
therefore, are unhindered by isoleucine. 
Another alternative for imatinib- and TKI-resistant CML is the use of reactive 
oxygen species (ROS).  ROS are the main catalysts of redox dysregulation and 
oxidative stress within cells, especially cancerous cells (Wondrak 2009).  The BCR- 
 
 
 
Figure 6: Molecular structure of 
nilotinib. Like imatinib, nilotinib 
binds only the inactive conformation 
of the BCR-ABL protein. Source: 
Chabner et al. 2011 
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Table 1: Response to Second-Generation TKI’s 
PERCENT RESPONSE 
  Dasatinib  Nilotinib  Bosutinib  
  C
P 
A
P 
M
yBP 
L
yBP 
C
P 
A
P 
M
yBP 
L
yBP 
C
P 
A
P 
B
P 
  N
=387 
N
=174 
N
=109 
N
=48 
N
=321 
N
=137 
N
=105 
N
=31 
N
=146 
N
=51 
N
=38 
Median 
follow-up 
(mo) 
1
5 
1
4 
1
2 
1
2 
2
4 
9 3 3 7 6 3 
% Resistant 
to imatinib 
7
4 
9
3 
9
1 
8
8 
7
0 
8
0 
8
2 
8
2 
6
9 
N
R 
N
R 
% 
Hematologi
c Response 
  7
9 
5
0 
4
0 
9
4 
5
6 
2
2 
1
9 
8
5 
5
4 
3
6 
CHR 9
1 
4
5 
2
7 
2
9 
7
6 
3
1 
1
1 
1
3 
8
1 
5
4 
3
6 
% 
Cytogenetic 
Response 
N
R 
4
4 
3
6 
5
2 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Complete 4
9 
3
2 
2
6 
4
6 
4
6 
2
0 
2
9 
3
2 
3
4 
2
7 
3
5 
Partial 1
1 
7 7 6 1
5 
1
2 
1
0 
1
6 
1
3 
2
0 
1
8 
% Survival 
(at 12 
months) 
9
6 (15) 
8
2 (12) 
5
0 (12) 
5
0 (5) 
8
7 (24) 
6
7 (24) 
4
2 (12) 
4
2 
(12) 
9
8 (12) 
6
0 
(12) 
5
0 
(10) 
CP, chronic phase; AP, accelerated phase; BP, blast phase; MyBP, myeloid blast phase; LyBP, 
lymphoid blast phase; NR, not reported.                                         Source: Pemmaraju et al. 2011 
ABL oncogene promotes ROS-generated redox imbalances, and this 
dysregulation can be manipulated to induce cell death.  The introduction of exogenous 
ROS-generating species increases oxidative stress in cancerous cells, leading to rapid 
protein degradation and cell death (Zhang et al. 2008).  Redox imbalances operate 
under synthetic lethality, which means that only cancerous cells are killed, not normal 
cells (Wondrak 2009).  PEITC (&-phenylethylisothiocyanate) is a naturally-occurring 
ROS-generating agent.  In one experiment, when introduced in cells bearing normal 
BCR-ABL and cells with the T315I mutation, PEITC completely inhibited cell 
growth, raised oxidative levels twofold, and caused over 60% cell death (Zhang et al. 
2008).  The viability of ROS-generating agents like PEITC in vivo has not yet been 
established, but early research shows promise (Wondrak 2009). 
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SUMMARY 
Chronic myeloid leukemia is no longer as frightening a diagnosis as cancer can 
be.  The historic median survival of 4-5 years is a thing of the past.  Novel targeted 
drugs can restrain BCR-ABL+ stem cells to the point that the disease is virtually 
undetectable.  Imatinib, the first molecularly targeted anticancer therapy, is so 
effective that over 95% of patients maintain progression-free survival at five years.  
Even the few patients who are resistant to imatinib are not left without hope.  
Allogeneic stem cell transplants can cure the disease in healthy patients with a well-
matched donor.  Second-generation tyrosine kinase inhibitors can effect remission in 
most patients bearing imatinib-resistant BCR-ABL mutations.  Dasatinib, nilotinib, 
and bosutinib are second-generation TKIs with differing potentials against the 
different mutations.  Though none of these TKIs can counter the T315I contact site 
mutation, other therapies can.  Aurora kinase inhibitors and ROS-generating agents 
are in various stages of clinical trials and show tremendous potential for treatment of 
T315I+ CML.  Aurora kinase inhibitors do not bind to the threonine at 315, so they 
are not rendered ineffective in blocking the tyrosine kinase activity.  ROS-generating 
agents prevent proliferation and induce cell death by critically raising intracellular 
oxidative levels in cancerous cells.  With the wealth of scientific research and 
experimentation that has abounded regarding CML in the past 15 years, chronic 
myeloid leukemia has become a truly treatable disease. 
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MOLECULAR MECHANISM OF XY GONADAL 
DYSGENESIS  
Griendy Indig-Weingarten 
One of the fundamentals of human sociology is the characterization of the 
people around us based on gender.  We tend to think of gender as a strict binary 
system where the option is clear: boy or girl. Although society usually honors this 
dichotomy, biology allows more flexibility to the definition of male versus female. 
Estimates state that one in every 2000 births is one with a disorder of sex development 
(The Intersex Society of North America 2006). Some of the disorders are visually 
obvious while others are only discovered later on in life. Regardless of when the 
disease first becomes obvious, all of these disorders constitute a variation along the 
standard development of a male or female. Therefore, to understand disorders of sex 
development, one must first understand what constitutes normal sex development. As 
in all of embryology, development is controlled by many different genetic codes and 
the pathways they encode. Therefore, variation along any gene responsible for any 
part of the sex differentiation mechanism will result in a deviation from the expected.  
NORMAL SEX DEVELOPMENT 
The identity of the sperm that successfully penetrates the ovum is the official 
beginning of sex determination. When meiosis of the spermatocyte is completed, the 
mature haploid spermatozoa can either have an X or a Y as its twenty-third 
chromosome. When this particular sperm penetrates the ovum, the identity of its 
twenty-third chromosome determines the genetic sex. This is the first step of sex 
determination. Further sex development is divided into two parts: primary sex 
determination and secondary sex determination. Primary determination involves the 
development of the fetus’s gonads. Once formed, the gonads start producing hormones 
which initiate secondary sex development. Secondary sex development includes the 
development of duct systems and external genitalia. Secondary sex development is 
only complete after puberty (Gilbert 2010). 
PRIMARY SEX DIFFERENTIATION 
Regardless of their karyotype, initially all embryos present a common set of 
genital structures. These include the gonads, the internal duct system, and the external 
genitalia. The development of the genital system begins at the fourth week of 
embryonic life. The entire genital system is derived from the intermediate mesoderm 
and urogenital sinus except for the gametes which emigrate from the mesoderm of the 
yolk sack. The intermediate mesoderm differentiates to form the adrenal cortex and 
the start of the urogenital ridge originating as the nephrogenic cord. The urogenital 
ridge is the site of the development of the urinary and reproductive system. The 
cephalic portion of the nephrogenic cord further matures to form the pronephros, 
which is mostly an embryonic structure. The more caudal portions of the nephrogenic 
cord form the mesonephros and the pronephric duct which later forms the 
mesonephric duct. The genital ridge arises along the middle portion of the 
mesonephros. This is the central location for the development of the gonadal and 
genital structures. The caudal (posterior) portion of mesonephric duct fuses with 
mesonephric tubules and continues to extend and connect to the urogenital sinus.  
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Then the most caudal 
area of the nephrogenic 
ridge further develops 
into the metanephros 
which is the permanent 
kidney (Figure 1) 
(McMahon et al. 2008).   
GONADS 
The gonads are 
unique embryonic 
structures because they 
are the only bipotential organs. They can develop into ovaries or testes. Gonads 
usually appear at week four but remain undifferentiated until week seven. At about 3-4 
weeks, the mesonephros is at its largest size, and it is at this point that the epithelial 
layer of the mesonephros, also known as the coelomic epithelium, starts to proliferate 
into the surrounding mesenchyme, or undifferentiated loose connective tissue, and 
form the primary sex cords. These cords will surround the entering germ cell to form 
the gonadal cord. At this point, the gonadal tissue will start to differentiate to testes or 
ovaries. 
MALE GONADAL DEVELOPMENT  
An XY fetus, at around the eighth week, will start developing testicular tissue. 
This begins with the differentiation of the gonadal cord into the Sertoli supporting 
cells. These cells form processes that surround the primordial germ cells and 
eventually mature into Sertoli cells. At the same time, cells migrating from the 
mesonephros, called peritubular myoid cells, form a single layer around the gonadal 
cords. These peritubuluar myoid cells contribute to the structural integrity of the testis 
cord and will support spermatogenesis later in the adult male’s life (Buehr et al. 1993). 
It is at this point (around the eight week) that the gonadal cord is recognizable as the 
first form of the testis cord. The testis cord then comes in contact with the mesonephric 
tubules which are connected to the mesonephric duct, causing a capsule called the 
tunica albuginea to form around the testes. Meanwhile, the testis cords continue to 
create a dense network called the rete testis. The rete testis functions later on as the 
carrier of sperm from the seminiferous tubules out of the testicles through the efferent 
duct which was derived from the mesonephric tubules. At 20 weeks, the testis cord 
forms the straight and convoluted seminiferous tubules. The straight tubules are 
connected to the rete testis and do not have any germ cells within them. The 
convoluted tubules are a continuation of the seminiferous tubules and contain the 
primordial germ cells. Spermatogenesis takes place in the convoluted tubules (Celio et 
al. 1999). Once the testis is formed, some primordial germ cells differentiate into a pre-
sperm state called T1-prospermatogonia and remain that way until puberty (Gilbert 
2010). 
Another important part of testicular development is the differentiation of the 
Leydig cells. These cells originate from mesenchyme, or the undifferentiated loose 
connective tissue in between the testis cords. These Leydig cells eventually produce 
testosterone which will be crucial to further male differentiation. Because of its steroid 
Figure 1: Nephrogenic Cord.  
Source: http://vanat.cvm.umn.edu/TFFlectPDFs/LectEmbUrinarySys.pdf. 
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producing nature, Leydig cells tend to cluster near the testicular vasculature (Wilhelm 
2007). 
FEMALE GONADAL DEVELOPMENT  
In the case of an XX embryo, the gonads usually develop into ovaries. The 
ovaries start developing during the eight week. In the absence of testis determining 
genes, the genital ridge will differentiate into ovaries. However, unlike testis, in which 
the testis cord forms early on in embryogenesis, the functional unit of the female 
gonads—the ovarian follicles—completely mature only at puberty. During fetal 
development, primordial follicles are formed.  These follicles are usually formed 
around 16-24 weeks after fertilization (Celio et al. 1999). The ovarian development 
begins with the migration of the primordial germ cells into the genital ridge and the 
gonadal cord partially atrophies. Later on, the primordial germ cells proliferate and 
form the primordial oocyte, or the oogonium. At around the fifth month, the oogonia 
are arrested at prophase of the first meiosis and are subsequently surrounded by 
pregranulosa cells which differentiated from the gonadal cord. These granulosa cells 
are connected with cellular bridges and high levels of vasculature. One of the key 
differences between the male and female primordial germ cells is that while all the male 
cells will continue to proliferate and mature to sperm from the age of puberty 
throughout a lengthy adult life, only the female cells that have matured and were 
arrested at prophase of the first meiotic division in utero will mature into ooctyes.  
MOLECULAR GENETICS OF GONAD DEVELOPMENT 
TESTIS PATHWAY 
 Genetic sex is defined as the presence of an XX or XY karyotype. In either 
case, one X will be inactivated, allowing the X or the Y to be the defining chromosome 
in sex determination. The Y chromosome carries a dominant testis-determining gene 
which actively promotes testicular development. Absence of the gene, regardless of the 
identity of the rest of the chromosome, will cause the embryo to go into “default” 
development and continue to develop as a female. It is for this reason that sex 
determination is sometimes equated with testis determination. This was proven by 
Alfred Jost when he castrated rabbits in utero and the rabbits’ development continued 
according to the female pattern (Jost 1972). Later research showed the testis-
determining gene to be the SRY gene on the short arm of the Y chromosome. In fact, 
the research that discovered the connection between the SRY gene and testis 
determination was carried out on XY females and Turner Syndrome patients (Berta et 
al. 1990). 
SRY: SEX- DETERMINING REGION Y 
The SRY gene is located on the upper short arm of the Y chromosome. In 
studies using XX reversed males and XY reversed females, results showed that a fetus 
with the Y short arm, even when missing the long Y arm, would develop testis. 
Accordingly, any individual missing the Y short arm would not develop testis. 
Additionally, if the SRY gene is inserted in the genome of a normal XX mouse, the XX 
mouse would develop testis (Koopman et al. 1991). The SRY gene is expressed in the 
bipotential gonads immediately before differentiation of the Sertoli cells begins, at 
around eight weeks, and is deactivated a few days later (Cotinot et al. 2002). Although 
SRY is deactivated after a short window, while active, it synthesizes the SRY 
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transcription factor whose primary role is to activate the SOX9 gene, allowing 
differentiation to continue even after SRY is deactivated. 
SOX9 
The SOX9 gene is located on the seventeenth chromosome. SOX genes are 
called transcription factors due to their nature of transcribing proteins that can bind to 
specific locations on DNA to control gene activity. SOX9 is involved in many 
developmental processes, particularly skeletal formation. In fact, the role of SOX9 in 
testis formation was discovered when a link between SOX9 and a condition called 
campomelic dysplasia was discovered. Campomelic dysplasia patients exhibit multiple 
skeletal abnormalities.  Interestingly enough, however, 75% of the 46 XY patients with 
campomelic dysplasia were sex-reversed females (Cooke et al. 1985). This led 
researchers to discover that when SOX9 is activated in the genital ridge, it induces 
testis formation. Studies have shown that mice missing the SRY gene but possessing an 
extra copy of the SOX9 will develop as male. Accordingly, mammals possessing the 
SRY gene but lacking the SOX9 gene will not develop male (Huang et al. 1999).  
SOX9 works in several different manners: 
• It activates its own promoter, creating a positive feedback loop which allows it 
to be active for a longer period of time (Sekido and Lovell-Badge 2008). 
• It blocks genes that are involved in ovary formation (de Santa Barbara et al. 
2000).  
• It can bind and activate different genes necessary for testicular development. 
• It promotes the gene expression necessary to produce fibroblast growth factors 
that are critical for Sertoli Cells precursors.  
• It binds to the gene that promotes the production of anti-mullerian factor (de 
Santa Barbara et al. 2000).  
SOX9 is detected in 
the somatic cells in the 
human fetal gonads as early 
as the sixth week. When the 
Sertoli cells start 
differentiating, SOX9 is 
expressed in the nuclei of 
the cells (de Santa Barbara 
et al. 2000).  Studies done 
on SOX9 have found that it 
very often works together 
with a nuclear receptor 
called steroidogenic factor-1 
(SF-1) which is activated 
by the NR5A1 gene. The 
relationship between the 
SRY, SOX9, and SF1 is 
explained in Figure 2.     
NR5A1 
NR5A1 is sometimes 
referred to as the SF-1 gene 
In the cytoplasm, SRY is bound by 
calmodulin (CaM) and importin & 
(Imp&), which recognize the N- and 
C-terminal nuclear localization 
signals (NLSs) on SRY, respectively, 
and recruit it to enter the nucleus. At 
10.5 dpc, SRY and steroidogenic 
factor 1 (SF1) bind directly to 
specific sites (`TESCO', testis-
specific enhancer of Sox9 core) that 
lie within the gonadal specific 
enhancer of Sox9 (indicated by the 
coloured regions on the DNA) and 
upregulate Sox9 expression 
cooperatively. At 11.5 dpc, after 
initiation of Sox9 expression, an auto-
regulation system operates in which 
SOX9 also binds directly to TESCO 
with SF1 to prolong and amplify Sox9 
expression. Abbreviations: SOX9, 
SRY box containing gene 9; SRY, 
sex-determining region on the 
chromosome Y. 
 Figure 2: Cellular mechanism of SRY function. Source: 
http://dev.biologists.org/content/137/23/3921.full 
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because it encoded the SF-1 receptor. The NR5A1 gene spans seven exons and is 
located on the ninth chromosome (Johns Hopkins University School of Medicine 
2011). It functions in gonadal differentiation and in steriodogenesis. Knockout mice 
(mice that were genetically altered) missing the NR5A1 gene developed with complete 
adrenal and gonadal agenesis. Studies show that SF-1 is involved early in 
embryogenesis during development of the bipotential gonad. Although it is not 
completely understood how SF-1 functions in the embryogenetic stage, mice missing 
the part of the NR5A1 gene that encodes for SF-1 never developed a genital ridge. SF-1 
is already active in humans at four weeks when the gonadal ridge starts to form, and its 
levels remain high in the testis even once the SRY shuts off. SF-1 aids in activating 
SOX9 and continues to work with SOX9 to elevate the anti-mullerian hormone 
transcription. As the name steriodogenic indicates, SF-1 is involved in hormone 
production. It is involved in multiple steroid-producing functions, such as 
collaborating with SOX9 to produce AMH (anti-mullerian hormone), and activating 
genes involved with testosterone production in Leydig cells (Shen et al. 1994). Mice 
lacking the SF-1 gene lack both adrenal glands and gonads, proving that the SF-1 gene 
is involved in early embryogenesis of the urinary and reproductive system (Luo et al. 
1994). 
OVARY PATHWAY 
In order to provide a complete picture of development, the molecular pathway 
of the ovaries is briefly discussed, although these genes are not involved in XY 
Gonadal Dysgenesis.  
WNT4  
Early on, WNT4 is expressed in the genital ridge in both male and female 
embryos. However, its expression, while still maintained in the fetal ovaries, is 
undetectable in the fetal testes. Mice that lack the gene will fail to develop ovaries 
(Cotinot et al. 2002).  
R-SPONDIN-1 
Another critical gene is R-spondin-1, a protein expressed by RSPO1. An XX 
fetus with gene mutation in RSP01 will be XX male. RSPO1 acts together with WNT4 
to produce beta-catenin, which activates further ovarian development, and block SOX9 
production. An XY fetus with a duplication of the WNT4 and RSPO1 on its 
chromosome will develop ovaries instead of testis (Gilbert 2010).  
(There are many other genes involved in both testis development and ovarian 
development that are not discussed in this paper.) 
SECONDARY SEX DEVELOPMENT  
Once the gonads are formed, they start to produce hormones. These hormones 
are initiators of secondary sex development. Once these hormones begin to be 
secreted, secondary sex development can start. It is important to note that primary and 
secondary developments do overlap, as the testes and ovaries continue to develop once 
steroids are produced. 
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INTERNAL DUCT SYSTEM  
The gonads are just one part of the 
sex differentiation process. The ducts 
system, like the gonads, start out in an 
undifferentiated state. In the 
undifferentiated stage, the embryo presents 
with mesonephric ducts, also known as the 
Wolffian ducts. Paramesonephronic ducts, 
which appear in the sixth week, form part 
of the urogenital cord. The Wolffian ducts 
form from the nephrogenic cord and 
develop toward the cloaca. Mesonephric 
tubules, another part of the mesonephros 
involved in the development of the internal 
ducts, arise from the mesenchyme of the 
mesonephros and eventually fuse with the 
mesonephric duct to create a passage to the 
cloaca (Schoenwolf et al. 2009). The Mullerian Duct is formed when the coelomic 
epithelium, near the top of the mesonephros, invaginates. Both the Mullerian and the 
Wolffian ducts continue to grow caudally towards the urogenital sinus (Figure 3) 
(Sweeney 1998 ). 
MALE DUCT SYSTEM DEVELOPMENT  
During early embryogenesis, the Wolffian duct serves as an excreting duct for 
the mesonephros. Once the metanephros becomes functional, most of the mesonephric 
duct atrophies, and the part that remains is dependent on the testosterone released 
from the Leydig cells in the fetal testis. In the eighth week of gestation, the Leydig cells 
start releasing testosterone and thus begin two important aspects of the internal male 
duct system development. One is the atrophying of the paramesonephric duct, and the 
other is the further development of the mesonephric duct (Celio et al. 1999).  The 
undifferentiated state includes both sets of ducts, and with the start of duct 
differentiation, the paramesonephric duct starts to atrophy due to the effect of anti-
mullerian hormone released by the Sertoli cells within the seminiferous tubules. It is 
interesting to note that a small part of the paramesonephric duct does remain and 
differentiates into the appendix testis (Jacob and Barteczko 2005). Meanwhile, the 
Leydig cells begin releasing testosterone to support the development of the 
mesonephric duct. Most of the top portion of the Wolffian duct atrophies, leaving only 
the portion which differentiates into the efferent duct, epididymis, vas deferens, and 
seminal vesicles.  
FEMALE DUCT SYSTEM DEVELOPMENTS 
In a human embryo, the absence of the anti-mullerian hormone causes the 
undifferentiated ducts to develop into the female duct system. The mesonephric ducts 
and tubules atrophy, and the paramesonephric duct further develops. In the eighth 
week, the two lower portions of the mullerian duct fuse. This fused portion is the site 
of the uterus. The upper portion of the paramesonephric duct proliferates outwards 
towards the gonad and develops as the fallopian tubes. The lowest portion forms the 
utero-vaginal canal (Celio et al. 1999).  
Figure 3: Internal Duct System 
1-Mesonephros 
2-Paramesonephric Duct 
3-Mesonephric Duct 
4-Indiffernt Gonads 
5-Urogenital Sinus  
Source: Celio et al. 1999. 
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EXTERNAL GENITALIA DEVELOPMENT 
The external genitalia arise from the genital tubercle, the urogenital groove and 
sinus, and the labioscrotal fold.  
 As opposed to male development where testosterone plays a key role in 
differentiation, estrogen is not involved in female sexual differentiation. Instead, it is 
produced by the ovaries to function as support for follicular maturation. In fact, both 
male and female fetuses are exposed to high amount of estrogen from their mother. 
The embryo has a predisposition to develop internal female duct systems (fallopian 
tubes and uterus), so unless there is an active intervention by anti-mullerian hormone 
(secreted by Sertoli cells) and testosterone (secreted by the steroidogenic Leydig cells) 
to promote development of the epididymis, vas deferens, efferent ducts, and other male 
organs, a female system will develop. Furthermore, male external genitalia are 
dependent on specific hormonal activity. The undifferentiated embryo is very rich in 
androgen receptors. Once the Leydig cells start producing androgen, particularly 
dihydro testosterone, the male external genitalia develop, first into a phallus, and then 
further into the mature penis, phallic urethra, and scrotum. The absence of androgen 
causes the development of the clitoris, urethra, vagina, and labia. This further 
demonstrates that male external genitalia formation requires active intervention 
(Schoenwolf et al. 2009). This is why it is said that an embryo, if left to its own 
devices, will go to “default development” and develop female. 
This concludes a summary of sex differentiation (Figure 4). Most discoveries of 
the mechanisms involved in this development were discovered when studying patients 
with an abnormal sex development or disorder of sex development. 
DISORDERS OF SEX DEVELOPMENT 
Disorders of sex development are defined as any congenital condition in which 
development of chromosomal, gonadal, or anatomical sex is atypical (The Intersex 
Society of North America 2006). As seen earlier, sex differentiation is a complex and 
lengthy process, involving many different genomic pathways. As a result, there are 
many different variations along the developmental process which can cause atypical 
presentation. If a mutation exists which impedes the development of one of the 
necessary functions, it is expected that an abnormal phenotype will occur. Disorders of 
sex development is a very broad term which spans a spectrum of various different 
phenotypical presentations. The defining factor in determining the outcome of a 
variation depends on which point of development it affects. The first step of sex 
differentiation is genetic sex. Examples of disturbances in the proper genetic sex 
Figure 4:  Timeline of the primary and secondary sex development. Source: 
http://www.embryology.ch/images/imagegraphe/u1e_schemdifferentEn.gif. 
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development are Turners Syndrome (45 XO female), Klinefelters Syndrome (47 XXY 
male), XYY syndrome, and a few others. The next step in sexual determination is 
gonadal sex. Disorders of gonadal sex include XX Gonadal Dysgenesis and XY 
Gonadal Dysgenesis. The final part of sex development is anatomical sex. Variations in 
anatomical sex are the broadest of the three steps of sex development. Conditions 
range from phenotypical female, ambiguous genitalia, and phenotypical male. These 
conditions include congenital adrenal hyperplasia, androgen insensitivity syndrome, 
hypospadias, 5-alpha-reductase deficiencies, and many others (The Intersex Society of 
North America 2006).  
XY GONADAL DYSGENESIS 
One of the defining moments in male or female sex differentiation is the identity 
of the mature undifferentiated gonad. Once the gonad has differentiated to either testis 
or ovary, it initiates steroidogenic activity which will define the rest of the anatomical 
development. If gonadal development were to halt at the stage of indifference, such an 
occurrence would be called XY gonadal dysgenesis. The term gonadal dysgenesis 
involves the broader group of conditions that would cause the dysgenesis, or failure to 
develop, of the gonads. In Turner Syndrome, gonadal development fails due to a 
monosomy of the sex chromosome; the gonads are missing crucial genes for gonadal 
development. In a condition known as XX gonadal dysgenesis, gonads which should 
develop into ovaries are missing ovarian defining genes or receptors to complete 
ovarian development. Perhaps the most fascinating is that of an XY fetus developing 
phenotypically as a female due to gonadal dysgenesis in a condition called XY gonadal 
dysgenesis (Sinclair and Cameron 2004).  
CLINICAL PRESENTATION 
XY Gonadal Dysgenesis is usually diagnosed when a patient who failed to 
develop secondary female sex characteristic undergoes testing to determine the cause. 
The patient usually presents a female phenotype but no or sparse pubic and underarm 
hair, no or little breast tissue development, and amenorrhea. Examinations and 
ultrasound images reveal usual female external genitalia, fallopian tubes, and uterus 
but no visible ovaries. The incidence of occurrence is hard to estimate, with some 
papers stating numbers as frequent as 1:30,000 and others quoting numbers as low as 
1:150,000 (Wilhelm 2010).  
TREATMENT 
Although XY Gonadal Dysgenesis is not a diagnosis that comes along with 
serious medical conditions (except in gene specific abnormalities that will be discussed 
later), it does come along with some medical aspects that need to be addressed.   
HORMONE REPLACEMENT THERAPY (HRT) 
One option is to substitute the hormones that the patient is missing due to the 
dysfunctional gonads. Patients with XY Gonadal Dysgenesis need to start hormone 
replacement therapy to initiate pubertal development, and they need to remain on the 
therapy to maintain optimal health. The doctor will usually start off the patient on a 
low dosage of estrogen, most often in the form of a 0.3 mg tablet of premarin, a form of 
estrogen. The dose will increase over a span of 2-3 years. The incremental increase is 
intended to mimic the hormonal activity that normally would take place at the start of 
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puberty. During this time, all the expected secondary sex characteristic should 
develop. 
 Because the uterus is also maturing during this time, it is important to initiate 
menstruation with progesterone to reduce the risk of uterine cancer. A doctor will 
usually recommend bringing on a menses a minimum of four times a year for the 
upkeep of optimal uterine health. There are a number of different forms of HRT: 
tablets, patches, gels, injections, and implantable pellets. Some health professionals 
recommend taking a combined form of estrogen and progesterone, and some add a low 
dose of testosterone to more accurately mimic the natural hormone production in 
healthy females. There are conflicting reports as to what form and dose is optimal, and 
most patients find that the process to find the right regimen depends on what works 
best for them personally (WebMD 2009).  
GONADECTOMY  
Patients with XY gonadal dysgenesis must undergo a gonadectomy, surgery to 
remove the streak gonads so that they do not develop into dysgerminomas (germ cell 
tumors). The risk of an XY gonadal dysgenesis patient developing cancer is estimated 
at around 30% occurrence rate, which is why doctors recommend that gonadectomy 
be preformed soon after diagnosis. Dysgerminomas can develop in adults with streak 
gonads due to their indifferent embryonic structures which are not intended to be 
mature organs. The gonadal tissue of the 
streak gonads contains germ cells and many 
pre-Sertoli/granulose cells scattered 
throughout the stroma. These cells can 
develop into gonadoblastomas, benign 
neoplasms, exclusive to these types of cells. 
These neoplasms can become malignant and 
form dysgerminomas and other malignant 
growths (Michala et al. 2008). Cases have 
been reported in which patients as young as 
nine months have developed dysgerminomas 
(Dumic et al. 1993); therefore doctors 
recommend removing the gonads as early as 
possible. With the advances of modern 
surgical techniques, most gonadectomies are 
done laparoscopically and involve minimal 
recovery with little scarring (Figure 5).  
GENETIC CAUSES OF XY GONADAL DYSGENESIS 
Five genes have been identified in relation to XY gonadal dysgenesis. Because 
of the rarity of the condition and the constantly developing field of molecular genetics, 
many of their mechanisms are poorly understood. 
SRY 
Mutations in the SRY gene (the testis-determining gene) have been found in 10-
15% of all XY Gonadal Dysgenesis. Most mutations are in the HMG (High Mobility 
Group) box on the SRY gene. The HMG box is capable of sequencing specific DNA 
binding and bending. This is crucial in the SRY gene, because it is the specific bending 
pattern which activates the SRY in the gonads. The bends act by changing the 
Figure 5:  Laparoscopic removal of streak 
gonads (indicated by the white arrows) in 
patient with XY Gonadal Dysgenesis.  
Source: 
http://radiographics.rsna.org/content/28/7/1891
/F14.large.jpg 
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chromatin structure in the regulatory region of the target gene that starts the assembly 
of the regulatory complex. The identification of HMG as the critical region was 
formed when researchers noticed that there are variations in the non-HMG portions of 
the SRY nucleotide sequences which do not have any effect on testicular development. 
This finding demonstrated that these regions are not involved in testis development. As 
previously mentioned, SRY is expressed in the genital ridge for a brief time, stimulating 
Sertoli cell and testis determination (Sinclair and Cameron 2004). A few factors have 
been identified as regulators for SRY. The WT1 may activate SRY through an SRY 
promoter region which it expresses. It is also hypothesized that the SRY gene itself 
might have a transcription site on it for auto regulation (Vilain et al. 1992). The roles 
identified in SRY include the induction of the mesonephric cells into the ridge to form 
the testis cord, proliferation of the cells, and inducement of Sertoli cell differentiation. 
The lack of SRY also causes the failure of the SOX9 and any other gene relying on SRY 
as its regulatory “switch.”  
SRY related XY gonadal dysgenesis has been observed in familial lines, but 
most cases are de novo mutations which cause the loss of binding and its subsequent 
failure to initiate testis differentiation. Although SRY is expressed in somatic cells in 
different areas in the body, no other effects have been observed as a result of the SRY 
mutation (Simpson 2008). 
DHH 
DHH, the desert hedgehog gene, is located on the twelfth chromosome and is 
composed of three exons. DHH expression was observed in the testis of fetal mice. In 
the ovaries of fetal mice, however, little DHH expression was observed. This led to the 
initial belief that DHH is involved in testis development. The product of the DHH is 
found in Sertoli cells and in Schwann cells. Therefore, patients with DHH mutation 
usually have polyneuropathy (many nerves acting simultaneously). Unlike SRY which 
directly affects Sertoli cell development, DHH affects the development of different cells 
called peritubular myoid cells, which are cells that make a thin lining around the testis 
cord. Interruption of peritubular cell proliferation will cause a failure in the 
development of the testis cord, which will cause a failure in gonadal development. In 
fact, DHH-deficient knockout mice showed male sterility, peritubular defects, and 
testis-development failure. In addition to its role in testis cord development, studies 
suggest that the DHH is a regulator signal for the differentiation of Leydig cells in the 
fetal testis and is also involved in upregulating the SF-1 factor (Canto et al. 2004).   
Patients with DHH mutation may have complete or partial Gonadal Dysgenesis. 
Partial gonadal dysgenesis usually presents itself with slightly masculinized external 
genitalia and some internal male ductal development. Some development does occur, a 
result of some androgen production, usually due to a mosaic presentation, meaning 
that not all cells have the mutation of the DHH gene. In complete gonadal dysgenesis, 
most patients posses homozygous mutations which do not allow any DHH expression 
to reach the threshold for testicular development.  
DHH is also expressed in Schwann cells along peripheral nerves. Therefore, 
mutations in DHH can cause a condition called polyneuropathy. Polyneuropathy is a 
neurological disorder which causes many nerves to malfunction simultaneously. 
Impaired nerve transmission occurs due to reduced insulation of nerves by the affected 
Schwann cells (Canto et al. 2004). DHH-related gonadal dysgenesis is estimated to 
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account for 20% of all complete gonadal dysgenesis cases and 50% of all partial 
gonadal dysgenesis cases. 
NR5A1 (SF-1) 
NR5A1 encodes the SF-1 (steroidogenic factor-1) and is sometimes referred to 
as the SF-1 gene. It is a nuclear receptor that binds to and regulates the transcription 
of many target genes involved in gonadal and adrenal development. SF-1 was first 
studied in XY gonadal dysgenesis patients displaying complete adrenal failure. This 
was a direct indication of the role SF-1 plays in the formation of both gonadal and 
adrenal glands. These patients had homozygous mutations and did not have any SF-1 
expression.  In most human studies, it is rare to find a patient with complete 
adrenogonadal failure due to NR5A1. Later studies dealt with patients with 
heterozygous missense and frameshift mutation affecting only parts of the gene. These 
patients presented little or no adrenal failure. Many of these patients displayed 
androgen biosynthesis failure and impaired leydig cell development. Some even 
presented testicular tissue development (Achermann et al. 2002). This highlighted the 
fact that SF-1 acts within a dose-dependent function as opposed to acting as an on and 
off switch. 
The prevalence of NR5A1 XY gonadal dysgenesisis low. 
CBX2 
A fourth gene whose mutation can cause XY Gonadal Dysgenesis is the 
Chromobox homolog protein 2 (CBX2). The CBX2 gene is part of   Polycomb 
Recessive Group 1 on the seventeenth chromosome, which encodes polycomb group 
proteins. These proteins form large protein complexes capable of chromatin 
remodeling on primordial germ cells. Chromatin remodeling initiates the transition 
from mitotic division early in embryogenesis to meiosis once they are in a specific 
gonad. Research also indicates that the CBX2 might have a role as a promoter of the 
SF-1 (Baumann and De La Fuente 2011).  Knockout mice missing the CBX2 gene 
expressed skeletal abnormalities and sex reversal (Lauber et al. 2009). 
DMRT1/ 9P DELETION 
Deletion of the tip of the 9p chromosome is associated with gonadal dysgenesis. 
This association, however, was discovered quite recently, so most research is still based 
on presumption. Because the deletion of the tip of 9p affects a number of 
chromosomes, patients present with complex phenotypic features including ambiguous 
genitalia and craniofacial abnormality. Deletion of the DMRT1 gene, located on the 
ninth chromosome, has been identified as a cause of XY gonadal dysgenesis. DMRT1 is 
unregulated in the genital ridge and is, therefore, linked to testis development. 
Research shows that DMRT1 is critical for maintaining the activity of other male 
differentiation genes like SOX9. It is a sequence-specific transcriptional regulator, 
meaning that it will regulate the transcription of other genes. In this case, it is likely 
that it binds to NR5A1 and promotes SF-1 production to upkeep the continued gene 
expression of SOX9. Loss of the DMRT1 gene in mice, even after undergoing complete 
male development, can cause reversal of the Sertoli cells into granulose cells by 
promoting the production of female promoting genes. In humans, this deletion does not 
result in female development as is does in mice, but it does halt male development, 
causing XY gonadal dysgenesis (Matson et al. 2011). 
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CONCLUSION 
With the discovery of sex chromosomes in 1921, the scientific world anticipated 
that the genetics of male and female differentiation would become clearer. However, it 
was not until the 1990s that the SRY gene was discovered when XY females were 
studied. The study of XY females also revealed other genes involved in the different 
aspects of sex differentiation. The connection between DHH and the development of 
the peritubular myoid cells is evident in patients with XY gonadal dysgenesis due to a 
mutation of the DHH gene. NR5A1 plays a crucial role in encoding the steriodogenic 
factor-1 which plays multiple roles in gonadal cord development and further 
differentiation of the testis. Another gene mutation in XY gonadal dysgenesis patients, 
a mutation in CBX2, provides insight into its role in regulation of primordial germ cell 
development. Studying the role of DMRT1 in regulating continued male differentiation 
helps scientists gain a deeper understanding of the mechanisms involved in testicular 
development.  
Science is constantly evolving, and research conducted on patients with XY 
gonadal dysgenesis and other disorders of sex development will further the 
understanding of the different components of male differentiation and development.  
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ABSTRACT 
Drug addiction is a prime example of biochemical psychology. When people use drugs 
such as nicotine, they trigger dopamine receptors in the brain, causing a pleasurable sensation. 
People want to repeat the feeling and thus get addicted to the drug. With the development of a 
vaccine to treat addiction, researchers attempt to prevent drugs from crossing over the blood-
brain barrier and triggering the dopamine receptors. Experiments and clinical trials prove the 
efficacy of the nicotine vaccine. However, Phase III trials and additional research are 
necessary before the vaccine can be launched for public use.   
INTRODUCTION 
Addiction is one of the greatest issues facing our society today. Thousands of 
people struggle with smoking, drugs, and other addictions on a daily basis. What starts 
as one cigarette or one sip of alcohol often develops into a daily necessity or an ever-
present need. However, it is not the cigarette or alcohol that satiates a person; it is the 
chemical reaction of the dopamine receptors that the addictive substance triggers in 
the brain that satisfies (Koob and Moal 2001). Addiction is a classic case of 
biochemical psychology, in which certain activities in the brain cause specific forms of 
behavior. In this case, the chemical reaction occurring in the brain in response to a 
drug causes the user to feel a certain reward. This eventually causes one to become 
dependent on the drug, to the extent that one is willing to forego all ethical limits to 
obtain more of it. Numerous researchers have attempted to find a way to help addicts 
recover (Koob and Moal 2001). Previous experiments as well as cutting-edge research 
have furthered this discovery. Researchers have developed a vaccine to aid in the 
treatment of nicotine addiction and restore normal brain receptor activities. However, 
what is the efficacy of the "nicotine vaccine" in treating smokers addicted to nicotine? 
Before analyzing the effectiveness of the vaccine, a complete understanding of 
dopamine receptors and their effects on the body and behavior must be gained.  
THE BRAIN-BEHAVIOR CONNECTION: DOPAMINE RECEPTORS 
Psychologists and scientists have been mystified by the brain-behavior 
connection in drug or alcohol abuse and have been trying to determine how to treat 
addiction.  Drugs and other addictive substances cause a surge in levels of a brain 
chemical called dopamine, the neurotransmitter that is responsible for feelings of 
pleasure. The brain remembers this pleasure and wants to repeat it (Long 2011). 
Neurons containing the dopamine receptors are clustered in the substantia nigra, an 
area in the midbrain (Schultz 2010). The pleasure sensation creates the motivation for 
a person to proactively pursue activities such as eating and drinking that are crucial for 
survival.  A person is driven to perform these vital functions because the brain is 
conditioned to expect the dopamine rush that accompanies them. Drugs such as 
methamphetamine, heroin, and cocaine produce their effects by acting on the flow of 
neurotransmitters and affecting the brain chemistry (Schultz 2010). They can cause 
profound changes in human behavior (Wise and Rompre 1998) that can have negative 
consequences in varying areas of an individual's life (Chandler et al. 2009).  
Widely documented experimental evidence suggests that the mesolimbic 
dopamine system is hypofunctional in the addicted brain (Melis et al. 2005). When 
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using addictive drugs, the brain is flooded with up to ten times the normal amount of 
dopamine. The mesolimbic dopamine system becomes hypofunctional due to down-
regulation of the dopamine receptor because of excess dopamine present when certain 
addictive drugs are used. By decreasing the dopamine (DA) system function in 
addicted subjects, there will be a decreased interest in non-drug related stimuli and 
increased sensitivity to the drug of choice (Melis et al. 2005). When a user’s brain 
adapts to a higher level of dopamine to get pleasure, it begins associating the addictive 
drug with this neurochemical reward, and eventually, the drugs create a scenario that 
only they can meet (Diana 2011). This process leads to addiction, in which a person is 
left with a drive to compulsively take the drug, conditioned to expect artificially high 
levels of the neurotransmitter. The brain begins to require more dopamine than it can 
naturally produce, and it becomes dependent on the addictive drug, which never 
actually satisfies the need it created (Kosten 2011). 
Normally, dopamine conditions us to do what we need to do to continue 
surviving. Regulation of dopamine plays a crucial role in our mental and physical 
health. However, just as food is linked to survival in day-to-day living, addictive drugs 
triggering the release of dopamine begin to take on the same significance for the 
addict. The need to obtain and take drugs becomes more important than any other 
need, including truly vital behaviors like eating. Eventually, all ethical guidelines in a 
person's life, such as family, work, and community obligations and values, are lost to 
the disease of addiction (Koob and Moal 2001).  When the brain's dopamine receptor 
is down-regulated, greater amounts of dopamine are required to induce the normal 
effect. Eventually, the disrupted dopamine system renders the addict incapable of 
feeling any pleasure even from the drugs they seek to feed their addiction. The lack of 
control causes people who are addicted to continue using drugs, even when the drugs 
have lost their power to reward (Diana 2011).   
Based on the above, one form of treatment used to treat addicted patients is to 
block entry of the addictive drug into the brain receptor system (Kenny et al. 2006). In 
this way, the DA system hypofunction will eventually revert to normal functioning 
with time.  
NICOTINE ADDICTION AND TREATMENT 
Cigarette smoking is the most common cause of death in industrialized 
countries. Thirty percent of all deaths in smokers from 35-69 years of age are due to 
chronic smoking. Though there are many forms of medication available for the 
addiction, there is still an extremely low success rate for people who have tried to quit 
smoking. According to the American Lung Association, nearly half of U.S. smokers try 
to quit each year, and only 4% to 7% of the people who make the attempt are 
successful. Norman Edelman, the Chief Medical Officer of the American Lung 
Association, says that at best, only one out of three people trying to quit are successful 
(American Lung Association 2011).  
 Quest for Vaccines to Treat Addiction 83 
 
Therefore, a new approach to treating addiction has been developed. This 
technique utilizes injected vaccines to block addictive substances from reaching the 
brain. As indicated in Figure 1, the vaccine induces the immune system to produce 
antibodies that bind to nicotine. This prevents the nicotine from crossing the blood-
brain barrier and acting on dopamine receptors in the brain. When people smoke, the 
nicotine inhaled from tobacco moves 
from the lungs to the bloodstream, and 
up to the smoker's brain within 
seconds. There, nicotine triggers a 
number of chemical responses, one of 
which involves the dopamine receptors, 
creating feelings of pleasure and a 
variety of neural effects that initiate and 
maintain tobacco dependence. The 
sensation lasts minutes. However, as 
the nicotine levels drop, smokers feel 
agitated, a symptom of nicotine 
withdrawal. In order to relieve 
discomfort, they often light another 
cigarette, beginning a vicious cycle of 
addictive smoking. Therefore, efforts to 
develop treatment for people addicted 
to smoking have focused on targeting 
neural pathways involved in nicotine 
addiction (Hall 2005).  
When people take addictive 
drugs, the drug molecules travel 
through the bloodstream to the brain. 
Because addictive drugs are so small, 
they bypass the immune system 
completely. However, using the 
vaccine, scientists attach molecules 
similar to addictive drugs to much 
bigger antigens, such as deactivated 
versions of the common cold virus 
(Long 2011).  
When injected into lab animals and people, these so-called conjugate vaccines 
spur the immune system to create antibodies to fight the tiny, addictive drug molecules 
(Kosten 2011). The antibodies attach to molecules of nicotine and cocaine before they 
cross the blood-brain barrier, thereby blocking them from triggering the pleasure 
centers in the brain (Hall 2005).  
Vaccination against nicotine can reduce the risk of relapse in addicted smokers 
by easing the pharmacological effects of nicotine for the first few months after quitting, 
the period when most smokers relapse (Hall 2005). Unlike prior medications that 
worked via the brain, addictive-treatment vaccines work in the bloodstream (Long 
2011).  
Figure 1: With the administration of the vaccine, 
the body produces antibodies that bind to nicotine 
molecules and prevent them from crossing the 
blood brain barrier. Source: Long 2011 
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Vaccines against nicotine are a promising concept in smoking cessation 
research. This is because it can aid current smokers attempting to quit, former smokers 
wanting to avoid relapse, and adolescent smokers from becoming confirmed smokers. 
Because nicotine is the pharmacological agent controlling the rate of cigarette smoking, 
by reducing the rate and extent of uptake in the brain, researchers can attempt to treat 
the addiction (Vocci and Chiang 2001). Even if the smoker increases the dosage of 
nicotine, the rewarding effect would still be circumvented by the vaccine, hopefully 
ensuring that the lapse would not lead to daily smoking (Khoury et al. 2003). 
However, the vaccine does not combat cravings. They simply trick the body to reject 
drugs as if they are foreign pathogens. The vaccine also has the potential to work on 
many drugs aside from nicotine, such as cocaine and heroin, amongst other addictive 
substances.  
VACCINE FORMATION AND ADMINISTRATION 
Since nicotine is extremely small (molecular weight =167 kD) and therefore not 
immunogenic, the body does not create antibodies against it. By using a linker such as 
succinic acid, researchers can convert nicotine to an immunogenic carrier protein to 
form an immunogen, a conjugate nicotine vaccine. Multiple types of carrier proteins 
have been used, such as keyhole limpet hemocyanine, recombinant cholera toxin B 
subunit, and recombinant psuedomonas exoprotein A. The latter two have been used 
in vaccines administered to humans before. The vaccines are then mixed with an 
adjuvant such as alum, to enhance the immune response (Hieda et al. 1997).  
The ideal vaccine elicits antibodies that have the characteristics of 
immunogenicity, specificity, and affinity to bind to nicotine. Immunogenicity refers to 
the maximally effective serum concentration of antibody throughout the period of 
interest. In that way, there will be a higher ratio of antibody to nicotine to increase 
binding of nicotine to serum. Affinity refers to the strength of the antibodies binding to 
the nicotine, and specificity refers to the extent that antibodies bind to nicotine as 
opposed to other compounds (Hall 2005).  
EXPERIMENTATION PERFORMED WITH ANIMALS 
Studies performed with animals have proven that attaching nicotine to a viable 
antigenic protein produces antibodies that have a high affinity for nicotine (Hall 2005). 
A series of 2-4 injections of vaccine was given to rats over 4-8 weeks. The vaccine was 
aimed at eliciting higher serum concentration of nicotine specific antibodies that would 
not bind to nicotine metabolites (Pentel and Malin 2002). When the rats were 
vaccinated, they were given a single dose of nicotine, equivalent to the nicotine 
absorbed by a smoker from two cigarettes. The researchers then tested the serum and 
found that the nicotine delivered to the brain 1-3 minutes later was 60% less than that 
of the control group.  Even when the rats received heavier doses, equivalent to that of 
a chronic smoker, vaccination remained effective in reducing the early distribution of 
each dose to the brain. Vaccination of rats reduced the nicotine-induced release of 
dopamine from the nucleus accumbens, a neurochemical event that is thought to be a 
key mediator of nicotine dependence (Pentel and Malin 2002). 
These results indicate that there is potential usage for vaccines in the 
prevention of relapse. With the effect of the vaccine and the antibodies attacking the 
nicotine, the nicotine fails to pass through the blood-brain barrier and affect the 
dopamine receptors. By staying in the blood, there is no pleasurable response to the 
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nicotine. Cigarette smokers who quit often experience cravings and thus resume 
smoking to relieve their discomfort. However, if the vaccine renders the cigarette 
ineffective, the smokers will be less likely to smoke a cigarette. A downside of the 
experiment was that it only managed to prevent 60% of the nicotine from reaching the 
receptors. 
Investigators at the University of Minnesota also performed experiments with a 
vaccine to treat addiction to nicotine (Keyler et al. 2008). They began by taking a 
group of rats and injecting them with different types of proteins—proteins that would 
bind to the nicotine and attract the antibodies, preventing them from passing through 
to the brain. The experiment had three experimental groups, each injected with a 
different type of binding protein. The control group was a group of rats who received 
no protein injections at all. After three series of vaccinations, the rats were 
anesthetized with dropiridol/fentanyl, and then injected with .03/ mg/kg of 6-
CMUNic, 3-AmNic, and Bivalent over 10 sec via the jugular cannula. The rats were 
decapitated 3 minutes later and levels in the blood and brain were collected and stored 
at -20 degrees Celsius until processed. Serum and brain protein concentrations, 
nicotine protein binding parameters, and serum NicAb concentrations were compared 
among groups by one way ANOVA and individual comparisons were analyzed by t-
test. As seen in Figure 2, the results indicated that each of the vaccines increased the 
total serum nicotine concentration, and reduced the nicotine concentration in the brain 
compared to the control group.   
The results indicate that it is 
possible to design more than one 
immunological distinct hapten from a small 
molecule such as nicotine to inject via 
vaccine to bind to nicotine and prevent it 
from crossing the blood-brain barrier. The 
fact that the Bivalent showed evidence for 
antibodies in the blood, and lack thereof in 
the brain, shows the success of having the 
antibodies bind to the nicotine vaccine. The 
results show potential for using the vaccine 
to treat addiction for nicotine and ensure 
that the dopamine receptors are not 
affected by the drug (Keyler et al. 2008).  
CLINICAL TRIALS   
Researchers at Maastricht 
University extended the studies to human 
subjects. In this case, the researchers 
evaluated the safety and immunogenicity of 
four doses of a nicotine vaccine in smokers 
and non-smokers. The subjects were in 
good physical and mental health. Each 
volunteer either received an injection of a 
placebo in the control group, or the vaccine 
in the experimental group. In this case, the 
Figure 2: Results indicating the decreased 
nicotine levels in the blood of rats that were 
vaccinated, as well as the increased nicotine 
levels in the brains of non-vaccinated rats. 
Source: Keyler et al. 2008  
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scientists were not trying to see how much nicotine reached the brain. They were 
attempting to measure the success of the vaccine in creating nicotine-specific 
antibodies. The results would lead scientists one step further in treating subjects 
addicted to nicotine. The subjects received a vaccination of 3'-aminomethylnicotine 
conjugated to detoxified Pseudomonas aeruginosa r-exoprotein A each week. At first, 
no difference was seen between the two groups. However, after 21 days, 7 days after 
the second vaccination, significant increase in the geometric mean titer (GMT) levels 
of nicotine-specific antibodies were observed in the smokers. Nicotine-specific 
antibody levels rose to a GMT of at least 8 at day 49, and at least 10.8 at day 217. With 
each additional vaccination, the level continuously rose. These results indicate that the 
immunogenicity of the vaccine was not impeded by the presence of nicotine, thus 
providing evidence in humans that the vaccine used may represent a feasible strategy 
for evoking type-specific antibodies against nicotine. With these type-specific 
antibodies, the body can ward off nicotine and prevent it from reaching the brain 
(Wagena et al. 2008).  
Researchers at Yale University performed a similar experiment testing the 
therapeutic effects of a cocaine vaccine, using the same technique as the nicotine 
vaccine. The researchers used 34 former cocaine abusers as their experimental group. 
They were divided up and each was given a different dosage of the vaccine, 8 at 13 
micrograms of the active vaccine, 10 at 82 micrograms, and 10 at 709 micrograms. 
Two subjects in each group represented the control group who received a placebo. 
Each group got an intramuscular injection for up to 2 months and was monitored for 
safety and antibody production for 3 months. Twenty-seven of the subjects completed 
the full course of three injections. However, only 24 returned for the final scheduled 
visit on day 84. The vaccine had no drug-related adverse effects, but three subjects at 
the highest dose experienced brief twitching after being injected (Martell et al. 2007). 
Antibody levels were correlated with vaccine dosage and number of injections. 
Anti-cocaine antibodies were first detected after the second injection. The number of 
antibodies peaked after 3 months of treatment and then declined to baseline by 1 year. 
The therapeutic vaccine was well tolerated, with dose related increases in antibody 
levels, and a high proportion of patients recruited into the study were retained (Martell 
et al. 2007). 
Another experiment was performed using a vaccine to treat cocaine 
dependence. Eighteen subjects were tested with dose-escalation over fourteen weeks. 
Ten subjects received four 100 mg injections over the course of eight weeks. The other 
eight subjects received five 400 mg injections over twelve weeks. The urine 
toxicologies and cocaine antibody titers were compared, three times each week.  
Sixteen of the 18 subjects completed the study. The 2000 mg total dose group 
had significantly higher mean antibody titer response (2000 units) than the 400 mg 
total dose group. Despite the fact that there were relapses in both groups, the subjects 
said they lost the euphoric effect of cocaine at the six month follow-ups, 63% in the 400 
mg and 100% in the 2000 mg groups.  
The conjugated vaccine to treat cocaine addiction was well-tolerated and the 
antibodies were prevalent for at least six months. Additionally, the subjects who 
received the more intense vaccination schedule had less likelihood of using cocaine. 
These experiments prove that vaccines were effective in raising the antibody 
level in the body, as well as preventing the drugs from reaching the dopamine 
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receptors. However, the experimental groups were small and the researchers did not 
extend the experiment to see how long the effects lasted and if the dopamine receptor 
levels were up-graded and normal levels restored.  
Multiple pharmaceutical companies are performing vaccine clinical trials as 
well. The adjuncts used in the clinical trials are known as alum hydroxide or 
phosphate. All of the clinical trials have administered the vaccine via injection. The 
company Cytos has successfully completed a Phase I clinical trial involving 40 non-
smoking subjects who showed no unexpected toxicities. In Phase II of the study, 
individuals with antibodies in the highest percentile were able to avoid relapse to 
cigarette consumption for longer than the subjects who received a placebo vaccine. 
Abstinence rates in subjects with lower antibody responses were not significantly 
different from those in the placebo group (Escobar-Chavez et al. 2011). This 
experiment proved that elevated antibody levels are effective in preventing relapse to 
cigarette consumption. 
Cytos's nicotine vaccine program now collaborated with Novartis AG. 
Together they performed a double-blind placebo-controlled Phase I study evaluating 
immunogenicity and tolerability of the vaccine. The study contained four groups of 10 
non-smoking subjects who were given different doses of the vaccine. All of the subjects 
evaluated responded with high levels of nicotine-specific antibodies and a long-lasting 
immune response. Up to half of the patients reported negative effects such as muscle 
aches, fever, and chills.  Those symptoms disappeared within one day, and the elevated 
antibody level declined over time. 
In Phase II of the clinical trial, a group of 341 smokers were divided: two thirds 
received the active vaccine and one third received a placebo. Afterwards, five 
injections of 100 mg of vaccine conjugate were given monthly and the subjects received 
counseling for the first three months. The subjects were required to abstain from 
smoking from week 8 to week 52 after receiving treatment. The researchers used self-
reporting and biochemical markers to evaluate that the subjects were adhering to the 
regulations.  The participants reacted as predicted. The two thirds receiving the active 
vaccine developed elevated levels of antibodies, while the control group did not. 
Though the vaccine was tolerated, there were some side effects such as flu-like 
symptoms. However, the effects only lasted for one day.  
In May 2005, six-month results were published, and later that year, 12-month 
results were published. According to the results of the antibody levels, the smokers 
were divided into three groups: low, medium, and high responders. The high 
responders group had continuous abstinence after 6 to 12 months of 57% (P=0.004 as 
compared to the placebo group) and 42% respectively. The medium responders group 
had a result of 32% and 21% respectively, and the low responders group had 32% and 
26% respectively. The relatively high continuous abstinence rate for the placebo group 
was 32% and 26%.  
Another study Cytos performed with healthy volunteers evaluated giving 300 
mg per injection as opposed to 11 mg. The higher dose induced a greater mean 
antibody production that was four times higher than the initial Phase II study. The 
company also reported new formulations reducing the incidents of fever and flu-like 
symptoms to about 10% as opposed to the original 60% (Escobar-Chavez et al. 2011). 
The clinical trials performed by Cytos indicated the success of the vaccine in 
treating nicotine addiction. The subjects with increased levels of antibody production 
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maintained their smoking prevention and abstained from relapsing for longer periods 
of time. Immunization against nicotine can significantly ease some behavioral effects of 
nicotine. The results of these experiments suggest that immunologic intervention could 
have use in the treatment of tobacco dependence. However, further research and 
clinical trials are necessary to validate that vaccinations facilitate abstinence from 
nicotine use (Escobar-Chavez et al. 2011). 
POTENTIAL FOR THE NICOTINE VACCINE 
The nicotine vaccine certainly shows some degree of efficacy. Overall, the data 
indicated in the experiments and clinical trials support the vaccine in preventing 
nicotine from affecting the dopamine receptors. Clinically, though, the vaccine will not 
replace existing medication. Nicotine replacement therapy, such as bupropion and 
nortriptyline, will still be the main form of treatment. However, the vaccine can lessen 
the rewarding effects of nicotine, something which existing therapies cannot do 
significantly, thereby complementing current treatment (Escobar-Chavez et al. 2011).  
The nicotine vaccine can also be useful in relapse prevention by blocking the 
effects of using a cigarette. Vaccination can also be done while the individual is still 
smoking, thereby preparing the individual to quit. The vaccine may also have a 
possible role in preventing high-risk teens from becoming completely addicted to 
smoking. However, that will require additional confidence and safety assurances aside 
from proof of efficacy. 
Most importantly, vaccination can play a role in aiding individuals who are 
taking proactive steps to a complete recovery. Although research suggests that 
immunologic intervention can play an important role in treatment of tobacco addicts, 
the patients first need to be motivated to quit. The vaccine does not treat the non-
pharmacological factors that maintain tobacco dependence. By giving the vaccine in 
conjunction with behavioral intervention, patients can maximize the results and may 
quit their nicotine-dependence.  
More reports on the vaccine will be publicized within the coming year. Phase 
III trials and marketing launch dates for nicotine vaccines have yet to be announced. 
However, the results of the experiments and clinical trials performed thus far are 
indicative of the possibility of successfully distributing a vaccine to induce type-specific 
antibodies to prevent nicotine from entering the brain (Long 2011). These experiments 
provide a basis for creating vaccines to treat other substances as well, using the same 
strategy. Scientists are merely steps away from succeeding in creating an effective 
vaccine against nicotine, and perhaps with that success, they will attempt to create 
further vaccines type-specific for antibodies to bond to other addictive substances. 
DISADVANTAGES/ETHICAL ISSUES 
There are numerous ethical issues that arise with the possibility of producing 
and distributing a nicotine vaccine. Firstly, misconceptions may arise that the vaccine 
will give lifelong immunity against nicotine and may cause parents to vaccinate their 
children, and as minors, children will be unable to dissent. Some may say that parents 
have a right to protect their children, while others may fight this view, namely, tobacco 
producers. Additionally, there is a danger that people may overdose on drugs after 
receiving the vaccine due to their inability to feel pleasure from the drugs. 
On the other hand, the vaccine used for treatment of addiction has many 
advantages. Most importantly, though not eliminating the cravings, the vaccine will 
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help the addict stick to his recovery, in that after his injection he will be free of the 
drug induced chemical reactions that he relied on so heavily (Kosten 2011). With this-
once-a-month vaccine, the recovering addict has a stronger chance of maintaining his 
treatment plan, as it only takes a monthly injection to ensure that he does not feel the 
affects of succumbing to his desire to relapse, and thus can overcome the initial most 
difficult moths of addiction treatment (Long 2011). The most crucial part of any drug 
treatment is the prevention of relapse. With the antibodies from the vaccine remaining 
within the user's system for an entire month, the user will be protected from relapses 
throughout that time period, and hopefully remain drug-free by choice after that.  
Additionally, the vaccine poses minimal danger to the subject's health and 
normal brain functioning. By blocking the brain from receiving the chemicals from the 
drugs, the user will be able to stop his behavior and control his addiction.  The vaccine 
can also be used alongside psychological therapy because it does not affect normal 
brain functioning; it prevents both the vaccine and the drug from entering the brain 
(Long 2011). Another advantage of the vaccine is that it saves time, since it only has to 
be given once a month. It saves money as well, as other forms of pills, compresses and 
treatments may be minimized or eliminated. Though it is advisable for subjects of 
addiction to see a psychologist continuously, the vaccine helps prevent a relapse 
because they will stop using the drug once they realize it has no effect on them, thus 
eliminating relapse costs.  
Another major advantage is that the addictive substance is not being treated 
with another addictive substance, drug for drug. With the vaccine, the effect of the 
addictive substance is being eliminated, while refraining from adding additional 
potentially addictive substances to the body. Traditional addiction treatments typically 
involve medications that mimic a drug in the brain. For example, methadone will stand 
in for heroine and a nicotine patch will substitute for cigarettes. Other medications 
block activity in the brain's reward system, such as Vivitrol injections for alcoholics 
and Pfizer Inc.'s Chantix pills that block the brain's pleasure receptors from being 
activated when people smoke. Some of these drugs function inside the brain and thus 
can pose potential damage to the brain. Warnings include depression and suicidal 
thoughts (Long 2011). On the other hand, vaccines pose no risk to normal brain 
functioning. 
CONCLUSION 
Addiction is a clear indicator of biological and biochemical psychology and the 
way the brain controls behavior. The brain plays a strong role in human behavior in 
that ultimately, addicts are craving the chemical reaction that the drug causes. Though 
there are many medications for addicts, psychologists have noted that the success rate 
of treatment for drug-abuse is unfortunately low (Koob and Moal 2001). The fact that 
the development of a vaccine may be able to treat addiction poses a new hope for 
addicts' recovery. 
The idea of using the body’s innate immune system functions to treat addictions 
is brilliant. By using antibodies, no risk is posed to the brain or normal functioning. 
This technique may also be implemented for other health issues that involve chemicals 
reaching the brain. The development of such a vaccine can be the basis for further 
development and treatment for other dangerous chemicals that reach the brain. Using 
vaccines to treat addiction is just one step in using the antibodies already in our bodies 
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to treat illnesses. Antibodies are G-d's army to fight disease; why not utilize them to 
their complete capacity? 
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INTRODUCTION  
Spinal cord injury is defined as a “disconnection syndrome” that results in a loss 
of ability of the spinal cord to communicate ascending and/or descending impulses 
(Hamid and Hayak 2008). Due to its role as the primary conduit of motor and sensory 
impulses, spinal cord injury is widely regarded as one of the most catastrophic, 
survivable injuries a person can suffer. Depending on the severity and placement of 
the injury, the patient can experience a wide range of disability or death. A mild injury 
may result in the patient lacking strength in one limb, while a severe injury can place 
the patient on a ventilator for life (Field-Fote 2009).  
Before World War II, treatment for a spinal cord injury was very limited and 
rehabilitation was almost non-existent. Life expectancy for a patient with a spinal cord 
injury (SCI) was very short. In most cases, secondary renal, cardiovascular, and 
pulmonary conditions took the life of the individual shortly following the injury. 
Advances in the past forty years have improved care to the extent that individuals 
living with a spinal cord injury can now expect to live nearly as long as able-bodied 
individuals (Hamid and Hayak 2008). The increased use of intermittent bladder 
catheterization dramatically cut down the chances of an individual developing renal 
complications, and advances in emergency medical care resulted in fewer incomplete 
spinal injuries turning into complete spinal cord injuries during stabilization and 
transport of the patient (Field-Fote 2009). 
According to the Spinal Cord Injury Statistical Center, there are roughly 
250,000 individuals living with spinal cord injury, with approximately 11,000 new 
injuries happening yearly. Between the 1970s and 2000, the average age of an 
individual with a spinal cord injury has risen from 28.7 years to 38 years. The rise in 
average age indicates that people are living longer with spinal cord injuries.  
As people live longer with spinal cord injuries and the population of spinal cord 
disabled people increases, secondary conditions that SCI patients suffer become more 
apparent. The question of how the medical community can best service them becomes 
of more pressing importance. While the possibility of regaining the body’s natural 
conduction system of sensory and motor impulses is far off in the future, there are 
numerous rehabilitative measures that can be employed to maximize the remaining 
healthy neural pathways and maintain optimal health.  
While the central nervous system has suffered a cataclysmic injury from which 
it may never recover, the peripheral nervous system emerges mostly intact. This being 
the case, it is possible to generate muscle contractions in spinal cord patients using an 
external device to generate the impulse that would have otherwise descended from the 
brain via the spinal cord. Since as early as the eighteenth century, clinicians were using 
electrical impulses to generate muscle contractions (Hamid and Hayak 2008). In the 
1960s, researchers began systematically applying electrical stimulation with the hope 
of helping patients recover. Muscle contractions were generated by stimulation that 
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was delivered via electrodes placed proximal to the nerve that innervated the desired 
muscle.  
As technology advanced, stimulation patterns became increasingly 
sophisticated and useful. Therapists and doctors began using this system, called 
Functional Electronic Stimulation (FES), to assist spinal cord patients with their 
rehabilitation and daily functioning needs (Prochazka 2009). 
While the initial use of Functional Electronic Stimulation was simply to make 
the muscle contract and to apply the contraction to a functional motion, researchers 
began to notice that the technology may have other positive physiological effects on the 
users.  
Aside from the obvious sensory and motor deficits that arise from a spinal cord 
injury, spinal cord injury patients typically suffer from a variety of secondary 
conditions caused by the injury itself and the sedentary lifestyle imposed on them by 
the injury. Muscular spasticity, muscular atrophy, cardiovascular and 
cardiopulmonary deficits are all common conditions amongst spinal cord injury 
patients (National Spinal Cord Injury Statistical Center 2009). 
Researchers hypothesized that if they could utilize FES to keep spinal cord 
patients reasonably active, there is a good possibility that they can stop, slow, or even 
reverse the secondary conditions arising from the injury.  
Care must be taken to distinguish between “neurotherapeutic” achievements 
and “neuroprosthetic” effects. The former refers to rehabilitative methods that result in 
a lasting therapeutic benefit that persists after the intervention is removed. The latter 
refers to the application of an external stimulus that allows for functional movement 
only as long as the external device is in use (Nogan-Bailey et al. 2010). 
While many spinal cord patients regard walking again as the ultimate goal of 
rehabilitation, there are a number of issues that must be resolved before ambulation 
can be safely considered. This paper will follow the logical sequence of recovery that 
the patient and therapist must follow if he or she is to regain locomotion capacity. 
Spasticity management, atrophy reduction, and cardiovascular/cardiopulmonary 
fitness are all preconditions to successful, safe ambulation. For each of these, this 
paper discusses what it is, how it arises in spinal cord patients, how it affects spinal 
cord patients, and how FES may reduce its severity. Finally, an extensive look is taken 
at post-spinal cord injury locomotion. 
To do this, published, peer-reviewed research on Functional Electronic 
Stimulation is reviewed and an attempt is made to state what, if any, are the 
therapeutic, rehabilitative, and functional improvements that patients experience when 
using Functional Electronic Stimulation as part of their rehabilitative regimen. 
In preparing for this paper, twenty-five published peer-reviewed papers, 
eighteen of which are cited in the paper, were critically reviewed. A comprehensive 
textbook, Spinal Cord Injury Rehabilitation, written by Edelle C. Field-Fote, PT, PhD, a 
leading researcher in the field, provided much of the introductory material in each 
section of this paper. Data from the National Spinal Cord injury Statistical Center was 
also utilized.   
SPASTICITY 
While the descending excitatory impulses the spinal cord transmits may be the 
most noticeable, the inhibitory impulses are no less important. When these are 
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disrupted by a spinal cord injury, the inhibitory functions of the spinal cord are 
affected. The lack of inhibition is most noticeable in the symptoms of spasticity. 
Spasticity is a hyper-reflexive response of a muscle to an outside stimulus (Field-Fote 
2009). Spasticity is described as the fourth and final stage of spinal shock (Ditunno et 
al. 2004). Spinal shock is a condition immediately following a spinal cord injury that 
progresses from a period of absent reflexes, or hypo-reflexia, to the eventual 
emergence of hyper-reflexia. The reflexes emerge in a predictable pattern. The 
polysynaptic reflexes occur first, followed by the monosynaptic reflexes some weeks 
later. When the monosynaptic, deep-tendon reflex emerges, it is often highly sensitive 
to stimulation. The response is inappropriate in relation to the stimulus received and 
interferes with many activities the patient performs. Occasionally, the patient is able to 
anticipate the stimulus that causes the spasm and actually use the spasm for functional 
movement. More often, though, the spasm is an impediment. For example, some 
paraplegic patients are able to drive vehicles modified specially to accommodate their 
disability. For others, muscle spasms are triggered by passive stimulation as mild as the 
pressure the seat exerts on the driver when the driver executes a turn. The resulting 
spasm makes driving unsafe (Hamelburg 2009). 
FES has been applied in an effort to reduce spasticity. Krause, et al. (2008) 
performed a crossover study of five patients with acute T3-T7 spinal cord injury. The 
patients performed both passive and FES activated leg-cycling movements on an 
ergometer. The FES activated muscles were the quadriceps, hamstrings, and gluteal 
groups. The results showed a consistent decrease in spastic muscle tone following the 
FES applied exercise, which was not always present following the passive muscle 
movements. Whatever reduction was experienced was gone by a week after the 
exercise. The reduction in spasticity can be explained by something as simple as 
muscle fatigue following the exercise, with the greater fatigue following active 
movement of the muscles involved. This study, however, is limited in a number of 
ways. The sample group was very small, and because the study was performed in an 
outpatient setting, the clinicians only personally tested the spasticity immediately 
before and after each session. All other data was subjectively reported by the 
participants themselves. 
The Ashworth scale is a test often used to measure spasticity. Researchers 
question the validity of the test, because spasticity is an issue that can be more or less 
severe depending on the time of day, prior muscle activation, and patient fatigue. The 
test only scores spasticity at a single point in time. In this regard, subjective assessment 
by the patients themselves may actually be more useful than the Ashworth scale 
(Johnston et al. 2007). 
Other studies have shown reductions in spastic muscle tone, but these, too, 
have been small studies. The physiological explanation of such reduction is also 
unclear. The use of FES in spastic muscle reduction thus seems limited (Thomas and 
Field-Fote 2009). 
ATROPHY    
In the months following a spinal cord injury, the individual undergoes a 
dramatic amount of musculoskeletal atrophy. The atrophy carries with it a higher risk 
for secondary complications of SCI, such as pressure sores, deep vein thrombosis, and 
bone fractures (Baldi et al. 1998). 
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Muscles undergo two distinct types of atrophy following a spinal cord injury. 
The first is “disuse atrophy” and the second is “denervation atrophy.” Disuse atrophy 
results from damage to the central spinal pathway. By interfering with the 
transmission of upper motor control, the injury prevents the patient from voluntarily 
initiating a contraction. The muscle remains physiologically capable of contracting, yet 
undergoes atrophy because the patient is unable to use it. Denervation atrophy results 
from damage to the lower motor neuron itself. The ability to conduct an impulse to the 
muscle is lost. Following this type of injury, an FES contraction is much harder to 
generate because the lower motor neuron is affected. The amount of muscles that 
undergo denervation atrophy is usually very small; the injury will only directly affect a 
small number of lower motor neurons. The majority of atrophy spinal cord injury 
patients experience is disuse atrophy (Gordon and Mao 1994). Even regarding 
denervation atrophy, the ability to contract the muscle is not lost completely. Because 
most muscles are innervated by more than one motor neuron, the intact remaining 
motor neurons can still generate a contraction. However, as the ratio of motor neurons 
to muscle decreases, the ability to grade contractions is compromised (Field-Fote 
2009). 
Reducing atrophy is crucial for the patient who wishes to walk again. If the 
muscle is unable to bear the weight of the patient, walking will remain impossible. It is, 
therefore, essential that the occurrence of atrophy be reduced as much as possible 
(Janssen and Pringle 2008). 
Many studies have substantiated the claim that FES is useful in stopping 
atrophy. The increased muscle use of the activated muscles directly reduces the 
incidence of muscular atrophy (Nogan et al. 2007; Hamid and Hayak 2008; Johnston 
et al. 2007; Field-Fote et al. 2005). In fact, the use of resistance FES has been 
documented to prevent atrophy in weightless non-disabled individuals (i.e. 
astronauts), giving reason to believe that FES may also benefit neurologically deficient 
individuals (Baldi et al. 1998). 
In using FES to reduce muscle atrophy, it is important to determine the best 
method of applying the stimulation to achieve the desired outcome (Gordon and Mao 
1994). In this instance, the desired outcome is sufficient muscle strength and 
endurance to allow the patient to walk. The therapy is designed to enhance the 
muscle’s ability to bear weight, as well as make the muscle less prone to fatigue. 
Generally speaking, exercises which are of a small load and long duration are best for 
increasing endurance, while exercises that place the maximum safe stress on the 
muscle, with fewer repetitions, will increase strength (Gordon and Mao 1994). 
In targeting the muscles that need intervention most, studies have shown that 
weight-bearing muscles, such as the soleus (plantarflexion), undergo significant 
atrophy, while non weight-bearing muscles, such as the tibialis anterior (dorsiflexion), 
undergo little atrophy (Gordon and Mao 1994). 
FES generated contractions do little to reduce existing atrophy in chronic 
spinal cord injury patients. Baldi et al. (1998) suggests that perhaps FES would be 
more successful in stopping or slowing atrophy than in reversing it. Until twenty years 
ago, there was no research that studied the effect of FES induced contractions on 
slowing the atrophic progress of spinal cord injury patients. Most of the research had 
been done on chronic SCI patients (>1 year post-injury), attempting to reverse existing 
atrophy. Baldi et al. cites animal studies that indicate that more muscle mass is lost 
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during the first eleven months following injury than during the next eight years. While 
previous attempts at reversing atrophy in patients had been largely unsuccessful, 
researchers concluded that these disappointing results were because the muscle had 
reached a new “steady state” from which it was nearly impossible to be removed. By 
the time the patient received the FES, it was corrective, as opposed to prophylactic, in 
nature. Addressing this concern, Baldi et al. designed a study of six spinal cord injury 
patients in the acute stage of the injury to determine if preventive FES is more 
successful than the current model. He hypothesizes that if FES would be applied early 
enough, it would ward off the muscle atrophy, thereby reducing the degree of 
secondary complications the SCI patient suffers.  
The study had two goals. One goal was to identify the amount of atrophy that 
occurs in the six months, starting not less than 4 weeks and not more than 15 weeks, 
after the injury. The second objective was to study the differences between cycle 
ergometer-load bearing (aka resistance training) and isometric FES.  
Twenty-six subjects were randomly assigned to the FES-cycle ergometer load-
bearing group, isometric FES group, or control group. All subjects were 4-15 weeks 
post a cervical or thoracic spinal cord injury. The FES-cycle ergometer group used the 
cycle ergometer three times a week for 30 minutes each session. Each participant wore 
a fitted garment over the surface electrodes to minimize slipping of the electrodes. The 
device stimulated the hip extensors, knee extensors, and knee flexors. The FES 
isometric contraction group received similar stimulation for one hour, five times 
weekly.  
Six months following the start of the study, the participants were assessed to 
determine the lower-limb lean body mass (LL-LBM). The results were as follows: The 
control group lost 21.4% of LL-LBM. The cycle ergometer-load bearing group gained 
9.3% LL-LBM. The isometric FES group lost muscle mass, but far less than the 
control group.  
The finding that the isometric FES group experienced minimal amounts of 
atrophy is consistent with earlier findings that non-load bearing contractions are not 
capable of building muscle mass. 
The results show that starting FES as soon as possible after the injury is 
beneficial in preventing or diminishing the degree of atrophy the individual will suffer. 
Safety of the patient must be taken into account, however. Following injury, most SCI 
patients experience “spinal shock” in which the muscles do not respond with a 
contraction to any stimulation at all. Patients also frequently experience hypotension, 
necessitating bed-rest. Therapists must also watch for dangerous conditions that are 
specific to spinal cord injury patients, such as autonomic dysreflexia, at all times. 
CARDIOVASCULAR/CARDIOPULMONARY 
The sedentary lifestyle that follows a spinal cord injury puts SCI individuals at 
a higher risk for conditions associated with lower fitness levels. Obesity, diabetes, and 
cardiovascular disease are all far more prevalent amongst spinal cord patients than the 
general population. While the normal resting heart rate for an able-bodied person is 
between 60-100 beats per minute, a spinal cord injury patient has a normal resting 
heart rate of only 50 beats per minute (Perret et al. 2010). According to the National 
Spinal Cord Injury Statistical Center, renal failure was the leading cause of death in 
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spinal cord injury patients until the 1970s. With the increased use of intermittent 
catheterization, renal failure has ceded its top spot to cardiovascular problems.  
Besides for the obvious difficulty in getting enough exercise if one is motor 
deficient, there are other cardiovascular problems that contribute to the overall 
reduction in cardiac health. If the injury is above T1, sympathetic activation of the 
heart is compromised and a low resting blood pressure is the result. Lower blood 
pressure causes atrophy of the left ventricle and further compromises the circulatory 
system. The lower blood pressure can increase the likelihood of heart disease or a deep 
vein thrombosis (Nash 2009). Decreased circulation coupled with muscle atrophy 
results in lower systemic O2 consumption and, consequently, a lower CO2 production 
(Janssen and Pringle 2008).     
Typically, SCI individuals are limited to upper body exercises, neglecting the 
greater mass of the lower body. The need for safe methods for spinal cord patients to 
achieve their daily exercise needs is great (Field-Fote 2009). 
Since the early 1980s, it has been well documented that FES is a relatively easy 
way for a spinal cord injury patient to maintain heart health (Janssen and Pringle 
2008; Nash 2009). As the technology becomes increasingly convenient and affordable, 
FES is becoming a popular method of cardiovascular health maintenance for spinal 
cord compromised individuals. There is one device that has been the focus of a 
significant amount of research. The FES leg-cycle ergometer is a machine that 
activates the major muscle groups of the lower body and moves them around a 
stationary bicycle. The leg-cycle ergometer is a safe way for many spinal cord patients 
to maintain cardiovascular health.  
The benefits of FES to a tetraplegic are obvious. Lacking motor capability in all 
limbs, the only means of cardiovascular benefits is an electronically stimulated 
contraction. Even for paraplegics, the FES leg-cycle ergometer is a useful way to 
reduce reliance on the possibly overburdened upper limbs (Perret et al. 2010).  
Nogan et al. (2007) conducted an exhaustive case study of a participant with a 
C6-C7 injury. The participant received an implanted 8-channel system that allowed 
limited community ambulation once mastered. While the main focus of the study was 
the ambulation of the participant, the participant also underwent a thorough cardio 
evaluation pre and post FES training. Following the twelve weeks of training, the 
participant presented a reduced resting and working heart rate. The patient showed 
greater oxygen consumption, attributed to the increased walking speed achieved from 
the FES. 
It was noted that after a period of several weeks of training, the patient reaches 
a plateau of cardiac activity that is hard to pass. This discourages the patient from 
maintaining the exercise schedule. Janssen and Pringle (2008) hypothesized that the 
plateau observed in patients using the leg-cycle ergometry training could be due to the 
design of the regimen of stimulation they use. Perhaps by modifying the stimulation 
pattern to generate greater overload of the muscles, better cardiac and muscular results 
would be observed. In effect, shorter, more intense sessions may prove better for those 
purposes. This would be accomplished by maximizing the current amplitude used to 
generate contractions and by modifying the duration of the sessions. To address this, 
they developed a modified method of applying the stimulation.  
They tested the effects of the modified stimulation patterns on 12 patients, six 
tetraplegics and six paraplegics. The patients used the system 18 times over 6 weeks. 
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As stated earlier, the sessions were designed to apply shorter, more intense exercise 
periods on the participants. The results indicate that the maximum possible gain is 
observed after training on a system that is designed to produce more intense 
contractions for shorter duration.  The significant findings are summarized in Table 1. 
Table 1: Effects of Modified Leg-Cycle Ergometry. 
 Standard Modified After Training 
Peak O2 Consumption 
(mL/min) 
670 ± 208 818 ± 287 1065 ± 264 
Peak CO2 Production 
(mL/min) 
765 ± 228 1154 ± 390 1405 ± 363 
Peak Pulmonary 
Ventilation (L/min) 
30.1 ± 9.0 41.3 ± 12.3 49.1 ± 9.1 
Max Cardiac Output 
(L/min) 
6.5 ± 1.4 8.6 ± 1.9 9.5 ± 2.3 
Stroke Volume (mL) 82.6 ± 20.6 91.7 ± 23.5 91.2 ± 28.7 
Max Heart Rate (bpm) 81.9 ± 17.3 97.4 ± 11.2 113.3 ± 23.0 
Source: Janssen and Pringle 2008 
 
There are findings in reviewing the data that highlight some interesting cardiac 
occurrences in the participants. While heart rate increased, cardiac output and stroke 
volume did not. This can be contributed to dilation of lower-limb blood vessels 
resulting in lower venous return, indicated by the lightheadedness reported by some of 
the participants following the treatments (Janssen and Pringle 2008). 
Another interesting result was the increase in oxygen consumption that was not 
accompanied by any concurring increase of cardiac output. This could be explained by 
stating that there was improved blood distribution. The oxygen differential between 
the arteries and veins is, thus, improved while the cardiac output does not change. As 
noted earlier, better circulation through the body tissues reduces the atrophy that 
muscles undergo and the occurrence of pressure sores. 
Generally, the recommendation for SCI patients is to use 1000-2200 kcal per 
week to maintain heart health. Perret et al. (2010) conducted a study to determine how 
much activity is needed to achieve this goal and whether or not this is practical for the 
general SCI community. The study looked at eight otherwise healthy individuals who 
had sustained a T3-T9 injury more than three years earlier. They conclude that 4-8 
hours of intense FES cycling is enough to generate the 1000-2200 recommended kcal. 
Considering the normal variation of responses between different individuals, this is 
fairly consistent with the 30 minutes daily recommended by most therapists who work 
with FES. 
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While clearly beneficial, the system still has downsides. It is very time 
consuming to set up, and, often, the individual needs assistance in properly setting up 
the equipment. Given these facts, it may be better to use it fewer times a week for 
longer sessions (Perret et al. 2010). This conclusion does not accommodate the 
previous recommendation of shorter, more intense bursts of FES to maximize muscle 
overload and cardiopulmonary benefits. It disregards the benefit of the combination of 
short-intense and long-intense sessions which maximize strength as well as endurance 
and reduce occurrence of muscle atrophy. Reasonable disagreement in this regard is 
expected. One must keep in mind that the SCI patient has a disability that presents a 
logistical transportation obstacle that must be overcome each time he or she is to 
participate in therapy away from home. The benefits of frequent sessions are of little 
use if the patient cannot practically maintain the exercise schedule. The therapist must 
design an exercise schedule on a patient-by-patient basis, making sure to factor all 
considerations when recommending what the session duration and intensity should be.  
Finally, Perret et al. (2010) suggest that the use of a rowing type machine for 
paraplegics, where the lower limbs are stimulated electronically and the upper-limb 
use is voluntary, could provide a good combination of upper and lower body exercise 
while maximizing cardiopulmonary advantages. This combination needs to be studied 
more before a recommendation can be made. 
LOCOMOTION/AMBULATION 
The use of FES to assist spinal cord injury patients in standing, sitting and 
walking started in the early 1980s. In 1982, a device was introduced by researchers at 
Wright State University in Ohio that could stimulate a spinal cord patient’s muscles to 
allow for standing and level ground walking. The disadvantages of this early 
technology were obvious. The battery pack needed to operate this device weighed 
nearly eight pounds and was worn on the user’s back. This was the lightweight option 
and was for walking only. A heavier battery was needed when the user wished to make 
use of the stand and sit feature. An updated device introduced in 1989 had its 
disadvantages too. Putting on and removing the system took around an hour. Phillips 
(1989) outlines in agonizing detail the procedure for generating the necessary pattern 
of stimulation and positioning of the patient to allow rudimentary locomotion. Clearly 
this was not a practical option for the average disabled individual.   
In a case study, Nogan-Bailey et al. (2007) reports that some non-ambulatory 
individuals are able to combine their remaining volitional motor, sensory, and 
proprioceptive abilities with an FES device to allow limited ambulation.  
For FES-assisted walking, the stimulation was formulated to accomplish three 
goals. The first goal was to “augment” existing volitional contraction. The second 
objective was to initiate contraction of paralyzed muscle. The third purpose was to 
reduce extensor tone for easier walking; for example, stimulation of hip flexors 
(iliopsoas) reduced tone in the hip extensor (biceps femoris) dramatically, making hip 
flexion easier for stepping. “Stimulation was the means to reducing extensor tone 
during standing to allow stepping.” 
The goal was to generate the strongest contraction that would not hurt the 
patient or overflow to a neighboring muscle group. Once this was accomplished, the 
maximum threshold has been reached.  
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 The variable used as the baseline index for the study was voluntary walking 
following aggressive pre-study rehab using robotic-assisted body-weight-supported 
treadmill training. They hypothesized that “exercise and gait training with FES would 
improve voluntary motor control and baseline volitional walking ability. It would also 
increase the strength, endurance and repeatability of muscle contraction over maximal 
pre-implant levels.”  
This hypothesis was tested with pre and post implant assessments of gait 
function (speed, distance, symmetry, and physiological cost) and isokinetic muscle 
contractile properties (strength, endurance, and repeatability) of the knee extensors on 
a dynometer. The goal was to improve a nonambulatory patient’s function to that of 
independent household ambulation or limited community ambulation. The patient 
selected for the study was unable to voluntarily initiate a single step with either leg.  
The patient was evaluated at the following points: after the pre-study therapy, after the 
implant, six weeks into FES training, and 12 weeks into FES training. 
The participant used a hand trigger to manually initiate the impulse for each 
step. The patient needed to be trained in this device with a specific sequence of 
switches at different points in the gait.  
While there were some small improvements attributable to the pre implant 
therapy, the patient remained functionally non-ambulatory prior to the implant 
(Nogan-Bailey et al. 2007). 
At the 12-week assessment, the following results were obtained: Walking 
distance improved 20x (14m in 11 min to 309m in 30 min). Walking speed increased 
10x (0.02m/s to 0.20m/s). The patient needed less standby assistance and a smaller 
walking aid than before.  
The FES did not improve volitional ambulation or motor control at all. The 
results signified that the device is useful for household or limited community use.  
While walking speed and cadence improved from pre to post implant, it peaked 
at 6 weeks and did not get any better at the 12-week checkup. The reason for this was 
a technical limitation of the system. Speed is largely a function of plantarflexor 
strength. The primary muscle of plantarflexion is the gastrocnemius. The 
gastrocnemius was not implanted due to a limited number of channels available on the 
system; priority was given to muscle groups needed for ambulation. The participant 
“thus relied on voluntary plantarflexion strength during walking … and this strength 
was lacking” (Nogan-Bailey et al. 2007).  
In 2010, researchers published a single-subject study on the therapeutic effects 
of FES. The hypothesis was that it would seem reasonable to expect increases in 
volitional motor control following therapy which utilizes FES. “Neuroprosthetic 
interventions may have neurotherapeutic value” (Nogan-Bailey et al. 2010). 
The subject was C6 incomplete. He was unable to stand without support and 
able to walk only limited distances (<30m) using both a wheeled walker and a left 
ankle-foot orthotic. The limiting factor in his ambulation was upper body exhaustion 
due to the use of his trunk and hip to elevate his weak left leg during the swing phase 
of gait. He presented with significant left side weakness as well as weakness in his 
trunk and upper limbs. Because the main deficit was on his left side, only the left leg 
was implanted. The muscles implanted were the iliopsoas (hip flexion), tensor fasciae 
latae (hip flexion and abduction), gluteus medius (hip abduction), posterior portion of 
adductor magnus (hip extension), gluteus maximus (hip extension), vastus lateralis 
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(knee extension), tibialis anterior (ankle dorsiflexion), and peroneus longus (foot 
eversion). The patient followed a home exercise routine to build strength in the muscle 
groups that were stimulated. This included exercising the extensors as a group 
(standing), the flexors as a group (swing phase of gait), the ankle dorsiflexor, and the 
knee extensor. The patient self-reported participation in the home portion of the 
program. 
At first, the therapist triggered the stimulation of the left leg as needed to 
initiate and continue the walking. As proficiency increased, the patient himself took 
over that function. Eventually, the patient was able to start a “continuous cycling 
stimulation” for locomotion (Nogan-Bailey et al. 2010). 
Data was collected at the start of the program and after 36 sessions of FES 
training. The testing schedule was staggered to avoid any fatigue factors that could 
interfere with the results. 
The data was statistically analyzed to determine the therapeutic effect of FES, 
how much the voluntary control of the muscles in question improved, and how useful 
the neuroprosthetic effect of FES was in restoring function 
The patient experienced significant improvements in volitional walking ability. 
The max distance he could walk in six minutes increased to 80 meters from 28 meters, 
indicating a “strong neurotherapeutic effect.” With the use of FES, his maximum walk 
distance in the six-minute test jumped to 248 meters, sufficient to allow limited 
community ambulation for the user. Similar results were obtained for the walking 
speed test. The baseline speed of 0.17 m/s increased to a volitional speed of 0.22 m/s, 
with a further increase to 0.27 m/s while employing the FES system. The 
neuroprosthetic effect here is an additional 20% walking speed. The gait analysis 
revealed a reduction of double support time, indicating a more dynamic gait.   
The patient was unable to extend the knee voluntarily pre implantation. Post 
implantation, the patient was able to consciously generate 8.78±2.59 Nm of knee 
extension moment on the implanted side. When FES assisted, the patient was able to 
generate 30.22±1.07 Nm. The improvements in volitional abilities post training in 
walking speed, walking distance, and double support time demonstrate the 
neurotherapeutic effects of FES. These benefits can potentially increase the mobility of 
an individual to the level of limited community ambulation while using FES. Even 
without being attached to the FES system, the use of FES in rehabilitation seems to 
have led to significant improvements in walking speed, distance, and gait quality 
(Nogan-Bailey et al. 2010). 
While there were therapeutic gains, it is difficult to determine which of these 
gains are results of FES and which would have happened with traditional gait training 
alone. Further studies are needed to determine the effect of FES that cannot be 
replicated by extensive traditional overground training and body-weight-supported 
treadmill training. In any case, this study demonstrated that FES is a viable 
therapeutic tool (Nogan-Bailey et al. 2010). 
There are various methods available for locomotor training of SCI patients. A 
study was designed in 2005 to collect data on the various advantages and 
disadvantages each method has to offer (Field-Fote et al. 2005). The study looked at 
27 patients with motor incomplete injuries at spinal level T10 or above, who were able 
to initiate a step with at least one leg. The methods tested were treadmill training with 
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manual assistance, treadmill training with stimulation, over ground training with 
stimulation, and treadmill training with robotic assistance   
While researchers agree that sensory input from locomotor training is an 
important aspect that contributes to the patient’s improvements, there is disagreement 
as to the best way to provide that sensory input. Manual assistance has the advantage 
of the physical therapist being “hands on” and thereby able to provide very precise 
levels of assistance based on a moment-to-moment assessment of the patient’s 
condition. The disadvantages of manual assistance are that the trainer cannot assist as 
consistently as an electronic stimulator and that therapist fatigue can also limit the 
duration of a session.   
FES, likewise, has a number of advantages. The FES uses a spinal reflex that is 
thought to be important in healthy locomotion. “As such, repeated activation of this 
reflex may be associated with beneficial neural changes and may improve the synaptic 
efficiency of this circuit.” The disadvantage of FES is that patients display a wide 
variety of therapeutic responses to the treatment. Thus, FES cannot be generalized as 
being advantageous and must instead be evaluated on a patient-to-patient basis (Field-
Fote et al. 2005). 
Overall, the various techniques resulted in a 37% increase in walking speed for 
a “long-bout” walking test (2 minutes) and a 55% increase in walking speed for a 
“short-bout” walking test (6 meters). 
Detailed statistical analysis of the data shows a trend toward better walking 
improvements for the groups that had FES assisted locomotor training. While it is 
tempting to deduce from this result that FES training works best, the authors of the 
paper warn that as their research team works primarily with FES, it is possible that 
their practitioners are simply better acquainted with FES therapy and, therefore, 
obtain better results. Other rehab venues may get better results as well with their 
preferred method of gait training.  
While all subjects in the study got better to some degree, none even came close 
to returning to community ambulation.  
Volitional locomotion benefits for individuals with SCI were only observed in 
incomplete SCI patients. Patients with complete SCI may have been able to generate 
locomotion like movement on a treadmill but were not able to accomplish this over 
ground (Field-Fote et al. 2005). 
THEORY OF GAIT TRAINING 
Why does gait training in general and FES-assisted gait training in particular 
have a therapeutic effect following a spinal cord injury? The following theory has been 
proposed. After an injury to the spinal cord, the loss of descending neural control 
results in a massive and ongoing reorganization of the cerebral and spinal pathways. 
This evolution continues for years following the injury. The reorganization includes 
the formation of many new synapses and connections. The new synapses are largely 
abnormal and interfere with normal transmission of impulses. The result of these 
abnormal connections is uncoordinated movements and spasticity. Fine movements are 
impossible to generate. For example, attempting to flex the ankle often results in the 
entire leg flexing from the hip down (Fong et al. 2009). 
 The spinal cord can be retrained in the use of its walking patterns with 
locomotion training, with FES providing afferent input of the sensory patterns 
 Functional Electrical Stimulation in Spinal Cord Injury Rehabilitation 103 
 
associated with walking. It has been theorized that when the descending motor 
impulse is generated at the same time that there are incoming sensory impulses that 
approximate normal ambulation impulses, this may retrain the spinal walking 
programs to allow for functionally useful synapses to form. Experiments on SCI cats 
demonstrate that the spinal cord has the ability to perform locomotion pattern 
behavior without upper nervous input. For many standard motor tasks, the spinal cord 
is, in large part, autonomous from the brain. The implications of these experiments in 
spinal cord rehab are enormous. If the spinal cord can generate walking patterns 
without being connected to the brain, there should be a way to rehabilitate SCI 
patients. This can help explain the therapeutic effects researchers have observed in 
patients who have used FES (Fong et al. 2009). 
Researchers suggest that when intact lower spinal motor neurons lose the 
neurotransmitter input from upper motor neurons following a spinal cord injury, the 
now inactive synapse sprouts new “collateral” dendrites. The emergence of these new 
synapses can cause unwanted motor activity. If FES is applied to generate functional 
movements while the sprouting is in progress, this afferent input can direct the 
sprouting dendrites toward pathways that are functionally useful (Ditunno et al. 
2004).     
ELECTRODE TYPE AND SPILLOVER 
There are two other general discussions related to FES induced walking. The 
first discussion is what type of electrode is used to generate the contraction, and the 
second is the concept of “spillover.” 
To generating contractions, the FES device can employ surface electrodes, 
percutaneous electrodes, or fully implanted electrodes. Surface electrodes have the 
advantage of no risk of infection and only a mild risk of skin irritation. The 
disadvantages of surface electrodes are threefold: first, they cannot be very precise; 
second, they cannot stimulate deep muscles; and third, when large muscles contract 
(i.e. the quadriceps) the trigger point can move two or more centimeters under the 
skin, thereby limiting the effectiveness of the impulse. Percutaneous electrodes have 
the advantage of precision but a very high risk of infection. Fully implantable 
electrodes are precise, long lasting, and only have a very small risk of infection. The 
disadvantages of fully implantable electrodes are that the procedure is invasive and 
that any repair to the equipment necessitates further surgery (Nogan-Bailey et al. 
2007).   
“Spillover” in FES refers to an unwanted contraction generated by the impulse. 
When the impulse reaches the minimum threshold of an unwanted muscle before the 
maximum useable contraction of the targeted muscle is reached, an unwanted 
contraction results. The rate of spillover was studied in 10 patients from 1988 to 1998 
(Triolo et al. 2001). The total number of electrodes studied was just over 600. The 
purpose of the study was to map the most frequent sites of spillover in order to help 
surgeons place the electrodes better, as well as to help the therapist understand and 
anticipate movements a patient may make during therapy.  
A common location of contraction spillover is where the desired contraction of 
the vasti muscles (vastus lateralis, medialis, and intermedius) to assist standing 
unintentionally generates contractions of the rector femoris and sartorius muscle, 
which leads to hip flexion that is counterproductive to standing. This happens because 
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the electrode is placed proximal to the femoral nerve and can easily produce the 
undesired contraction. Where the desired effect of the vasti contraction is standing 
still, activation of the unintended muscles flex the hip or tilt the pelvis anteriority. The 
hip flexion can cause the patient to adopt a lordotic posture. Additionally, if the hip is 
flexed, the sartorius can rotate laterally and abduct the thigh. The disadvantages of 
walking in this manner become clear when considering the fact that all of these 
patients must walk with an assistive device. 
LIMITATIONS 
The applications of FES are numerous, but so are the limitations. First, and 
perhaps most serious, a study done by Bickel et al. (2004) indicates that there is a very 
real risk of muscle damage when load-bearing FES is applied to muscles that have 
been inactive for some amount of time. The muscles of SCI patients after an injury 
undergo structural changes in which the percentage of fast twitch fibers goes up as the 
percentage of slow twitch fibers goes down. The muscle fatigues quicker and is more 
susceptible to damage. This hypothesis was confirmed with MRI imaging of eight 
subjects who had suffered C5-T9 injuries years earlier. The risk of further injury can 
prevent patients from participating in the treatment. An actual injury can set the 
patient back months or years in treatment. 
Getting up and walking around with a deficient spinal cord always carries 
greater risk than able-bodied walking. Muscle weakness and coordination difficulties 
make a fall more likely. Furthermore, bone density is typically compromised in SCI 
patients. This puts them at greater risk for fracture if they do fall. 
Another limitation of FES-assisted walking is that the patients need significant 
upper-body strength to manage the system. Many patients exhibit varying degrees of 
weakness or a lack of coordination in their upper body following a spinal cord injury, 
preventing them from making use of FES for walking. 
If sensation has been spared in the lower limbs, some patients will find the 
feeling of stimulation intolerable (Hamid and Hayek 2008). This presents another 
limitation to the use of FES. 
There are also limitations in the design of the studies on FES. For the most 
part, studies of FES have been of small sample size and only included short follow up 
time (Hamid and Hayek 2008).  Patients displayed a wide variety of therapeutic 
responses to the treatment. It is, therefore, difficult to predict what the benefit may be 
for a particular patient (Field-Fote et al. 2005).  
One study suggested that the ability for the patient to self-administer the 
therapy at home is beneficial because it cuts out the need to arrange transportation to 
and from therapy (Johnston et al. 2007). A second study suggested that compliance to 
the therapy session suffers if patients are trusted to administer the therapy themselves. 
Therapy with FES, according to this study, is most beneficial if administered in a 
monitored setting (Field-Fote et al. 2005). 
Finally, and perhaps most importantly, it is very difficult to generalize from any 
study of spinal cord rehabilitation for the rest of the “extremely heterogeneous” 
population of incomplete and complete spinal cord injuries. Because each patient has a 
unique degree of sensory and motor sensation loss, the effects of FES vary widely from 
patient to patient (Nogan-Bailey et al. 2010).  
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THE FUTURE OF FES 
Technological advances in the past ten years have made FES more accessible, 
portable, cosmetically appealing, and more therapeutically helpful. As computers get 
more powerful, the microprocessors in portable FES systems are better able to process 
a host of factors that give greater control to the user. Computers can calculate, in real 
time, the variable muscle forces, fatigue, joint position, and other data available. It can 
then make instant dynamic adjustments to allow for smoother and safer ambulation 
(Hamid and Hayek 2008). For tetraplegic patients who lack upper-limb strength, 
walking may still be out of reach, but there are FES systems that can facilitate hand 
movements. Using vibrations generated by tooth clicks and detected by a Bluetooth 
like device worn behind the ear, patients are able to initiate FES impulses to grasp, 
squeeze, pinch, pull, twist, and execute other hand motions (Harvey et al. 2011). 
In the future, FES systems may use more “natural” methods of activation. The 
descending motor commands would be intercepted, interpreted, and forwarded past 
the site of the injury to the limb. This would be particularly useful for tetraplegics who, 
due to their lack of upper-limb strength, are unable to utilize traditional FES to 
facilitate walking (Nogan-Bailey et al. 2010). 
CONCLUSION 
The uses of FES in spinal cord rehabilitation are numerous. Over the past 
thirty years, study after study has demonstrated the gains patients make in reduction 
of spastic muscle tone, attenuation of muscle atrophy, cardiovascular health, 
cardiopulmonary health, and volitional or FES-assisted walking. 
Spastic muscle tone is reduced by FES. This reduction is only temporary, but, 
nevertheless, proves an important point about functional electrical stimulation. There 
are enough real, demonstrable, repeatable benefits of FES that the application of the 
therapy is recommended. The temporary reduction in spasticity can be considered a 
side perk of the primary reason for therapy. 
Muscle atrophy is slowed by the application of FES. Research indicates that 
although the reversal of atrophy is not likely, nevertheless, FES slows the progress of 
atrophy. The earlier FES is applied, the better off the patient’s muscles will be. 
Healthy muscle mass reduces pressure sores and is a precondition for safe standing, 
sitting, and walking. FES thus aids in retention of healthy muscle mass. 
Spinal cord injury patients have a reduced resting and working heart rate. 
Vasodilation due to low smooth muscle tone causes low blood pressure that reduces 
venous return. Fewer skeletal muscle contractions means a further reduction in venous 
return. When applied as part of a structured routine that reaches the recommended 
level of weekly activity, FES serves the vital function of helping the patient maintain 
healthy cardiac performance. 
The instantly recognizable disability of many spinal cord injury patients is the 
inability to walk. FES has been able to return a small number of patients to limited 
community ambulation. Can activation of spinal walking patterns using FES help the 
injured spinal cord redevelop its ability to generate useful reflexive or volitional 
contractions? That remains unclear. Some studies have shown improvement in 
volitional abilities in patients with less severe injuries, while others indicate that 
volitional abilities remain unchanged. These differing results indicate that the use of 
FES does not carry the same level of benefit for all patients. Existing research does not 
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point to a conclusive recommendation regarding gait training using FES. Because the 
spinal cord population is “extremely heterogeneous,” risk of further muscle damage or 
falls must be weighed against the potential gains made possible by the therapy. Aside 
from the functional and therapeutic applications of FES, there is an undoubted 
psychological benefit for patients to be able to “walk” again. Patients reported better 
self-esteem and lower incidence of depression (Hamid and Hayek 2008). Many 
subjects reported great improvements in their mental state. The ability to use 
bathrooms not compliant with ADA (Americans with Disabilities Act), the ability to 
move around the kitchen using the counters for support, and the ability to climb a 
flight of stairs all contributed to the patient’s sense of purpose and functional well-
being (Field-Fote et al. 2005). Regarding walking with FES, the decision whether or 
not to use FES must be made only after carefully considering all risks and benefits on 
a patient-by-patient basis.  
FES definitely helps patients regain function. Exactly how FES achieves this 
and how to best use FES to achieve maximum function remains unclear. The studies 
cited in this paper and the majority of studies conducted overall are small and not well 
suited for generalization to the spinal cord injury population. There is a great need for 
large scale, long-term studies with control groups to further assess the role FES can 
play in spinal cord rehabilitation and to assess the methods of application that can elicit 
maximum recovery. Better understanding of the pathophysiology of the spinal cord 
disability can better guide research in the field. If the phenomenon of lower neurons 
stopping to communicate with each other following an injury is better understood, 
better treatments can be designed.     
It may be some time, if ever, before the medical community is able to cure 
spinal cord injury paralysis. It was once thought that when FES became sophisticated 
enough, disabled individuals would be able to simply plug their damaged bodies into 
the system and walk again. This is not yet the case. Walking with FES is still too risky 
and inefficient to be the used on a large-scale basis. In the meantime, the goal of 
patients and therapists is to prevent spinal cord injury patients from developing 
conditions secondary to the spinal cord injury. While FES can only help a very limited 
number of patients walk, many patients can, and do, derive crucial health benefits with 
regard to atrophy reduction and cardiac health maintenance from a carefully 
structured use of the FES systems currently available.   
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INTRODUCTION 
Rheumatoid arthritis is a long-term disease that leads to chronic inflammation 
of the joints and the surrounding tissue. Effects of the inflammation are pain and 
destruction of the bone and cartilage, which leads to severe disability and, possibly, 
shorter life expectancy. That is why early diagnosis and aggressive treatment is a 
fundamental strategy to stop the progression of the disease and suppress the 
inflammation before the damage is irreversible.  
In an attempt to avoid invasive treatments like arthroscopies and surgeries, the 
orthopedist’s first choice of non-pharmacological treatments includes physical and 
occupation therapies. Pharmaceutical treatments such as non-steroidal anti-
inflammatory drugs (NSAIDs) and non-opioid analgesics (pain medication such as 
acetaminophen and aspirin) work on reducing the inflammation caused by rheumatoid 
arthritis, which often results in pain relief. Glucocorticoids, a class of steroid 
hormones, also possess anti-inflammatory effects and were once considered the most 
powerful treatment of inflammatory arthritis, but their use was virtually abandoned 
due to their association with toxicity; they are only used nowadays in controlling acute 
flare-ups joint disease. While these therapeutic strategies reduce inflammation and 
pain caused by rheumatoid arthritis, they are not that beneficial in slowing down the 
joint and bone damage and the progression of the disease. Rheumatologists didn’t 
realize that while the pain was being covered by the medications and anti-
inflammatory drugs, the inflammation and pannus (an abnormal layer of tissue) were 
continuing to cultivate inside the patients joints and articular tissue. For this reason, a 
new and very important group of agents called disease modifying anti-rheumatic 
drugs, or DMARDs, have become a major interest as a potential new therapy in the 
treatment of rheumatoid arthritis.  
While most treatments focus on reducing the inflammation already present in 
the bone tissue and joints, DMARDs work on slowing down occurring bone damage 
and the progression of the disease by actually modifying the disease itself (Katzung 
2001). They are different than other rheumatoid arthritis treatments because they 
work by suppressing the underlying factors that result in synovitis, tissue reactivity, 
erosions, ligament and tendon laxity, subluxations and other complications caused by 
rheumatoid arthritis (Johnson 2011). Since there is no presently known cure for 
rheumatoid arthritis, a lot of research is being done in finding a treatment that will stop 
or at least slow the progression of the bone damage caused by the disease, so that the 
patient can be in remission for a long period of time. 
DISCUSSION 
Rheumatoid arthritis is an autoimmune disease that affects the synovia of joints 
and, eventually, the healthy surrounding tissue and bone, resulting in symmetric and 
erosive polyarthritis. According to Shah and Clair (2011), rheumatoid arthritis affects 
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approximately 0.5-1% of the adult population worldwide. The ratio of rheumatoid-
arthritis-affected women to rheumatoid-arthritis-affected men at premenopausal age is 
4:1 while the same ratio at postmenopausal age is 1:1; this is attributed to the role that 
estrogen has in stimulating tumor necrosis factor-#, a major cytokine in the rheumatoid 
arthritis pathogenesis (Shah and Clair 2011). The exact etiology of rheumatoid 
arthritis is still unknown.  It is known, however, that genetics plays some role in 
development and severity in certain patients. It remains a matter of debate whether the 
trigger of the disease is an exogenous infectious agent, a break in immune tolerance 
leading to classical autoimmunity, or simply random proceedings that accumulate with 
age (Klippel 2001). 
While the auto-antigen that triggers rheumatoid arthritis has not been identified 
yet, the progression and evolution of the disease can be blamed on immune cells and 
mediators that contribute to the inflammation response that occurs. The process of 
how inflammation and erosion develop in synovial tissue and periarticular bone has 
been studied and researched in patients with rheumatoid arthritis.  The primary agents 
involved in the immune response in rheumatoid arthritis patients are T-cells, which 
mainly function in stimulating other cells in the joint to produce and secrete cytokines. 
The most important cytokines involved in rheumatoid arthritis are tumor necrosis 
factor (TNF) and interleukin-1 (IL-1), both produced by macrophages and synovial 
lining cells that were activated by the T-cells in the joints. Once released, TNF and IL-
1 stimulate the synovial cells to proliferate and produce factors contributing to the 
destruction of cartilage, such as inflammatory mediators and matrix 
metalloproteinases, which are endopeptidases. Eventually, bone destruction is caused 
by osteoclasts activated by a TNF ligand called RANKL (Receptor activator of 
nuclear factor kappa-B ligand), which is produced by T-cells and synovial fibroblasts. 
As the hyperplastic and hypertrophy synovium grows over the articular surface, 
pannus develops, which stimulates the resorption of surrounding cartilage (Kumar et 
al. 2005). 
In addition to T-cells acting up, activated B-cells produce inflammatory-
contributing autoantibodies. Some rheumatoid arthritis patients possessor develop 
rheumatoid factors, auto-antibodies that bind to the Fc fragment of Immunoglobulin G 
to form immune complexes that lead to the recruitment of polymorphonuclear 
leukocytes, further exacerbating the ongoing inflammation. The increasing pannus and 
inflamed synovium that spread over the articular cartilage produce large amounts of 
degradative enzymes (e.g. collagenase and stromelysin) that assist in irreversible 
cartilage destruction and subchondral bone erosion (Heaverstock and Jorizzo 2008).   
Since it is a systemic disease, rheumatoid arthritis can affect internal organs as 
well, eventually leading to early death if left untreated. Rheumatoid arthritis typically 
affects joints of the hands and feet first, but can spring up in larger joints at any time. 
One of the essential factors of diagnosing rheumatoid arthritis is stiffness and soreness 
in the mornings after an extended lack of movement. Other clinical findings of 
rheumatoid arthritis are morning pain and swelling in areas such as the phalanges and 
on the balls of the feet. Routine morning activities, such as brushing ones teeth or hair, 
might become difficult due to the clinical manifestations. If left untreated, the disease 
will progress and result in increasing pain, swelling and stiffness caused by the 
destruction of the joints and healthy bones. Figure 1 shows irreversible bone and 
cartilage loss due to untreated rheumatoid arthritis. 
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DISEASE MODIFYING ANTI-RHEUMATOID DRUGS (DMARDS) 
DMARDs are a class of drugs that 
include a diverse group of non-biological and 
biological agents. Although both work on 
suppressing the underlying cause of the 
inflammation in the disease, biological 
DMARDs are protein therapeutics that are 
designed mainly to target cytokines and cell-
surface molecules that promote the 
inflammation response (Shah and Clair 2011). 
It may take 6 weeks to 6 months for the effects 
of the disease-modifying therapies to become 
evident since they are slow acting. It is 
necessary to start the use of DMARDs very 
early in the progression of the disease, since 
they work by slowing the progression and not 
reversing the damage already done. A large 
number of rheumatoid arthritis patients can 
reach remission or at least a low disease 
activity with the use of a single non-biological 
DMARD. However, for those patients with 
moderate or high disease activity or for those 
who failed to respond to a single agent due to 
prolonged disease duration, combinations of 
non-biological DMARDs are used.  
Clinicians realized inadequate response 
was being achieved by patients being treated 
with monotherapy DMARDs, and a more 
aggressive treatment with DMARDs was 
essential for improving rheumatoid arthritis 
symptoms and slowing the progression of the 
disease. The use of biological DMARDs is 
reserved for those who indicate poor prognosis of the disease and do not respond to 
non-biological DMARDs treatment. Many patients who don’t achieve sufficient 
results from either non-biological or biological DMARDS have treatment plans that 
include combining a synthetic DMARD with a biological DMARD in order to reach 
optimal responses from both agent types. DMARD agents are also commonly used in 
combination with non-steroidal anti-inflammatory drugs to reduce present 
inflammation and relieve pain. 
Figure 1: 
Interphalangeal joint abnormalities. 
Osseous erosions are evident at the radial 
and ulnar aspects of the PIP joint of the 
second finger (arrows). Soft-tissue 
swelling and loss of interosseous space are 
additional findings. Marginal erosion is 
also seen on the middle phalanx at the 
distal interphalangeal joint (open arrow) . 
Source: Kountz and Von Feldt 2007  
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Figure 2: The three major rheumatoid 
arthritis therapies.  
Source: 
http://stg.jfponline.com/ccp_article.asp?a=1&r
ef=5610ACCP_Supplement5#5610ACCP_Su
pplement5-fig7 
Rheumatologists are trying to achieve 
early and sustained suppression of the disease 
activity with DMARDs. They believe that 
early detection of the disease and treatment 
with DMARDs might negate the need for 
NSAIDs and corticosteroids. Each rheumatoid 
arthritis patient’s treatment is personalized, 
taking into account the severity of the disease 
and the potential adverse effects of the drugs. 
Since toxicity is a major concern with 
DMARDs, the effects of the drugs must be 
closely monitored, which can cost as much as 
the drug itself (Johnson 2011). Therefore, a 
large amount of effort and research is being 
put in to find the right combination of 
DMARDs that will work best on slowing the 
onset of the disease with reduction of the 
inconvenience of high costs and close 
monitoring. The latest research being done on 
the productivity and effectiveness of single, 
dual, and triple combination of synthetic 
DMARDs and biological DMARDs will be 
discussed in this paper, along with the safety 
monitoring that is necessary with the use of 
these drugs.   
It is important to understanding the mechanism of action of each individual 
drug, because DMARDs work by modifying the disease through inhibiting specific 
parts and pathways of the inflammatory response that occurs in rheumatoid arthritis. 
Knowing the mechanism also helps researchers decide which combination of drugs 
might work well together and which ones to experiment with, resulting in the finding 
of the most productive and effective treatment for the broadest variety of people.  
COMMONLY USED SYNTHETIC DMARDS 
Methotrexate, an analog of folic acid and of aminopterin, is the most commonly 
prescribed DMARD against rheumatoid arthritis in the United States and is usually 
the initial choice when using disease-modifying drugs in rheumatoid arthritis 
treatment.  While its mechanism of action when used at a low dose in rheumatic 
diseases is unclear, it may relate to the polyglutamates metabolized from the 
methotrexate that cause extracellular adenosine to be released, which has anti-
inflammatory and immunotherapy properties (Imboden et al. 2007). According to two 
meta-analyses, methotrexate has the best efficacy/toxicity ratio.  
The most important action shown in studies of methotrexate against 
rheumatoid arthritis is its effects in increasing adenosine (anti-inflammatory agent) 
levels, lowering the pro-inflammatory cytokine levels, and increasing the anti-
inflammatory cytokine levels (Swierkot and Szechinski 2006). Intensive treatment and 
observation while taking methotrexate is recommended in order to attain the most 
benefit from the drug. While patients tend to remain on methotrexate longer than any 
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other DMARD because of better clinical responses and less toxicity, a significant 
number of patients do not achieve premium control over the disease when taking the 
drug alone. As a result, methotrexate can either be used as a monotherapy or in 
combination with other synthetic DMARDs or anti-tumor necrosis factor agents, a 
class of biological DMARDs (Imboden et al.2007). 
A study was done in Japan to evaluate the effectiveness of the government 
recommended 8mg/week dose of methotrexate given to people with rheumatoid 
arthritis. One hundred seventy-six patients with active rheumatoid arthritis at Konan 
Kakagowa Hospital and Kobe University Hospital participated in the study. The 
effects of methotrexate were evaluated by the American College of Rheumatology 
(ACR) core set, which showed maintained improvements in the clinical signs and 
symptoms of rheumatoid arthritis for 24 months. However, according to European 
League Against Rheumatism (EULAR) response criteria, 63.5% of the patients were 
found nonresponsive at 24 months from the methotrexate therapy. Despite the 
treatment, x-rays showed the progression of joint destruction. This study is important 
because it verifies as mentioned before that many patients do not achieve sufficient 
disease control when using methotrexate as a monotherapy (Hashiramoto et al. 2009). 
Most combination therapies involve using another DMARD with methotrexate, to 
enhance the methotrexate clinical response. 
Leflunomide is another very important synthetic DMARD that is widely used. 
Once administered, leflunomide is well absorbed and quickly metabolized in vivo into 
A771726, which is the active form of the drug. At its molecular level, leflunomide is a 
pyrimidine synthesis inhibitor that inhibits dihydroorotatedehydrogenase, an enzyme 
involved in the synthesis of pyrimidines. Unlike other cells during proliferation, 
lymphocytes increase their pool of pyrimidines much more than their increase in 
purines, therefore synthesizing them from both salvage and de novo pathways. By 
inhibiting dihydoorotatedehydrogenase, A771726 prevents the damaging lymphocytes 
from accumulating enough pyrimidines to support DNA synthesis, which is why 
leflunomide is considered an immunosuppressive agent.  
In addition to being a pyrimidine synthesis inhibitor, current research is being 
done to investigate A771726’s effect on inhibiting the over-expression ofCD147, 
thereby resulting in the down-regulation of matrix metalloproteinase-2 (MMP-2) and 
matrix metalloproteinase-9 (MMP-9) in active macrophages. CD147 is a member of 
the immunoglobulin superfamily, which consists of autoantibodies that are linked to 
autoimmune diseases such as rheumatoid arthritis. Pro-inflammatory cytokines, such 
as TNF, interleukin 1 and interleukin 17 are released in patients with rheumatoid 
arthritis and work synergistically to release matrix metalloproteinase-3’s (MMP3) 
from fibroblast-like synoviocytes and macrophages. MMP3’s are connected to 
pathologic tissue destruction, making them a vital interest to the research being done 
to find a cure for rheumatoid arthritis.  
Since CD147 is known to induce several MMP3’s and its expression levels 
have been found elevated in the synovial membranes of rheumatoid arthritis patients, 
research is being done that focuses on CD147 as a novel target in the treatment of 
rheumatoid arthritis. A study was done on phorbol myristate acetate differentiated 
THP-1 cells line, a monocyte-macrophage, to observe the effects of leflunomide’s 
active metabolite on CD147 levels. As MMP3’s are the major MMPs secreted by 
activated inflammatory macrophages and markers of progression of joint damage in 
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early rheumatoid arthritis, the effects of A771726 on MMP3 gelatinases were also 
evaluated in this study.  
In the macrophage cell model used in the study, an increased mRNA 
expression of MMP-2 and MMP-9 (both of which can be activated by MMP3) 
occurred in addition to the up-regulation of CD147, once the cells differentiated. The 
results found in the study showed that A771726 did not affect the mRNA expression 
of CD147, but did inhibit CD147 protein expression on the cell surface in a dosage 
dependent manner, which demonstrates that A771726 only has post-transcriptional 
effect on CD147 production in THP-1 cells. The authors go on to suggest that future 
studies should be conducted on the effect of A771726 on the glycosylation of CD147, 
since abnormal glycosylation was the cause of the instability of the CD147 proteins in 
their experiment. The study also showed that A771726 inhibited the induced increase 
of gelatinolytic activity of MMP-2 and MMP-9. The authors conclude by saying that 
their study indicates that A771726 inhibits the production of CD147 and the 
gelatinolytic activity of MMP-2 and MMP-9 in THP-1 cells, and they suggest that 
serum concentration of the metabolite should be monitored in rheumatoid arthritis 
patients so that sufficient concentration is maintained to allow the patient to achieve 
remission (Juang et al. 2011).  
Leflunomide can also be given as a combo-therapy. The thought of combining 
leflunomide with methotrexate as a double combination therapy was inspired by the 
idea that combining methotrexate with an agent whose mechanism of action was 
different than its own might produce better results than methotrexate monotherapy. In 
1999, a study was done on the safety and efficacy of treating active rheumatoid 
arthritis with a combination treatment of methotrexate and leflunomide. It was a 52-
week open-label study in which 30 patients who had active rheumatoid arthritis 
despite previous methotrexate treatment participated. Adverse effects and clinical 
response, as judged by the American College of Rheumatology 20% response criteria, 
were assessed as end point results. Of the patients, 53% met the ACR 20% response 
criteria and 2 patients met the ACR remission criteria after 1 year. While the study 
was only done on 30 patients and only a little more than half the patients met the ACR 
criteria, the study did introduce methotrexate and leflunomide combination therapy as 
a potential rheumatoid arthritis treatment (Mroczkowski et al. 1999). 
In 2004, another study was done on the safety and efficacy of the combination 
therapy of leflunomide with methotrexate. After a 24-week, randomized, double blind 
trial of taking leflunomide or a placebo with methotrexate, the patients could enter a 
24-week extension to continue the study. Results showed a 48-week maintained 
response to therapy for those patients who continued to receive leflunomide plus 
methotrexate. ACR 20% responder rates improved in the patients who switched from 
taking placebos to leflunomide. Similar ACR 20% response rates were found between 
patients who switched from placebo to leflunomide without a loading dose to those 
who received a randomized loading dose of leflunomide. However, fewer adverse 
events of diarrhea and nausea were found in those who did not receive the extra dose. 
In addition, patients who switched from placebo to leflunomide in the extension 
exhibited a lower incidence of elevated transaminases compared to the patients who 
were initially taking leflunomide throughout the 48-week trial, which may indicate 
possible hepatotoxicity caused by leflunomide (Kremer et al. 2004). While leflunomide 
might slow the progression of the disease, patients must discuss with their doctors 
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required monitoring and possible combination therapies that will yield the best 
efficacy/toxicity ratio while taking leflunomide.  
Besides for leflunomide and methotrexate, there are other synthetic DMARDs 
used to treat rheumatoid arthritis. Both sulfasalazine and hydroxychloroquine were 
initially developed for other disease like inflammatory bowel disease and malaria, but 
they were coincidentally found to be effective in rheumatoid arthritis. They are weak 
DMARDs, which is why they are usually only used as monotherapy in the early stages 
of rheumatoid arthritis or used in combination with other DMARDs such as 
methotrexate. With the use of hydroxychloroquine, ophthalmologic examinations are 
required every six to twelve months to detect color change or evidence of drug in the 
retina. Sulfasalazine, the most common used DMARD in Europe, is usually combined 
with methotrexate, hydroxychloroquine, or both. It is recommended that blood cell 
counts, especially white blood cell counts, be monitored in the first six months of 
taking sulfasalazine.  
Required monitoring while taking these drugs is evidence of how expensive and 
time-consuming DMARD treatments can be. This is why such an abundant amount of 
research is being done to find the most effective and convenient DMARD treatment 
against the autoimmune disease.  
A study was done to compare the efficacy of double or triple combination 
therapies involving methotrexate, sulfasalazine and hydroxychloroquine in patients 
with rheumatoid arthritis. Combinations of the different therapies were either 
methotrexate (MTX) with hydroxychloroquine (HCQ), MTX with sulfasalazine 
(SSZ), or the triple combination of MTX, HCQ and SSZ. One hundred seventy-one 
rheumatoid arthritis patients who were not previously treated with the medications 
were randomized to receive one of the three treatment combinations in this 2-year, 
double blind, and placebo controlled trial. The end point goal was to find the 
percentage of patients after 2 years who had a 20% response to their assigned therapy 
according to the American College of Rheumatology. While all combination treatments 
were well-tolerated, patients receiving the triple treatment responded best with 78% of 
them achieving the 20% ACR response required, compared to the 60% percent of 
those receiving MTX and HCQ and only 49% of those receiving MTX and SSZ 
(O’Dell et al. 2002). 
COMMONLY USED BIOLOGICAL DMARDS 
Pro-inflammatory cytokines, especially tumor necrosis factor-# and interleukin-
1, have vital roles in the pathophysiology of rheumatoid arthritis. This fact led to the 
development of biological agents that target TNF-# and interleukin-1 cytokines. In 
addition, recent research has been done that shows promise for therapies that block T-
cell co-stimulation and those that target B-cells. Since biological disease modifying 
anti-rheumatoid drugs have only recently been studied, and possible long-term adverse 
effects are still unknown, they are usually saved for use in combination therapies with 
other DMARDs such as methotrexate and leflunomide, for those rheumatoid arthritis 
patients who did not respond to synthetic DMARD monotherapy.  
DMARDs that are anti TNF-# agents include etanercept, infliximab, and 
adalimumab. Etanercept, a protein genetically engineered from a fusion gene, consists 
of two soluble TNF p75 receptor functional groups linked to the Fc portion of human 
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immunoglobulin-1. It binds to TNF-# molecules, thereby preventing the activation of 
the inflammatory cascade, in addition to inhibiting lymphotoxin-# (O’Dell 2007). 
A study was done on the efficacy of etanercept combination therapy with 
methotrexate, where 89 patients previously treated with methotrexate, who still 
showed signs of active rheumatoid arthritis symptoms, were randomly assigned to 
receive either etanercept or placebo subcutaneously, while continuing methotrexate 
therapy. At 24 weeks ACR response criteria was used to measure clinical response in 
improvements. Results showed that at 24 weeks 71% of the patients receiving 
etanercept-MTX combination therapy met the ACR 20% response criteria, compared 
to 27% of the group receiving placebo plus MTX. Thirty-nine percent of the 
etanercept group reached ACR 50% response criteria compared to the 3% of the 
placebo group. Significantly better outcomes, according to all measures of disease 
activity, were present in the patients receiving the etanercept-MTX combination 
therapy. Adverse effects associated with etanercept in this trial included only mild 
injection-site reactions, showing etanercept as a safe and potential combination therapy 
in patients with active rheumatoid arthritis who didn’t respond sufficiently enough to 
methotrexate therapy alone (Weinblatt et al. 1999). 
Infliximab is a 25% mouse and 75% human monoclonal antibody that bind to 
soluble and membrane bound TNF-# cytokines with high affinity, preventing them 
from interacting with their receptors, resulting in the down-regulation of macrophage 
and T cell function.  
Adalimumab is a recombinant human anti-TNF antibody. By combining with 
TNF-#, it prevents its interaction with its p77 and p75 cell surface receptors, resulting 
in the down-regulation of macrophage and T-cell function, which is similar to 
infliximab’s mechanism of action (Furst et al. 2009). A 24-week, randomized, double-
blind, placebo-controlled study was done in 2002 to test the efficacy and safety of 
adalimumab in combination with MTX given to patients with active rheumatoid 
arthritis who have not responded adequately to previous MTX mono treatment. The 
results showed that an ACR 20%, 50% and 70% response were all achieved by a 
significantly greater proportion of patients in the adalimumab plus MTX administered 
group than in the groups given placebos with MTX. The greater the dose of 
adalimumab was given, increasing from 20-mg to 40-mg, to 80-mg, respectively, the 
higher the response rate appeared. Response seemed rapid, as the greatest proportion 
of adalimumab-treated patients achieving an ACR 20% response occurred at the first 
scheduled visit of one week. Adverse events were similar in both control groups, 
indicating that adalimumab was well tolerated (Weinblatt et al. 2003).  
While this clinical trial did demonstrate that adalimumab with combined MTX 
therapy has been effective in reducing signs and symptoms of active rheumatoid 
arthritis, and does give hope for potential combination therapy, the study was only 
held for 24 weeks. While this might be sufficient to show improvements caused by 
adalimumab in rheumatoid arthritis symptoms, it does not show how effective 
adalimumab is in the long run at stopping the progression of the disease, or pushing 
the patient into remission (Kremer et al. 2008). 
Abatacept, a recombinant protein, acts by blocking T-cell co-stimulation and 
preventing the autoimmune response caused by rheumatoid arthritis. A study was 
done on 652 patients who had active rheumatoid arthritis, despite previously being 
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treated with methotrexate, to see the efficacy of abatacept. 433 patients were randomly 
assigned to be given an infusion of a fixed dose of abatacept once a month, while 219 
received placebos. Results showed at one year, progression of structural joint damage 
was statistically slowed by abatacept. Physical function significantly improved in 
63.7% of the patients. While these results seem to be very promising for abatacept 
therapy, the study only involved 1 group of patients over 1 year and therefore is very 
limited in its evidence of the efficacy of the drug. Longer treatment in different 
populations is needed to establish its effectiveness against the progression of 
rheumatoid arthritis (Kremer et al. 2008).  
Rituximab is a genetically engineered humanized mouse monoclonal antibody 
that works against CD20 molecules on the B-cell surfaces, thereby depleting the B-
cells, stopping their immune response and thereby reducing inflammation (Furst et al. 
2009). The advantage of rituximab is that it works on B-cells rather than inhibiting 
TNF cytokines, which is a relief to patients who do not benefit from anti-TNF agents, 
either at the start of treatment or after receiving some treatment. A study was done in 
Finland to examine the effectiveness of rituximab on rheumatoid arthritis patients who 
failed to respond to TNF antagonists, or had a contraindication to these drugs. Data 
was collected from five rheumatology clinics and examined 81 patients in total who 
were treated with rituximab from April 2005 to June 2008, since previous therapies 
were unsuccessful in reaching adequate responses. Treatment response was defined 
according to EULAR response criteria and disease activity score using 28 joint counts 
(DAS28). The results of the trial showed adequate EULAR response in 77% of the 
patients and a suppressed DAS28 score of 2.08 units. Since the percentage of good 
responses of patients taking DMARDs other than methotrexate with rituximab, was 
somewhat higher than those taking methotrexate alone with rituximab, it’s obvious 
that rituximab is equally effective when combined with methotrexate and other 
DMARDs. The study concludes that rituximab was effective in controlling disease 
activity in patients who did not show adequate results taking other DMARDs alone 
(Valleala et al. 2009). 
Tocilizumab is the first of its kind as an anti-interleukin 6 receptor monoclonal 
antibody. Interleukin 6, a pro-inflammatory cytokine that is released by immune, 
endothelial and synovial cells, induces osteoclast differentiation, therefore contributing 
to the joint and bone destruction occurring in rheumatoid arthritis patients.  The drug 
is typically given with or without methotrexate, for patients who did not respond to 
single or multiple anti-TNF therapies. Similarly to those associated with other 
monoclonal immune suppressors, adverse effects include infusion reactions, 
development of neutralizing antibodies, hypersensitivity reactions, and increased risk 
of serious infection (Murri 2010).  
Studies done on rheumatoid arthritis patients who took tocilizumab with 
methotrexate revealed positive results. One study was done on 499 patients who had 
an inadequate response to one or more anti-TNF agents. Results after the 24 weeks 
showed that 50.0% of those who received 8mg of tocilizumab achieved ACR 20% 
response criteria, compared to the 30.4% in the 4mg group and the 10.1% in the 
placebo group. At week four, ACR 20% response criteria was reached by more 
patients receiving 8mg of tocilizumab than those in the control groups, as was DAS28 
remission rates achieved at week 24. The most common adverse events reported in the 
trial were infections, gastrointestinal symptoms, rash and headaches; however, most 
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were mild and moderate. This study demonstrates the potential benefit of tocilizumab 
given with methotrexate as an effective therapy against rheumatoid arthritis  (Emery 
et al 2008). Results showed rapid and sustained improvements of rheumatoid arthritis 
symptoms for those who failed to respond well to TNF antagonists and reported mild 
adverse effects.  
Even though the biological DMARDs mentioned above did show promising 
trial results when given with methotrexate, biological DMARDs are so fresh and new 
in research that efficacy and adverse effects are unable to be studied in the long run. 
Most of these trials are over a 1 to 2 year period, which is not an adequate amount of 
time to measure achievable long-term remission induced by these therapies. While they 
definitely show great potential in slowing down the progression of bone destruction 
and active symptoms caused by rheumatoid arthritis, more research and long-term 
studies must be done to evaluate the lasting effects and possible negative side effects of 
these young progressing therapies. 
ADVERSE EFFECTS AND DISADVANTAGES  
Potential increased risk of serious infection is one of the major side effects of 
biological DMARDs. TNF inhibitors in particular have been noticed to increase the 
risk of developing reactivation of dormant tuberculosis. This is why it is important for 
a patient who is about to start on anti-TNF agents to undergo tuberculin skin testing 
and even chest radiographs, if needed. A national prospective observational study was 
done on data collected from the British Society for Rheumatology Biologics Register 
(BSRBR) to test if different anti-TNF agents increase the risk of tuberculosis 
reactivity. A comparison of TB rates in 10712 patients who were either treated with 
etanercept, infliximab, or adalimumab showed three-to four-fold higher TB rates in 
patients taking infliximab and adalimumab, than those receiving etanercept (Dixon et 
al. 2010). 
Another prospective observational study was done from the BSRBR, where 
11,881 patients treated with anti-TNF agents were evaluated to research an increased 
risk of septic arthritis. While the results did not show that anti-TNF therapy was a 
significant cause of Septic Arthritis, they did find that it was associated with doubling 
the risk of developing SA.  
Both studies were done on an enormous number of subjects who might have 
had different contributing factors in developing tuberculosis or septic arthritis 
(Galloway et al. 2011). While these studies do not positively prove that anti-TNF 
agents used in rheumatoid arthritis patients increase the risk of infection and 
tuberculosis, they do show a probable basis for the fact that TNF inhibitors might 
contribute to these risks. For this reason, physicians and surgeons should be aware of 
these potentially life-threatening complications, and instruct their patients on how to 
manage and prevent these adverse outcomes.  
The cost of DMARDs and the necessary monitoring required while being 
treated with these drugs can be extremely expensive and burdensome, especially for 
elderly patients with severe rheumatoid arthritis. A large amount of monitoring is 
needed while on DMARD treatment, since complications such as infection and 
toxicity can occur. Tests such as CBCs and platelet counts are necessary periodically 
to rule out infection, and yearly ophthalmologic tests are needed for patients on 
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hydroxychloroquine. All in all, sometimes the excessive expense and adverse effects 
might prevent patients from benefiting from these new and promising treatments. 
CONCLUSION 
Rheumatoid arthritis can be a crippling and incapacitating disease, if left 
untreated. Disease modifying anti-rheumatic drugs work in the unconventional way of 
modifying the disease and inhibiting the underlying cause of inflammation present in 
rheumatoid arthritis, in order to reach sustainable remission. While it is a relatively 
new group of drugs, an abundant amount of research and effort has been put in to find 
the most suitable and effective treatment when using these agents. From the studies 
mentioned above, it is obvious that DMARDs has a tremendous potential of becoming 
the leading treatment in autoimmune inflammatory disease, such as rheumatoid 
arthritis. According to Tak et al. (2011), the complex and varied mechanism of actions 
of these drugs make it necessary for researchers to study the different mechanism and 
contemplate which combinations are effective and safe. What’s more, rheumatologists 
should put effort in predicting clinical responses of individual patients who they 
prescribe DMARDs to. By doing so, the physician may very possibly maximize the 
patient’s outcome, minimize safety concerns and reduce treatment costs caused by 
complications (Tak et al. 2011). Even though there is a long way to go, DMARDs are 
thriving at helping people overcome rheumatoid arthritis, and show great potential in 
some day reaching the ultimate goal of causing rheumatoid arthritis patients to go into 
permanent remission, thus becoming the cure for rheumatoid arthritis.  
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